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SUMMARY 
 
The research work compiled in this thesis was conducted, based on the fact that in 
India use of Non steroidal anti-inflammatory drugs (NSAIDs) is on a larger scale. It 
has been documented in several   International and National studies that Traditional 
NSAIDs (tNSAIDs) cause significant rise in the gastrointestinal adverse reaction and 
selective COX-2 inhibitors cause cardiovascular adverse reaction. A prospective, 
cross-sectional study was conducted in a tertiary care teaching hospital, an institute 
for medical care and research centre at Karamsad, situated in kheda district. Patients 
of different age group, including paediatrics and geriatrics are included in the 
research, to observed the utilization pattern of NSAIDs and adverse drug  
reaction (ADR) due to NSAIDs. The research work was aimed to see the influence of 
pharmacovigilance of NSAIDs so the effective preventive strategies may developed 
for local population. Utilization pattern frequently prescribed NSAIDs with their ATC 
code was analyzed. Pattern of use of NSAIDs in relation to age ,gender, history of  
over the counter use of NSAIDs, commonly use gastroprotective agentsand fixed dose 
combinations with NSAIDs, in relation to causing ADRs were analysed. The study 
found the positive and significant influence of ADR monitoring of NSAIDs. The 
study found that females, elderly and the patients with history of use of over the 
counter NSAIDs are some of the risk factors. The study results indicating that more 
longitudinal studies are required with more definitive investigations, so as to 
developed therapeutics strategies for prescribing NSAIDs in all age. 
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INTRODUCTION 
Drug utilization is an important component of many research initiatives that examine 
the clinical and economic effectiveness of pharmacotherapy. Monitoring medications, 
use and knowledge of prescription habits and its safety profile are some of the 
strategies recommended for containing and controlling medication cost and its effect 
on national budget. A globally accepted dose standard unit is important for drug 
utilization (DU) studies, particularly if the investigations are performed in countries 
situated in different geographic areas and are to be compared(1).   The Daily Defined 
Dose (DDD) is a technical unit for comparison - "the average recommended daily 
dose of a drug when used for its main indication"(2). Drug utilization has been defined 
as "the prescribing, dispensing and ingesting of drugs"(3). 
The Drug Utilization 90% (DU90%) index was introduced as a simple, inexpensive 
and flexible method for assessing the quality of drug prescriptions. It identifies the 
drugs accounting for 90% of the volume of prescribed drugs after ranking the drugs 
used by volume of DDD. The remaining 10% may contain specific drugs used for rare 
conditions in patients with a history of drug intolerance or adverse effects, complex 
co-morbid conditions and/or therapy prescribed by others(4).  It has been 
recommended the DU 90% method for assessing general quality in drug prescribing(1-
3,5) habits, this index is a reliable cut-off level for pharmacoepidemiology and 
economic surveys, and can be considered for the elaboration of a "health cost 
index"(6). It has been advocated that the Drug Cost 90% Index (DC90%) should be 
included in drug utilization research studies(7). Drug utilization studies in the in-
patient setting can provide a mechanism to assess drug prescribing trends, efficiency, 
and cost-effectiveness of hospital formularies and examine subpopulations for which 
prescribing habits may be different. In the realm of pediatric pharmacotherapy, the 
investigation of drug utilization is used to examine different outcomes, including the 
examination of prescribing trends in clinical settings, the extent to which best 
practices in children differ from drug monograms/labelling and adult dosing 
guidelines, the cost-effectiveness of hospital formularies, and the correlation between 
medication errors and utilization(8). Drug utilization research may provide insights 
into the some aspects of drug use and drug prescribing like pattern of use, quality of 
use, determinants of use, outcome of use (benefits and adverse effects)   and economic 
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consequences. Pharmacovigilance is term used to refer to monitoring of drug safety. 
Pharmacovigilance is the science of detection , assessment, understanding and 
prevention of adverse drug effects or any other drug related problems(9). The 
nationwide programme called National Pharmacovigilance Programme (NPP), 
sponsored and coordinated by the country’s central drug regulatory agency - Central 
Drugs Standard Control Organization (CDSCO) - to establish and manage a data base 
of Adverse Drug Reactions (ADR) for making informed regulatory decisions 
regarding marketing authorization of drugs in India for ensuring safety of drugs. 
The occurrence of ADR is a price that our patients have to pay for the great benefits 
that have been produced by modern medicines and which we anticipate will continue 
to be produced in the future.  
Adverse drug reactions may also result in diminished quality of life, increased 
physician visits, hospitalizations, and even death. In addition, they result in increased 
health care costs. The numerous medications, multiple chronic medical problems, and 
frequent acute illnesses experienced by the patients put them at increased risk for 
ADRs and makes detection more difficult. 
The Nonsteroidal anti-inflammatory drugs (NSAIDs) possess anti –inflammatory, 
analgesic and antipyretic activities.  More than 100 NSAIDs are marketed or at an 
advanced stage of development worldwide(8). The Indian drug industry is always ready 
to cater to the needs of medical professionals by developing combinations of various 
kinds of drugs that are capturing substantial market share. Their use is constantly 
expanding and the search for more efficacious and better tolerated compounds is still 
being pursued. In India, over 15 NSAIDs and their formulations (about 400) are 
marketed, resulting in enormous exposure of patients to this group of drugs and their 
associated risks(10).  
It has been reported that unauthorized handling of drugs and self-medication is on the 
increase worldwide with particular reference to Asia and Africa(11).In India, a variety 
of NSAID combinations are available, as over the counter (OTC) products and are widely 
misused and abused(12). The credulous patient then has to pay for the doctors' fees in 
terms of extra cost and extra adverse effects. The outcome of self-medication and 
possible ADRs are dependent on the quality of drug information given by the drug 
suppliers and the extent of use. Fever and pain are usually the early symptoms of most 
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of diseases. To cure and controls of these symptoms, NSAIDs have taken place in a 
large scale. To minimize the expenditure and hazards to consult with the physician 
and many more reasons people use to consume NASIDs by his/her own will 
throughout the world(13). 
Efficacy of NSAIDs has been documented in a number of clinical disorders, including 
osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, gout, dysmenorrhea, dental 
pain and headache(14). Predominantly used in the management of rheumatological 
conditions, NSAIDs are drugs of choice in the treatment of inflammatory 
arthropathies. However, their use has also been extended to many non-
rheumatological problems (for example dysmenorrhoea, pain of different origin, 
neoplastic fever, migraine, thromboembolic disease, and patent ductus arteriosus; they 
are also used for tocolysis and in some neoplastic diseases)(15). Several clinical, 
epidemiological, and animal studies have suggested that NSAIDs can reduce the 
occurrence or progression of colorectal cancer, polyps, and perhaps other 
gastrointestinal tumours(16-18) . Reports and epidemiological studies have shown that 
NSAIDs can protect against the risk of Alzheimer's disease(19-20). The range and 
incidence of these conditions clearly justifies extensive use of suitable drugs, and 
explains the pharmaceutical industry's interest in exploiting the potential revenues of 
such a large market.  
Nonsteroidal anti-inflammatory drugs (NSAIDs), including both traditional 
nonselective NSAIDs (tNSAIDs) and the selective cyclooxygenase-2(COX-2) 
inhibitors, are widely used for their anti-inflammatory and analgesic effects. The 
demonstration of two unique isoforms of cyclooxygenase-1 and   cyclooxygenase-2 
(designated COX-1 and COX-2) has led to a greater understanding of the mechanism 
of action of NSAIDs and has also provided an explanation for their toxicity(21). 
Selective COX-2 inhibitors were developed with the aim of minimizing 
gastrointestinal toxicity, while maintaining anti-inflammatory activity(22). 
There are clinically important differences in the efficacy and safety between the 
different NSAIDs(23), if there are differences, which are the ones, that are more 
effective and associated with fewer adverse effects, and(24) which are the effective 
therapeutic approaches that could reduce the adverse effects of NSAIDs. Finally, an 
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algorithm is proposed while delineates a general decision-making tree to select the 
most appropriate analgesic for an individual patient based on the evidence reviewed. 
Adverse Drug Reactions (ADRs) have been regarded as major public health problem. 
Adverse drug reactions have been creating headlines over the last forty years since the 
thalidomide tragedy. The adverse reactions profiles of many NSAIDs have proved to 
be unacceptable. Over the last 20 years, 18 NSAIDs have been withdrawn from the 
market or their clinical studies have been terminated because of unexpected 
toxicity(25). Issues, such as cardiovascular deaths in users of  COX-2 inhibitors, re-
examination of the risks and benefits of hormone replacement therapy and psychiatric 
reactions associated with selective serotonin re-uptake inhibitors, have attracted 
significant media and public attention(26) . 
Therefore, there is a need to monitor the safety of the drug after it has been released 
for general use. This is the primary function of post marketing surveillance studies, 
and is part of the science of pharmacovigilance. Although the physicochemical 
features, pharmacokinetics, and pharmacodynamics of individual NSAIDs differ, it is 
not known to what extent these differences are significant in the benefit-to-harm 
balance in the individual patient(27). Certainly they influence the adverse reactions and 
the general pattern of action of a particular subgroup of NSAIDs or a specific 
compound within a class, but this still provides no reliable prediction of what the 
individual patient will experience. 
NSAIDs have a wide range of adverse effects, including gastrointestinal (GI) 
disorders (from minor dyspepsia through to major ulcers, bleeding and perforation), 
kidney effects (leading to a variety of problems, such as increased blood pressure or 
heart failure) and cardiovascular effects(28-30). The gastrointestinal(GI) adverse effects 
have been proposed to be related to inhibition of one type of enzyme, 
cyclooxygenase-1 (COX-1); and COX-2 inhibitors were developed to be selective in 
the inhibition of the 'inducible' form associated with inflammation, COX-2(28). 
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Aims and Objectives of the Study 
i. To find out, the utilization patterns and the adverse drug reactions (ADRs) 
of non steroidal anti-inflammatory drugs(NSAIDs) in all age group of 
patients  
ii. To identify  the outcome of  adverse drug reactions due to   non-steroidal 
anti-inflammatory drugs (NSAIDs)  
iii. To compare the same data with international data 
iv. To provide the baseline data for future comparison of Cyclooxygenase-1 
(COX-1) and Cyclooxygenase-2 (COX -2) inhibitors 
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REVIEW OF LITERATURE 
0BThe history of medicines, which includes the use of prophylactics, therapeutics and 
diagnostics, is full of hits and misses, benefits and risks and blockbusters and 
commercial disasters. Historically, anti-inflammatory drugs had their origins in the 
serendipitous discovery of certain plants and their extracts being applied for the relief 
of pain, fever and inflammation. When salicylates were discovered in the mid-19th 
century to be the active components of Willow Spp., this enabled these compounds to 
be synthesized and from this, acetyl-salicylic acid or Aspirin was developed. 
Likewise, the chemical advances of the 19th-20th centuries lead to development of the 
non-steroidal anti-inflammatory drugs (NSAIDs), most of which were initially 
organic acids, but later non-acidic compounds were discovered. There were two 
periods of NSAID drug discovery post-World War 2, the period up to the 1970's 
which was the pre-prostaglandin period and thereafter up to the latter part of the last 
century in which their effects on prostaglandin production formed part of the 
screening in the drug-discovery process. Those drugs developed up to the 1980-late 
90's were largely discovered empirically following screening for anti-inflammatory, 
analgesic and antipyretic activities in laboratory animal models. Some were 
successfully developed that showed low incidence of gastro-intestinal (GI) side 
effects (the principal adverse reaction seen with NSAIDs) than seen with their 
predecessors (e.g. aspirin, indomethacin, phenylbutazone); the GI reactions being 
detected and screened out in animal assays. In the 1990's an important discovery was 
made from elegant molecular and cellular biological studies that there are two cyclo-
oxygenase (COX) enzyme systems controlling the production of prostanoids 
[prostaglandins (PGs) and thromboxane (TxA2)]; COX-1 that produces PGs and 
TxA2 that regulate gastrointestinal, renal, vascular and other physiological functions, 
and COX-2 that regulates production of PGs involved in inflammation, pain and 
fever. The stage was set in the 1990's for the discovery and development of drugs to 
selectively control COX-2 and spare the COX-1 that is central to physiological 
processes whose inhibition was considered a major factor in development of adverse 
reactions, including those in the GI tract. There was enormous commercial 
development following the introduction of two new highly selective COX-2 
inhibitors, known as coxibs (celecoxib and rofecoxib) which were claimed to have 
low GI side effects. While found to have fulfilled these aims in part, an alarming turn 
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of events took place in the late 2004 period when rofecoxib was withdrawn 
worldwide because of serious cardiovascular events and other coxibs were 
subsequently suspected to have this adverse reaction, although to a varying degree. 
Major efforts are currently underway to discover why cardiovascular reactions took 
place with coxibs, identify safer coxibs, as well as elucidate the roles of COX-2 and 
COX-1 in cardiovascular diseases and stroke in the hope that there may be some basis 
for developing newer agents (e.g. nitric oxide-donating NSAIDs) to control these 
conditions(31). Non-steroidal anti-inflammatory drugs (NSAIDs) makeup one of the 
largest groups of pharmaceutical used world the past, NSAIDs used by 20% or more 
of the population(32). NSAIDs are also one of the most common causes of adverse 
drug reactions (ADRs) reported to drug regulatory agencies as well as in many 
clinical and epidemiological studies. The most ADRs are those pertaining to 
gastrointestinal (GI) system, notably dyspepsia and bleeding. Clinical(33) and 
experimental well as reviews(34) suggest that use of selective COX-2 inhibitors is 
associated with increase in systolic blood pressure, a cardiovascular morbidity and 
mortality due to myocardial infarction. The risk of GI complications varies widely 
among NSAIDs and so does the cost. Since there are no important differences among 
these drugs with regard to efficacy, the choice of   first line treatment should be based 
on their relative toxicity. 
Pathophysiology  
More than 20 drugs fall under the category of NSAID. The major effect of all 
NSAIDs is to decrease the synthesis of prostaglandins by reversibly inhibiting 
cyclooxygenase (COX), an enzyme that catalyzes the formation of prostaglandins and 
thromboxanes from the precursor, arachidonic acid. This is in contrast to salicylates 
(eg, aspirin), which irreversibly bind to COX and inhibit production for the entire life 
of the cell, or acetaminophen, which inhibits COX centrally. The result of NSAID-
induced COX inhibition is decreased production of prostaglandins, which leads to 
decreased pain and inflammation. CNS, hemodynamic, pulmonary, and hepatic 
dysfunction may occur with certain agents, but the relationship to prostaglandin 
production remains uncertain. Prostaglandins are involved in maintaining GI mucosal 
integrity as well as regulating renal blood flow and both acute and chronic toxicity 
often involves the GI and renal systems. Cyclooxygenase-1 (COX-1) has been 
proposed to generate prostaglandins that maintain organ function, protect the integrity 
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of the gastric mucosa, and generate platelet-derived thromboxane responsible for 
platelet aggregation and vasoconstriction. COX-1 is expressed in all tissues, whereas 
cyclooxygenase-2 (COX-2) is induced during the inflammatory response and 
produces prostaglandins that mediate pain and inflammation. COX-2 is also expressed 
in kidneys and vascular endothelium(35). 
Pharmacology of NSAIDs 
37BNearly 30 years ago, cyclooxygenase (COX) was identified as an enzyme that 
initiates the biotransformation of arachidonic acid to prostanoids. It is now known that 
COX exists as two distinct but similar isozymes, COX-1 and COX-2. Based on 
structural differences in the active sites of COX-1 and COX-2, a new class of drugs 
has been developed that specifically inhibits COX-2 but not COX-1 activity. By 
preserving the synthesis of homeostatic PGs, these specific inhibitors of COX-2 
provide the clinical benefits of nonsteroidal anti-inflammatory drugs and minimize the 
consequences of nonspecific inhibition of PG synthesis(36). 
The role of  COX-1  and COX- 2) in the production of prostaglandins(37) 
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 Broad categories of NSAIDs : (38) 
NSAID can be segmented into three broad categories 
1) Traditional   NSAIDs (tNSAIDs): 
 Salicylates: Aspirin, Diflunisal 
 Para-aminophenol derivatives: Acetaaminophen 
 Acetic  acid derivatives: Indomethacin,Aceclofenac, Etodolac, Tolmetin, 
Ketorolac, Diclofenac 
 Fenamates: Mefenamic acid, Meclofenamates, Flufenamic acid 
 Propionic acid derivatives: Ibuprofen, Naproxen, Fenoprofen, Ketoprofen,   
Flurbiprofen, Oxaprozin 
 Enolic acid  (Oxicam)derivatives :  Piroxicam, Tenoxicam  
2) Prefential COX-2 inhibitors: Nimesulide,Meloxicam,Nabumetone  
3) COX-2  Selective  (COXIBS) : Celecoxib,Parecoxib,Etoricoxib, Lumaricoxib 
 According to the selectivity for inhibition of the two major isoforms of 
COX enzyme, the NSAIDs are classified as follows(39). 
(I)  Nonselective Irreversible Inhibitors of COX : Aspirin (acetylsalicylic acid) 
Sodium salicylate, Sulfasalazine, Olsalazine, Methylasalicylate. 
(II) Nonselective Reversible Inhibitors of COX : Phenylabutazone, 
Oxyphenbutazone, Indomethacine, Sulindac, Ibuprofen, Ketoprofen, 
Flurbiprofen, Naproxen, Mefenamic acid, Flufenamic acid, Tenoxicam, 
Piroxicam, Ketorolac, Tolmetin, Oxaprozin, Diflunisal, Diclofenac sodium.  
(III) Weak Inhibitor of COX – 1 and COX-2 Plus Other Modes of Anti-
inflammatory Action : Nimesulide ( 5 to 10 fold COX -2 selective) 
(IV) Preferential COX – 2 Inhibitors: (10 to 20 fold COX-2 selective) Meloxicam, 
Etodolac, Nabumetone. 
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(V)  Selective COX -2 Inhibitors : (> 50 fold COX-2 selective ) Refecoxib, 
valdecoxib, Etoricoxib. 
(VI) COX -3 Inhibitors or Reversible Inhibitor of COX- 1 (Except in 
inflammatory conditions where these are weak inhibitors of COX-1) : 
Paracetamol, Metamizol  
(VII)  NSAIDs Which do not Inhibit Prostaglandin Synthesis:) Nefopam 
ATC/DDD:  
Scandinavians pioneered the development of models to study drug use in populations, 
mainly through the work of the drug utilization research group under the auspices of 
WHO. Two inventions were crucial for this accomplishment .The first is a 
hierarchical system to classify drugs, the Anatomical-Therapeutic- Chemical (ATC) 
code. As an illustrative example, the ATC code for ibuprofen is shown below. It has 
five levels or seven digits. The first level, the M, indicates that the drug belongs to the 
class of drugs with action on the muskulosceletal system. The next level, indicated by 
01, specifies it further as belonging 
to the group of anti-inflammatory drugs, the next level A as an NSAID etc. This 
classification provides a consensus about how to collapse drugs with similar 
properties. By referring to, e.g., NSAIDs as any drug with an ATC-code of M01A in 
the first four digits, a researcher can avoid endless explanations of what particular 
drugs are the focus of a study of NSAID use. 
The ATC-system is not the only possible way to classify drugs, but it provides a well-
elaborated, well accepted, reasonable consensus. The other important development for 
the study of drug use in populations is the defined daily dose (DDD). It is established 
by an international expert panel as the typical maintenance dose for a drug when it is 
used by an adult for its main indication. The DDD for two different drugs should thus 
in principle express equipotent doses.  The DDD should not be interpreted as a dose 
recommendation, 
but rather as a technical unit of measurement that allows  to collapse data on drugs 
with differing potency. Again, the DDD is no God-given measure and particular 
values may be debated. It does, however, provide a reasonable consensus. The ATC 
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system and the DDDs are reviewed once annually by the WHO Collaborating Centre 
for Drug Statistics 
Methodology in  Oslo, to adjust for new developments in the clinical use of the 
drugs(2). 
M01AE01 
M   -              Muscles/joints                    ( 1ST level, anatomical main group) 
M01    -       Antiinflammatoric drugs      ( 2nd level, therapeutic subgroup 
M01A   -      NSAIDs                               ( 3rd level , pharmacological subgroup) 
MO1AE -      Propionic acid derivates     ( 4th level, chemical subgroup) 
M01AE101 -   Ibuprofen                          (5th level, chemical substance) 
History of adverse drug reaction 
According to WHO’S definition an Adverse Drug Reaction (ADR) is a response to a 
drug that is noxious and unintended, and occurs at doses normally used in human for 
the prophylaxis, diagnosis, and treatment of disease, or for modification of 
physiological function 
Since the first major Drug- related disaster involving the elixir of Sulfanilamide in 
1937, which killed 107 children, there have been several cases of severe adverse 
reactions and even deaths, eg., Thalidomide in 1961, Practolol in 1974, Benoxaprofen 
and Phenformin in 1982 and several others, leading to withdrawals and banning of 
these drugs. Since 1993, seven other drugs were withdrawn from the market due to 
fatalities and unacceptable side-effects. There are several issues involved with all 
these cases. Not in all cases, correlations between the drug and adverse effects were 
unambiguously established. The nature and intensity of side-effects, the risk to benefit 
ratios, the availability or otherwise of alternatives for treatment, are all considerations, 
which weigh in favor of ,or against withdrawal or banning of a marketed product. 
Even when a drug has not been unambiguously implicated, the policy of responsible 
companies has been to withdraw the drug or issue cautionary warnings through 
mailings and revised labels(40). 
11 
Development of COX-2 inhibitors: (35) 
 1998  – 1st COX-2 inhibitor – celecoxib was discoverd 
  1999 –  2nd COX-2 inhibitor – rofecoxib was discoverd 
  2000  –  sale of coxibs was on its highest  
  2001  –  FDA Arthritis Advisory Committee   reviews trials done with 
celecoxib and rofecoxib  
 2002  –  3rd COX-2 inhibitor – valdecoxib was discovered  
  2003  –  sale of COX-2 inhibitors declines 
  2004  –  Merk voluntarily withdraws rofecoxib  
  2005  –  Valdecoxib removed from the market, Etoricoxib was introduced 
  2006  –  lumiracoxib discovered 
Most new drug concepts are launched with fanfare, and it takes many years on the 
market for their appropriate role in practice to be established. An excellent  example 
of the concept of COX-2 selective NSAIDs, which was launched in Canada, in early 
1999 with cclecoMb (Celebrex). The launch of the COX-2 selective NSAIDs was 
based on 2 hypotheses. The first hypothesis is that the major adverse effects limiting 
the usefulness of non selective NSAIDs are gastrointestinal symptoms, and ulcers 
complications  leading lo death(41). The second hypothesis is that COX-2 selective 
NSAIDs are associated with less gastrointestinal toxicity than non selective 
NSAIDs(42). 
At the time of the launch of COX-2 selective NSAIDs neither of these hypotheses had 
been proven and, as documented both remain uncertain. However skilful marketing of 
these hypothesis  without any published complete trial reports by the fall of 1999(43),  
resulted in celecoxib's achieving a record for the most sales in the shortest period of 
time. Worldwide sales of celecoxib exceeded $3.1 billion in 2001(44). 
In 2000, two large randomized controlled trials testing, the second hypothesis were 
published. In the Celecoxib long-term Arthritis Safety Study (CLASS)(45) and the  
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Vioxx Gastrointestinal Outcomes Research (VIGOR) study(46), celecoxib and 
rofecoxib respectively were compared with nonselective NSAIDs. These well-
designed trials claimed to prove the safety of these agents but the results became 
controversial(33, 47). 
38BComparative studies of COX-2 inhibitors (45,46) 
In a metaanalysis of eight osteoarthritis studies, the incidence of HwithdrawalH because 
of adverse gastrointestinal events was 3.5% for Vioxx, compared to 4.8% for 
ibuprofen, diclofenac, or HnabumetoneH . HEndoscopicH studies of patients receiving 
Celebrex 50–400 mg twice daily for 12–24 weeks found rates of upper 
gastrointestinal complications similar to placebo and significantly lower than 
HnaproxenH 500 mg twice daily and ibuprofen 800 mg three times daily, but not 
statistically significantly different from patients receiving HdiclofenacH 75 mg twice 
daily. The analysis found that Vioxx provided significant gastrointestinal benefits in 
patients both at high risk and at low risk of developing gastrointestinal problems; 
patients at low risk still had 88% fewer gastrointestinal problems with Vioxx. 
The results of the CLASS study were confirmed by the Successive Celecoxib Efficacy 
and Safety Studies (SUCCESS) study, which examined the effectiveness and safety of 
celecoxib 200 mg and 400 mg daily and how well it was tolerated by patients in terms 
of adverse effects, compared with the most common NSAID regimens (i.e diclofenac 
100 mg daily and naproxen 1000 mg daily). SUCCESS showed that celecoxib was as 
effective as the conventional NSAIDs in controlling the pain of arthritis, and caused 
fewer gastrointestinal ulcers or ulcer complications (such as perforations or bleeding) 
and fewer upper gastrointestinal adverse effects, e.g. 29% less chance of having 
nausea and 22% less chance of abdominal pain. In addition, hospitalization rates for 
upper gastrointestinal problems were 2 to 4 times lower with celecoxib, and because 
there were fewer adverse effects, there was 23% less chance of a celecoxib patient 
stopping treatment. The study also found that there was no real advantage to taking a 
bigger dose of celecoxib: the 200 mg dose was found to be just as effective as the 
400 mg dose. 
The VIGOR study was followed by the Assessment of Difference between Vioxx and 
Naproxen to Ascertain Gastrointestinal Tolerability and Effectiveness 
(ADVANTAGE) study, which showed that 9.1% of people taking Vioxx received a 
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gastro-protective medicine compared with 11.2% of people taking naproxen, a 
reduction of 19%. In addition, after 3 months, 5.9% of people stopped taking Vioxx 
compared with 8.1% who stopped taking naproxen, a reduction of 27%. 
ADVANTAGE was the first study comparing the gastrointestinal tolerability of 
Vioxx and naproxen in a group that included patients taking low-dose aspirin for 
cardiovascular reasons.  
However, when the FDA later presented more complete data from the CLASS and 
VIGOR trials on its web site, the results were less certain. The CLASS trial was 
revealed to also have twelve and fifteen month time points which had not been 
discussed in the JAMA publication; in this segment of the trial, the number of ulcer-
related complications for Celebrex caught up to the control NSAID group. Similarly, 
the complete VIGOR study data revealed that in fact, when all adverse events, not just 
gastrointestinal, were tabulated, the patients receiving VIOXX had suffered (barely) 
significantly higher incidence of adverse events overall than the control NSAID 
group. In particular, the risk of serious cardiovascular HthromboticH events, e.g. 
Hmyocardial infarctionH, was 1.7% in the VIOXX patients versus 0.7% in the control 
group, and there were significantly more withdrawals in the Vioxx group for causes 
including HhypertensionH, HedemaH, HhepatotoxicityH, heart failure, or pathological 
laboratory findings. The mean increases in HsystolicH and HdiastolicH Hblood pressureH in 
the Vioxx group were 4.6 mmHg and 1.7 mmHg respectively, compared to 1.0 and 
0.1 mmHg in the control NSAID group. An estimated 43,000,000 Americans, nearly 
one out of six, suffers from HarthritisH. However, 42% (18 million) of these also suffer 
from HhypertensionH. While HendoscopicH evidence of gastrointestinal damage is 
frequently seen in studies of nonspecific NSAIDs, the actual incidence of clinically 
evident symptoms and patient discomfort is much lower; furthermore, in cases of 
short-term therapy, any such damage generally reverses itself quickly after 
termination of the drug.  
1BTherapeutic arthritis research and gastrointestinal event trial (TARGET)  was a 
randomized, double-blind, 52-week study of lumiracoxib 400 mg once  daily versus 
naproxen 500 mg twice daily or ibuprofen 800 mg three-times daily in patients with 
osteoarthritis. Randomization was stratified for low-dose aspirin use and age (< or = 
64, 65-74, > or= 75 years). The study was powered to investigate upper 
gastrointestinal ulcer complications (primary endpoint) in patients not taking aspirin 
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and in the overall study population; other endpoints included cardiovascular, renal and 
hepatic measures(48). 
Gastrointestinal  (GI) effects of NSAIDs   
The GI effects of NSAIDs are cause for concern because of their frequency and 
potential seriousness. GI toxic effects induced by NSAIDs are common. 
Approximately 1 - 2% of NSAID users will develop GI complications yearly(49). 
Studies and quantitative systematic reviews, comparing NSAID users against well-
matched controls, show NSAIDs to be associated with a 1.5 to 7.2-fold increase in 
serious adverse GI events across various agents and risk profiles. GI damage may 
extend from the oesophagus to the rectum although the acid contact areas of the 
stomach and duodenum are a more substantial problem. NSAID-induced GI adverse 
events range from dyspepsia to ulceration and, most seriously, ulcer complications 
(haemorrhage, perforation and death). NSAID-related GI adverse events can be 
classified into three broad categories ( minor symptoms, significant mucosal lesions, 
serious gastrointestinal complications) based on severity and percentages of patients 
affected(50).  
Minor GI side effects are common and affect 10 - 60% of NSAID users. Aspirin, 
traditional NSAIDs and coxibs increase the risk of upper GI symptoms. NSAID-
associated dyspepsia is common and has been reported in up to 25–50% of patients. 
Minor symptoms are heartburns, nausea, dyspepsia, flatulence and abdominal pain.  
Significant  mucosal lesions is ulcer (asymptomatic/symptomatic) and serious 
complications are perforated ulcers and catastrophic bleeding(49). 
Dyspepsia is the most common reason for stopping use. However, the presence of 
dyspepsia does not predict the presence of mucosal lesions in patients taking NSAIDs. 
Endoscopic studies have demonstrated that gastric or duodenal ulcers develop in 15% 
to 30% of patients who regularly take tNSAIDs(51). The intestinal damage may 
contribute to the iron-deficiency anaemia and hypoalbuminaemia which is evident in 
some elderly patients who chronically consume NSAIDs, and which is often 
attributed to underlying disease processes. Mucosal lesions are also common, with 
more than half of all patients who take NSAIDs on a regular basis having gastric 
erosions and 15 - 30% having endoscopically detectable ulcers. The majority of these 
lesions do not cause significant symptoms. The distinction between erosions and 
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ulcers depends on pathological and endoscopic definitions, with ulcers defined as 
lesions that penetrate to the level of the submucosa (involving endoscopically evident 
depth) and erosions defined as lesions confined to the mucosa (without 
endoscopically appreciable depth). Ulcers may give rise to major bleeding, 
perforation, or obstruction. Clinically significant GI events occur in 3 - 4.5% of 
NSAID users annually. The majority of these events are symptomatic ulcers whereas 
a smaller percentage (approximately 1-3%) are clinically serious and associated with 
GI bleeding, perforation, or obstruction(51). 
Serious NSAID ulcer complications have a significant mortality rate: One study found 
10.6% die in hospital and 14.4% within 3 months of the event. Serious life threatening 
adverse effects such as ulcer haemorrhage, Stevens-Johnson syndrome or 
agranulocytosis are rare, with incidences ranging from between one in several 
hundred to one in many thousands of users(52,53) susceptibility is linked to amino acid 
polymorphisms of the CYP2C9 enzyme. The association of variant CYP2C9 alleles 
and the risk of acute gastrointestinal bleeding shows a gene–dose effect (i.e. the risk 
increases with the number of mutated allelic variants), and it is higher in patients 
receiving drugs that are mainly metabolised by the CYP2C9 enzyme. This suggests 
that CYP2C9 genotyping may identify a subgroup of individuals who are at a 
potentially increased risk of acute gastrointestinal bleeding when treated with 
NSAIDs(54). 
Upper GI tract damage associated with NSAIDs  
Upper GI symptoms are a common problem associated with the use of NSAIDs, 
including COX-2 selective NSAIDs. A meta-analysis of eight trials found the 
cumulative incidence of dyspeptic side-effects over a 6-month period to be 25.5% 
with non-selective NSAIDs and 23.5% with a COX-2 selective NSAID(55). The 
incidence of dyspepsia among patients taking non-selective and COX-2 selective 
NSAIDs in the CLASS study was also similar, being reported by 14.4% of patients 
taking a COX-2 selective NSAID for 6 months, compared with 16.1% of those taking 
non-selective NSAIDs. Thus, as with non-selective NSAIDs, a significant proportion 
of patients are likely to experience upper GI symptoms during treatment with a COX-
2 selective NSAID. Acute GI bleeding is a potentially life-threatening abdominal 
emergency that remains a common cause of hospitalization. Upper gastrointestinal 
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bleeding (UGIB) is defined as bleeding derived from a source proximal to the 
ligament of Treitz.  The incidence of UGIB is approximately 100 cases per 100,000 
population per year(56). Bleeding from the upper GI tract is approximately 4 times as 
common as bleeding from the lower GI tract and is a major cause of morbidity and 
mortality. Mortality rates from UGIB are 6-10% overall(57).  
Lower GI tract damage associated with NSAIDs 
In contrast to the well-documented risk of upper GI damage associated with NSAIDs, 
NSAID-related lower GI damage has not been widely studied and remains poorly 
characterized. This damage includes increased mucosal permeability, mucosal 
inflammation, overt or occult blood loss, malabsorption, protein loss, ileal 
dysfunction, diarrhoea, ulceration, strictures, major bleeding and perforation. Data on 
the incidence of NSAID-related lower GI side effects come from observational or 
case–control studies, and from analyses of outcome trials in which the primary 
endpoints were related to upper GI or cardiovascular events(58). 
Traditional NSAIDs & GI effect 
Upper GI symptoms occur in up to 50% of patients taking traditional NSAIDs, and 
some 5-15% of patients with rheumatoid arthritis discontinue NSAIDs because of 
dyspepsia. Serious events including upper GI bleeding, perforation and gastric outlet 
obstruction occur in approximately 1-1.5% of patients within the first 12 months of 
treatment with a traditional NSAID. The worst GI outcome results in death, but 
mortality data associated with NSAIDs treatment are scarce. One large meta-analysis 
concluded that 1 in 1200 patients taking tNSAIDs for at least 2 months dies from 
gastroduodenal complications(45, 48). 
The GI risks are not limited to the upper gastrointestinal tract. GI complications 
beyond the duodenum may represent 25-50% of all complications associated with 
tNSAIDs. These drugs can cause small bowel ulceration, haemorrhage and strictures 
and can precipitate bleeding from colonic diverticula. Increased mucosal permeability 
and mucosal inflammation are often silent but occur with most tNSAIDs. Other 
findings include anaemia, occult blood loss, malabsorption and protein loss. A 
systematic review reported a consistent increase in lower gastrointestinal injury and 
clinical events in patients using tNSAIDs compared to those not using NSAIDs. In 
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addition, data from RCTs have demonstrated that the risk of lower gastrointestinal 
events is higher with tNSAIDs than with coxibs(58-62). 
Selective COX-2  inhibitors (Coxibs)  &GI effects 
Coxibs have an improved upper GI safety profile, extensively shown in endoscopy 
and clinical outcomes studies. Two large outcomes trials show high-dose rofecoxib 
and lumiracoxib were associated with a 50-60% reduction in upper GI complications 
when compared to traditional NSAIDs. As with standard NSAIDs, individual coxibs 
may vary in their propensity to cause GI effects, and the effects may vary with dose 
and duration of treatment although no studies directly compare the GI risk of different 
coxibs(45,63). 
There are approximately 13 million individuals who use NSAIDs by prescription. 
Extrapolation of these data reveals that every year in the U.S.. at least 103,000 
individuals are hospitalized for serious gastrointestinal toxicity from NSAID use, and 
an estimated 16.500 will not survive the complication. Based on these estimates, 
death from gastrointestinal complications of NSAIDs represents the 15th cause of 
death in the U.S. This means that every year NSAIDs kill approximately the same 
number of people as does AIDS and considerably more people than does asthma, 
cervical cancer and Hodgkin's disease combined. These figures are conservative since 
they do not take in account users of over-the-counter NSAIDs. What is even more 
worrisome is that patients are by large, unaware of the risks associated with the use of 
these drugs. A  survey revealed that 75% of patients taking NSAIDs regularly were 
not aware or were not preoccupied with the possibility of gastrointestinal 
complications, and almost two thirds of them incorrectly believed that there would be 
warning signs preceding the insurgence of gastrointestinal complications(64). 
Therapeutic Approaches to Reduce Gastrointestinal Toxicity of tNSAIDs 
Several strategies may be used to decrease the risk of tNSAID associated 
gastrointestinal events. First, GI complications can be avoided by the use of tNSAID 
analgesics, when possible (e.g. acetaminophen).Second use of the lowest effective 
does of a tNSAID will decrease the incidence of complications. The analgesic 
property of tNSAIDs has a ceiling effect, meaning that higher does not result in 
enhanced pain control but merely result in more adverse effects. Third, anti-ulcer co-
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therapy can be used in high risk patients. Finally, the COX-2 inhibitors can be used as 
an alternative analgesic to decrease the risk of gastrointestinal events(64). 
Risk factors for NSAID- induced gastrointestinal adverse event 
 Patients over the age of 65 years, 
 Patents with a history of previous peptic ulcer disease, 
 Patients taking corticosteroids, 
 Patients taking anticoagulants, 
         Patients taking aspirin. 
Cardiovascular Risks of NSAIDs 
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with fluid 
retention and the onset of CHF in several publications. Congestive heart failure which 
is induced or exacerbated by NSAIDs is not mediated by a direct myocardial 
depressant effect of NSAIDs. The major mechanism of action of NSAIDs is the 
interference with prostaglandin (PG) biosynthesis by inhibiting the function of the 
enzyme cyclooxygenase (COX). Furthermore, NSAIDs also interfere with the effects 
of diuretics and angiotensin-converting enzyme inhibitors .In healthy individuals, PGs 
play a negligible role in maintaining renal blood flow and consequently, NSAIDs 
usually exert no significant effects on renal hemodynamics. In patients with an 
impaired left ventricular function, however, PGs play an important role in the 
maintenance of cardiovascular and renal homeostasis. Prostaglandins have a 
vasodilatory effect on the afferent arteriole, oppose the effects of angiotensin II on the 
systemic circulation and decrease total body sodium and water. These effects of PGs 
are considered to contribute significantly to the maintenance of compensated heart 
failure in patients with impaired left ventricular function. In these patients, NSAIDs 
may interfere with cardiovascular homeostasis and may induce or exacerbate       
CHF(65-77). 
COX-1 is mainly responsible for the synthesis of prostaglandin E2 (PGE2) and PGI2 in 
kidney and stomach(58) prevent the potentially adverse effects on renal function, so-
called renal-sparing NSAIDs, such as sulindac, nabumetone and meloxicam. These 
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agents have been reported to exert less adverse effects on renal function .However, 
comprehensive data on the effects of these agents on renal function and cardiovascular 
homeostasis in patients with decreased left ventricular function are not yet  
available(78-82). 
At therapeutic doses, the COX-2 inhibitors are thought to inhibit only the COX-2, but 
not the COX-1 enzyme. The problem with inhibiting only the COX-2 enzyme is that 
metabolism imbalances may occur, resulting in an overproduction of harmful by 
products that may damage the arterial wall and induce arterial blood clotting. When 
COX-2 is inhibited, less PGI2 is synthesized from arachidonic acid and more 
leukotriene B4 and thromboxane A2 (TXA2) are produced. PGI2 is vasodilatory and 
antiaggregatory, while TXA2 is vasoconstrictive and proaggregatory. This tip of 
balance allows TXA2 to function unopposed, leading to increased risk for 
cardiovascular adverse events . However, results from other RCTs indicate that 
adding a COX-1 inhibitor, e.g., aspirin, does not prevent the cardiovascular adverse 
effects observed with COX-2 inhibitors. Moreover, if the PGI2/TXA2 hypothesis 
represented the only mechanistic explanation for these events, it would have expected 
the use of tNSAIDs (which have considerable COX-1 effects) to be associated with 
little cardiovascular effects. However, the observation of a trend toward increased 
cardiovascular events with naproxen when compared with placebo and celecoxib in 
the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) highlights the 
need to scrutinize these agents(83-84). 
The absolute rate of patients experiencing a thrombotic event in the APPROVe 
(adenomatous polyps prevention on Vioxx) trial. It was fortunately low at 1.5 per 100 
patient  per years suggesting that the majority of patients were treated without 
incident(85). Withdrawal of rofecoxib was based on the results emerging from the 
APPROVe trial. Total 2586 patients with history of colorectal adenomas were 
randomized to receive either rofecoxib (25 mg/d) or placebo and were followed up to 
158 weeks.  The study results demonstrated that 3.6% patients of rofecoxib arm and 
2% patients of placebo arm had experienced various thrombotic events, including 
cardiac, cerebrovascular, and peripheral vascular events.   The biological mechanism 
that triggers these cardiovascular events is still unclear; however, previous  research 
has shown that the individual therapeutic response to COX-2 inhibitors varies and that 
this variation may be associated with genetic polymorphisms within the COX 
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pathway(86-88). Therefore, it is plausible that the presence of one or more genetic 
polymorphisms may create an environment in which a COX-2 inhibitor will trigger 
cardiovascular events leading to a myocardial infarction or stroke. 
Genetic associations with NSAIDs and/or COX-2 inhibitors  
The biological plausibility of a genetic contribution to the safety of COX- 2 inhibitors 
and NSAIDs is supported by evidence that the efficacy of these drugs is modulated by 
genetic variation. Furthermore, several studies have shown that coxibs and NSAIDs 
are also associated with changes in the expression of genes linked to other 
inflammatory pathways. Moreover, it is also plausible that NSAIDs may accelerate 
cardiovascular events if an individual is already genetically susceptible to 
cardiovascular complications. The (PTGS1) (PTGS2) genes encode COX-1 and 
COX-2 respectively. A study  showed that the prostaglandin endoperoxide  synthase 1  
(PTGS1) and prostaglandin endoperoxide synthase 2   (PTGS2) genes may contain 
single nucleotide polymorphisms that could influence the efficacy or safety of 
NSAIDs or COX-2 inhibitors. According to a study by Lee et al(86) ibuprofen and 
rofecoxib significantly altered the expression of PTGS2 and this expression was 
significantly different among individuals with a G/G allele at the position -765 G>C 
in the PTGS2 gene, compared with individuals with the G/C and C/C alleles.  
Furthermore, the degree of pain relief experienced upon treatment with rofecoxib and 
ibuprofen varied by allele group. These results suggest that functional polymorphisms 
within the PTGS2 gene may be predictive of the analgesic efficacy of NSAIDs and 
COX-2 inhibitors. Moreover, Lee et al. report that, in vitro, several genetic variants in 
the PTGS1 gene alter arachidonic acid metabolism.  Furthermore, a  studies  showed 
that heterozygotes at two SNPS located within the PTGS1 locus showed significantly 
greater inhibition of prostaglandin H2 formation upon administration of aspirin 
compared with homozygote carriers of the common allele(86-91).  
The Prostacyclin Synthase Gene (PTGIS) 
It has also been hypothesized that NSAIDs and COX-2 inhibitors may reduce the 
production of prostacyclin . PGI2 is the most potent inhibitor of platelet aggregation 
and a strong vasodilator suggesting a role as a cardioprotective mediator. 
Consequently, it is also believed to be involved in vascular remodeling diseases and to 
play important roles in angiogenesis and apoptosis. Furthermore, prostacyclin couples 
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with COX-2 to sustain production of prostacyclin in circulation and endothelial cells 
The production of PGI2 is regulated by the Prostaglandin I2 Synthase gene (PTGIS) 
which facilitates the isomerization of Prostaglandin  H2 (PGH2) to PGI2(91-93). 
The Matrix Metalloproteinase (MMP) Genes  
Previous research has shown that COX-2 derived prostaglandins are involved in the 
regulation of the matrix metalloproteinase (MMP) genetic pathway in various cell 
types.   
Wang et al(89) found that rofecoxib alters the expression of several genes related to the 
matrix metalloproteinase (MMP) pathway. He found that, following tissue injury, 
treatment with rofecoxib  upregulated the MMP1 (matrix metalloproteinase 1), 
MMP3 (matrix metalloproteinase 3), PLAT (tissue plasminogen activator), and IL8 
(interleukin 8) genes and down-regulated the CD36 (CD36 antigen), VIP (vasoactive 
intestinal peptide), VIPR1 (vasoactive intestinal peptide receptor I), and TIMP3 
(tissue inhibitor of metalloproteinase 3) genes. Treatment with ibuprofen also up 
regulated MMP1 and MMP3, compared with placebo treatment where gene 
expression remain unchanged. The significance of the MMP1 and MMP3 genes is 
that they are associated with inflammation and are likely to have roles in 
atherogenesis. A variety of hepatic P450 enzymes including CYP2C9, CYP2C8 and 
CYP3A4 are involved in the metabolism of NSAIDs and COX-2 inhibitors. However, 
not all traditional NSAIDS are cleared by CYP2C9. Like rofecoxib, naproxen and 
diclofenac are metabolized by non-P450 mechanisms. Furthermore, several  
studies(94-103) have shown that genetic variation within the CRP gene is associated with 
circulating CRP concentration. To date there is some evidence that genetic variation 
has implications for the therapeutic efficacy of NSAIDs and COX-2 inhibitors.  
Effects on blood pressure  
All NSAIDs in doses adequate to reduce inflammation and pain can increase blood 
pressure in both normotensive and hypertensive individuals. The average rise in blood 
pressure is 3/2 mm hg but varies considerably(104). In addition, NSAID use may reduce 
the effect of all antihypertensive drugs except calcium channel blockers. These effects 
may contribute to the increase in cardiovascular risk associated with the selective 
COX-2 inhibitors. The prohypertensive effect is dose-dependent and probably 
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involves inhibition of COX-2 in the kidneys, which reduces sodium excretion and 
increases intravascular volume(105). In the doses used, aspirin has no COX-2-inhibiting 
or prohypertensive effects, and low dose aspirin does not interfere with the efficacy of 
antihypertensive drugs(106). Two meta-analyses have demonstrated that, after pooling 
data drawn from published reports of randomised trials of younger adults, NSAID use 
produces a clinically significant increment in mean blood pressure of 5 mm Hg, most 
marked in patients with controlled hypertension.(107-108). NSAIDs raise systolic blood 
pressure in elderly individuals by approximately 5 mm Hg and may antagonize the 
effects of antihypertensive medications. Users of NSAIDs are also twice as likely to 
have systolic blood pressure higher than 140 mm Hg, compared to nonusers(109). 
Hepatotoxicity & NSAIDs 
Serious Liver reactions to NSAIDs are rare and unpredictable, suggesting that most 
reactions are due to hypersensitivity(110). The epidemiological risk of clinically 
apparent liver injury is low (1–8 cases per 100 000 patient years of NSAID use), but 
when it occurs, it can be serious and can cause diagnostic confusion (111,112). However 
FDA has recognized liver reactions as a class effect of NSAIDs. Severe injury and 
even deaths have been reported(113). Abnormal liver function was defined as any 
increase between the upper limit to normal range and twice the upper limit of normal 
for alanine aminotrasferase, aspartate  aminotrasferase,alkaline phosphatase or total or 
conjugated bilirubin. Liver injury was define as the increase over twice the upper limit 
of  normal  alanine aminotrasferase, or conjugated bilirubin or combined increased of 
aspartate aminotrasferase,   alkaline phosphatase and total bilirubin ,provided one of 
them was above twice the upper limit of normal(114-115). 
39BMechanism of hepatotoxicity of NSAIDs  
Two main mechanisms are responsible for injury: hypersensitivity and metabolic 
aberration. Reported risk factors for NSAID-induced idiosyncratic hepatotoxicity 
include female sex, age > 50 years and underlying autoimmune disease. However, 
whether these are true risk factors or merely represent the population taking NSAIDs, 
remains to be established. In one retrospective cohort study, NSAID users with 
rheumatoid arthritis had a ten-fold increased risk of NSAID-related hepatotoxicity. 
Another risk factor is concomitant exposure to other hepatotoxic drugs. Patients who 
have experienced hepatotoxicity to one NSAID, often have the same reaction if the 
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drug is restarted or a sister drug is given, particularly if the sister drug is structurally 
similar, e.g. diclofenac and tiaprofenic acid. Rechallenge with the drug results in a 
repeat increase in anti-nuclear factor titres. A  rechallenge from an error caused by 
generic and non-generic prescribing of diclofenac resulted in a liver transplantation 
for one patient. Metabolic aberrations can occur as genetic polymorphisms and alter 
susceptibility to a wide range of drugs. It may account for the incidence ratio of 1–8 
per 100 000 prescriptions of NSAIDs(116-119). 
40BImplications  of hepatotoxicity for clinical practice 
NSAID-induced hepatotoxicity must be considered in the differential diagnosis of all 
patients presenting with a spectrum of disease, ranging from isolated deranged liver 
function tests in an otherwise well patient, to fulminant hepatic failure. Because of the 
availability of these drugs over the counter, many patients will not disclose their use 
of these agents to their doctor as they do not perceive them to be 'prescribed' 
medication. The quoted incidence of NSAID-induced hepatotoxicity is likely to 
represent significant under-reporting of the condition, as many cases are subclinical 
and are never detected, or are detected fortuitously as part of a routine biochemical 
work-up and may not be correctly ascribed to their true aetiology(120). 
Nimesulide, a preferential COX-2 inhibitor is a non-carboxylic acid nonsteroidal anti- 
inflammatory drug (NSAID) that has been effectively used for the treatment of a 
variety of inflammatory and painful conditions, including osteoarthritis in European 
and Asian countries for more than 15 years. Its market share is reported to be fifth 
amongst the NSAIDs in the worldwide market(121). It was introduced in the Indian 
market in the early 1990s. The drug is marketed in more than 50 countries, including 
India. There are more than 70 brands available in the Indian market. The drug is also 
available in a fixed dose combination with serratiopeptidase, a proteolytic enzyme and 
other classes of agents, but its combination with paracetamol needs critical evaluation 
as regards its rationality(122). 
An increased risk of hepatotoxicity with Nimesulide was suggested by spontaneous 
reports. Nimesulide induced liver injury gained investigative interest and was found to 
present with hepatocellular necrosis or cholestasis. Many cases of nimesulide induced 
hepatotoxicity have been reported(123) some of which have been fatal(124).  Patients 
with liver toxicity had the hallmark of hypersensitivity with an increase in blood and 
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tissue eosinophilia. From clinical and histological data, it appears that both 
immunologicaland metabolic idiosyncratic reactions can be involved as the 
pathogenetic mechanism of nimesulide induced liver disease. Even if the risk of 
hepatotoxicity is small and fatality rare, nimesulide use for fever particularly in 
children cannot be justified when a safer alternative like paracetamol is available. 
Neonatal renal failure following the use of nimesulide has been reported(125). In March 
2002 , Finland suspended the marketing of Nimesulide because of an associated high 
frequency of hepatotoxicity.Spain followed in May 2002, but not other European 
countries,such as Italy and France(126). 
Renal effect of NSAIDs 
One of the expectations on the COX-2 selective inhibitors was a reduction in the 
untoward renal effects associated with nonselective NSAIDs. Selective COX-2 
selective inhibitors impair renal function in elderly individuals with or without 
concurrent medical conditions that may put them at risk of experiencing adverse renal 
effects(127). 
Data of researches suggested that COX-2 is not constitutively expressed, but can be 
rapidly induced in response to inflammatory stimuli, it was speculated that the 
functions of the COX isoforms were mutually exclusive. The paradigm that COX-1 
maintains the normal physiological functions of the kidney and that COX-2 is 
involved primarily in inflammatory processes was appealing. However, evolving 
knowledge of the biological activity of COX-1 and COX-2 has suggested that the 
original paradigm is an oversimplification. Whilst it is true that COX-2 is induced at 
sites of inflammation and plays a major role in the production of PG E2 and other 
arachidonic acid metabolites produced at inflammatory sites, COX-1 may also 
contribute to inflammatory responses(128-129). Importantly, a critical role of COX-2 in 
in the maintenance of renal function has come to light. COX-2-dependent renal 
physiological effects can be inferred from observations that demonstrate  constitutive 
expression and up-regulation of this isoform in the kidney. As such, COX-2 may have 
an important role in the synthesis of prostanoids integral to the regulation of renal 
perfusion, salt and water handling and renin release. 
Although normal regulation of renal blood flow does not depend on PGs, it is possible 
that COX-1 has some role in normal renal hemodynamics. This function may explain 
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the observation of a few reported cases of acute renal failure induced by nonselective 
COX inhibitors in apparently healthy subjects, and the studies showing that selective 
COX inhibitors have no effect on GFR, whereas non-selective COX inhibitors slightly 
reduce GFR in sodium replete healthy subjects(130-131). In contrast, the observation that 
coxibs reduce GFR to the same degree as nonselective COX inhibitors in sodium 
restricted subjects and in patients with chronic stable renal insufficiency support the 
above paradigm(132). 
Dose-dependent, renal-based side-effects have been demonstrated in a small but 
consistent fraction of patients treated with  NSAIDs(133). Most common are peripheral 
edema, elevations of blood pressure, and attenuation of the effects of diuretics  and 
some antihypertensive agents, particularly ACE inhibitors and beta adrenergic 
blockers.; Acute renal failure, hyponatraemia, hyperkalaemia, interstitial nephritis and 
papillary necrosis have been also observed with nonselective COX-inhibitor therapy. 
Selective COX inhibitors have a risk profile similar to traditional NSAIDs in 
reference to electrolyte and fluid adverse events. This is particularly true in patients at 
risk of adverse renal effects related to the use of nonselective COX inhibitors, 
including patients with hypertension, cirrhosis, nephrosis and renal insufficiency. 
Fluid retention is the most common NSAID-related renal effect; it has been reported 
to occur in approximately 5% of treated patients(130). Oedema, generally in the lower 
extremities, is commonly reported in the Coxib clinical studies as it is during therapy 
with traditional NSAIDs.  
The effect of drug half-life, on oedema formation (longer half-life) also needs to be 
considered as they  lead to more sodium retention over the 24-h period. The risk of 
congestive heart failure, the most serious complication of fluid retention, has been 
reported uncommonly in large clinical trials with selective COX inhibitors, and not 
significantly different in respect to comparison with conventional NSAIDs. However, 
COX-2 inhibitors decrease urinary potassium excretion in healthy subjects and 
patients with other risk factors for hyperkalaemia. It is interesting that hyperkalaemic 
effects are indistinguishable from nonselective COX inhibitors. Hyponatraemia may 
also occur from water retention induced by the Coxibs. Generally, acute renal failure 
develops only in susceptible patients such as those with underlying volume depletion, 
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renal in sufficiency, congestive heart failure, diabetes, nephrosis, cirrhosis and old 
age(131). 
Several cases of acute renal failure associated with selective COX inhibitors have 
been reported, all of which occurred in   patients with risk factors for conventional 
NSAID-related adverse renal effects(133). Furthermore, cases of interstitial nephritis  
associated with the use of  Coxibs have been described(134-135). Currently there is 
insufficient clinical experience or long-term data with Coxibs to assess the frequency 
of rare renal events such as nephrotic syndrome, papillary necrosis or analgesic 
nephropathy. 
One probable mechanism is the 'shunting hypothesis', where arachidonic acid is 
shunted from the COX to the LOX pathway (during COX inhibition). It has been 
proposed that the 'COX to LOX' shunt also contributes to the development of the 
nephrotic syndrome that occurs with interstitial nephritis(53). Furthermore; it is stated 
that NSAID-related acute renal failure and NSAID-related hypertension may also 
depend on the shunt of arachidonate to the LOX pathway. NSAID-related acute renal 
failure is commonly considered to develop from inhibition of PG synthesis in patients 
with PG-dependent renal hemodynamic. COX inhibitor-induced hypertension is also 
considered to result from PG  synthesis, inhibition. It is therefore possible that the 
nephrotoxic potential of conventional NSAIDs and Coxibs are related to a 
derangement in the equilibrium between COX and LOX derivatives(53). 
Recently, the use of nitric oxide (NO) donors in combination with NSAIDs has been 
proposed, to reduce adverse renal effects. NO counteracts the vasoconstrictor effect of 
thromboxane and compensates for the NSAID-induced reduction in prostacyclin 
synthesis, preserving renal blood flow and GFR(136). Furthermore B-NOD, a NO 
donor, has been shown to, prevent renal depletion of prostacyclin during either 
nonselective and selective COX-inhibitor administration. 
Overall incidence of NSAIDs induced renal toxicity is 3%; but over-the-counter 
availability of these drugs puts a large population at risk. Conditions causing NSAID-
induced hemodynamic deterioration of renal function - Higher than usual dose, 
volume depletion due to flow loss diarrhoea, congestive heart failure, nephrotic 
syndrome, cirrhosis particularly with ascites, preexisting renal disease, third space 
fluid sequestration, diuretic therapy, age > 65 years(137). 
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Syndromes of NSAID nephrotoxicity  
Acute effects 
1. ARF - usually oliguric 
2. Acute interstitial nephritis (AIN) - Associated with heavy proteinuria (>3 g/24 hr);   
usually non-oliguric; rarely without proteinuria; takes weeks or months to resolve 
3.  Hyperkalemia 
4.  Sodium and water retention 
5.  Hypertension 
Chronic kidney disease (CKD) and NSAIDs -  also known as “analgesic 
nephropathy”.  
It is chiefly a chronic interstitial nephritis associated with capillary sclerosis of the 
vessels of renal pelvis and renal papillary necrosis followed by calcification. It is due 
to medullary ischaemia induced by loss of vasodilatory effects of prostaglandins on 
vasa recta. Long term toxicity of individual drugs are unknown and so are incidence 
and prevalence in view of most drugs available over-the-counter. Classically seen 
with consumption of any NSAID for over 20 years. The potential of CKD exists with 
use of analgesic mixture .Incidence is higher in females and in patients suffering from 
rheumatic disorders and migraine. Diagnosis is difficult as there is lack of a simple 
non-invasive test that reliably implicates analgesics as a cause of renal injury(138). 
Respiratory and Skin effect 
As 2-20% of adult asthmatics have aspirin hypersensitivity(139) they must be 
considered at risk from NSAIDs. It is difficult to estimate the frequency of skin side 
effects with NSAIDs as they are commonly purchased without prescription, and only 
those reactions worrying enough to present to a hospital are usually recorded. In one 
prospective study of nearly 20,000 inpatients, 0.3% of those prescribed a NSAID 
developed a generalized skin reaction including Hmorbilliform rashH, HurticariaH, 
HangioedemaH, Hserum sickness-like reactionH and Herythema nodosumH(140). In a meta-
analysis of randomized clinical trials, skin side effects were reported in 1–2% of 
patients using NSAIDs(141). 
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The mechanism is related to a deficiency in bronchodilator prostaglandins; 
prostaglandin inhibition may make arachidonic acid produce more leukotrienes with 
bronchoconstrictor activity.As with most drug-induced skin reactions, withdrawal of 
the trigger medication results in resolution of the rash, although this may take some 
months and is not universal. NSAIDs can cause a pseudo-allergy due to their 
pharmacological effects with a prevalence rate of 0.1-0.3%. It is believed to be due to 
inhibition of the enzyme COX1. Typically in this condition, the reaction develops 
with multiple different drugs in this family, unlike a true allergy where it is a reaction 
to a specific drug(142). 
The most common presentation of NSAID hypersensitivity is facial swelling, 
particularly around the eyes (HangioedemaH). One third of patients present with a mixed 
pattern of skin (angioedema and/or urticaria) and respiratory symptoms including 
cough, breathlessness, rhinorrhoea (runny nose), tearing or upper respiratory tract 
swelling(139). 
Nervous system 
NSAIDs cause headaches and confusion in a relatively  small number of patients. 
Headache and dizziness are common with Indomethacin, and it has been suggested 
that its chemical similarity to serotonin, which can cause severe headaches, may be 
responsible. Headache due to long-term use of ibuprofen has been reported in chil-
dren(143). 
The Australian Drug Reaction Advisory Committee has reported paresthesia as a class 
effect of NSAIDs, although it is rare and reversible(144). A case-control study showed 
no increased risk of intracerebral hemorrhage in patients using aspirin or other 
NSAIDs in low dosages as prophylaxis against thrombosis(145). 
A review of the literature regarding central nervous system side effects of the NSAIDs 
revealed three general categories: aseptic meningitis, psychosis, and cognitive 
dysfunction. Aseptic meningitis is found most commonly in patients with lupus 
treated with ibuprofen, but it should be considered in any patient with meningitis if the 
patient has used NSAIDs. Psychosis, although infrequently reported with NSAIDs, 
should be suspected in any elderly patient started on a regimen of indomethacin who 
acutely develops disorientation, paranoia, or hallucinations. Finally, there appears to 
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be some potential for memory dysfunction and attention deficits in elderly patients 
treated with NSAIDs. Until further studies are available on the incidence and severity 
of these cognitive changes, physicians should use low doses of NSAIDs in the elderly 
and remain alert to the possibility of such adverse side effects(146). 
Electrolyte balance 
NSAIDs can interfere with fluid and electrolyte homeostasis, thereby causing oedema, 
hyponatremia, hyperkalemia, and blunting of the natriuretic effects of diuretics(147-148). 
Studies that have evaluated the renal effects of coxibs have demonstrated variable 
degrees of sodium and fluid retention, depending upon the agent(149-150). 
Prostaglandins are synthesized in the kidneys and disruption of their synthesis by 
NSAIDs can result in acute renal failure, acute nephritis, electrolyte imbalances and 
reduced renal perfusion. The most common renal side effect of NSAID therapy is 
fluid retention and edema resulting in inhibition of Prostaglandin E2 production, 
clinically evident in ≥3% patients(150). Prostaglandins act as modulators of physiologic 
functions in the kidney, and therapy with NSAIDs can have an effect on renal 
physiology(151). The most important PGs in the kidney are PGE2 and PGI2 
(prostacyclin). PGE2 is involved in the regulation of sodium reabsorption in the 
tubule and it acts as a counter-regulatory factor under conditions of increased sodium 
reabsorption. Prostacyclin increases potassium secretion mainly by stimulating 
secretion of renin and activating the renin-angiotensin system, ultimately resulting in 
increased secretion of aldosterone. In addition, this vasodilatory PG increases renal 
blood flow and GFR under conditions associated with decreased actual or effective 
circulating volume, resulting in greater tubular flow and secretion of potassium. In 
healthy hydrated individuals, renal PGs do not play a major role in sodium and water 
homeostasis(152). 
Under conditions of decreased renal perfusion, the production of renal PGs serves as 
an important compensatory mechanism. Renal effects of NSAIDs are based on their 
pharmacologic mechanism of action. These effects are relatively mild and rare in 
healthy individuals but can be serious in patients whose renal function is 
prostaglandin-dependent. Patients with contracted effective intravascular fluid volume 
as a result of congestive heart failure, cirrhosis, diuretic use, or restricted sodium 
intake, are more likely to experience NSAID-related changes in renal function(152). 
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Hematological Disorders & NSAIDs 
Blood dyscrasias related to HNSAIDH HtherapyH are clinically important, although rare. In 
the Danish study, one third of reported deaths associated with HNSAIDsH had 
hematologic causes. All blood cell lines can be affected, resulting in red cell aplasia, 
hemolytic anemia, agranulocytosis, thrombocytopenia, and aplastic anemia. Reduced 
platelet aggregation also occurs(153). The exact incidence of HNSAIDH-related blood 
dyscrasias is unknown. The investigation by the International Agranulocytosis and 
Aplastic Anaemia Study (IAAAS), showed thate  risk of aplastic anemia is 6 to 10 
events per million subjects per year, following an exposure of at least 5 months(154). 
Most of the hematologic effects of HNSAIDsH (agranulocytosis, red cell aplasia, aplastic 
anemia, hemolytic anemia, thrombocytopenia) are thought to result from an immune 
reaction and are, therefore, drug specific. HDrugsH that bind strongly to proteins, such as 
NSAIDs can act as haptens and elicit antibody production and other immune 
responses. Nonimmune hematologic effects of NSAIDs include inhibition of platelet 
aggregation and hemolysis.. Hemolysis can occur owing to the ability of NSAIDsto 
oxidize hemoglobin to methemoglobin or sulfhemoglobin. Patients of all ages appear 
to be at risk for HNSAIDH-related blood dyscrasias. Aplastic anemia associated with 
phenylbutazone and oxyphenbutazone use has occurred mainly in women older than 
60 years. In the IAAAS study, only indomethacin, diclofenac, phenylbutazone, and 
oxyphenbutazone were significantly associated with aplastic anemia, although there 
have been reports of an association with acetylsalicylic acid. Agranulocytosis has 
been associated with the use of indomethacin, phenylbutazone, oxyphenbutazone, 
sulindac, tolmetin, Hnaproxen Hand mefenamic acid(153). Thrombocytopenia is generally 
mild and reversible and has a low case-fatality rate, but deaths from bleeding have 
been reported, particularly with Indometacin, Oxyphenbutazone, and 
phenylbutazone(155). Pyrazolone derivatives and Butazones are most frequently 
blamed for causing agranulocytosis and aplastic anemia (SEDA-9, 85) (SEDA-11, 
89). Unfortunately, no reasonably accurate estimate of the overall incidence of either 
disease or of the risk associated with the use of any particular NSAID is available.  
Use of NSAIDs in Elderly  
The use of medications is common in elderly persons, and this population has the 
highest risk of medication-related problems. Elderly persons are more susceptible to 
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the effects of various medications for a number of reasons. It is well known that 
polypharmacy is one of the most serious problems in caring for elderly persons; 
however, many of these patients continue to receive medications that have an 
increased risk of causing harm(156). The high frequency of NSAID use in the elderly 
population is due to the high prevalence of chronically painful conditions such as 
osteoarthritis. NSAIDs do not affect the natural history of osteoarthritis or rheumatoid 
arthritis and are not considered disease-modifying drugs; they are used for symptom 
management only. Although NSAIDs provide the bulk of treatment for inflammatory 
musculoskeletal disorders, they also are prescribed frequently for noninflammatory 
conditions. There is little evidence to indicate that NSAIDs are superior to other 
analgesics without anti-inflammatory activity for these conditions(157). Currently, up 
to 4% of all prescriptions filled are NSAIDs(158). It is estimated that more than 1% of 
the US population use NSAIDs long-term. This percentage is even higher in the 
elderly population; an estimated 10% to 20% of those older than 65 years have a 
current or recent prescription for an  NSAID.65 Worldwide, more than 30 million 
patients receive prescriptions for NSAIDs daily(159). Approximately half of all NSAID 
prescriptions are written for patients older than 60 years(160). 
NSAIDs are highly lipid-soluble drugs with extensive protein binding. The high lipid 
solubility of NSAIDs results in their widespread distribution in elderly persons due to 
increased age-related adipose tissue stores. Elderly persons also have an increased 
concentration of unbound drug due to reductions in plasma protein found in many 
older persons. Since many elderly persons have reduced renal function, NSAIDs have 
decreased renal clearance in older patients, potentially resulting in excessive drug 
levels and toxicity. 
Complications from NSAID use are well documented and can affect the GI, renal, 
cardiovascular, CNS, and hematologic systems. Adverse effects from NSAIDs are 
relatively common in the elderly population, in part because these drugs are used so 
extensively in this segment of the population(161). Adverse effects tend to be more 
severe in elderly than in younger persons. Disability, associated with advanced age 
and multiple disease, is associated with an increased frequency of hospitalizations due 
to GI complications in those taking NSAIDs. NSAID-induced gastropathy is the most 
common and severe adverse drug effect. Damage occurs as a result of both topical 
injury and a systemic effect through inhibition of prostaglandin synthesis. Even 
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NSAIDs given rectally can produce gastric complications(162). Up to 20,000 patients 
die each year as a result of GI complications from NSAID therapy, 3000 of whom are 
elderly patients(163). The risk of developing peptic ulcer complications from NSAID 
use increases with increasing age and dose(164). Endoscopic studies have shown that 
when higher doses of NSAIDs are taken, there is a dose-response effect with greater 
mucosal injury and likelihood of ulceration. Lack of symptoms associated with 
NSAID gastropathy is more common with advanced age. NSAIDs can increase blood 
pressure level, with an increase in mean arterial pressure averaging approximately 10 
mm Hg(165). This is more common in elderly patients. The effects of various 
antihypertensive agents, especially those whose action is via renal prostaglandins such 
as β-blockers and angiotensin-converting enzyme inhibitors, are blunted by NSAIDs. 
NSAIDs also can produce renal insufficiency (both acute renal failure and worsening 
of chronic renal insufficiency), hyperkalemia, and fluid retention(166). When treatment 
with an NSAID is indicated in elderly patients, the lowest effective dose should be 
used. Higher doses producing anti-inflammatory effects may not always be necessary. 
The need for the NSAID should be reviewed periodically. Acetaminophen has been 
shown to be effective in the treatment of chronic pain from osteoarthritis. Up to 4 g/d 
is generally safe for elderly persons; however, caution must be used in prescribing to 
patients with any degree of hepatic disease and to those who ingest large quantities of 
alcohol. Beers(167) did not address NSAIDs as a group but did indicate that several 
NSAIDs were potentially inappropriate for use in the elderly population. 
Indomethacin was singled out because of its CNS toxicity(168). 
Because of the extremely widespread use of NSAIDs in the elderly population, large 
numbers of serious adverse effects occur. However, because of the health problems 
common in elderly persons that result in chronic pain and because NSAIDs benefit so 
many people, these drugs will continue to be used. There is not adequate evidence to 
label the entire class of anti-inflammatory drugs as inappropriate for use by the 
elderly population. However, NSAIDs have considerable potential for serious adverse 
effects, especially when used long-term and in higher doses. Therefore, NSAIDs 
should be used judiciously and in low doses when possible or should be replaced with 
lower-risk alternatives. Patients receiving long-term therapy should be observed 
closely for adverse effects. 
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41BPaediatric use of NSAIDs 
The safety of drug prescribing has become a highly visible topic in adult medicine, 
due in part to research suggesting that there are important ADRs caused by commonly 
used medications(169). Much less attention has been focused on neonates, infants, 
children and adolescents(170, 171) Paediatric patients constitute a vulnerable group with 
regard to rational drug prescribing since many new drugs are released onto the market 
without the benefit of even limited experience in this age group(172). This deficiency 
causes paediatricians to often prescribe children drugs in an ‘off-label’ manner, 
thereby increasing the risk of drug toxicity(173). Adequate controlled clinical trials in 
children are lacking, mainly because of issues of cost and responsibility, and to 
regulations that frequently act as major obstacles(174). Moreover, until recently, the 
few clinical trials that had been performed involving children focused on the efficacy 
of drugs and rarely monitored their safety(175). 
Meta-analysis is already a well-established methodological approach for evaluating 
the effectiveness of therapies. However, in contrast to the published experience of 
using meta-analysis to evaluate drug efficacy, the use of this method to also quantify 
the risk of therapies remains limited to date(176). A recently published meta-analysis 
on the incidence of ADRs in hospitalized US patients shows that ADRs represent an 
important public health issue, making these reactions between the fourth and sixth 
leading cause of death in the USA, even when the drugs are used in proper doses and 
for approved indications(177). Although paediatric pharmacotherapy has recently come 
to the fore both in Europe and USA(178), so far no meta-analytical review has been 
performed to assess the risk of drugs in the paediatric population. Prescribing 
restrictions within an institution can limit use of certain medications and contribute to 
prevention of ADRs by avoiding inappropriate prescribing; these prescribing 
restrictions should be regularly reviewed. For example, prescribing of COX-2 
inhibitors could require individual patient approval. Such restrictions may not extend 
to the community where several of the more severe, preventable ADRs in this review 
initiated. Regulatory changes in Australia have resulted in ibuprofen being readily 
available from supermarkets. The case of acute renal failure probably caused by 
ibuprofen may have been prevented if the drug had been avoided rather than 
administered for a viral infection in a setting of dehydration at home. It is well 
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recognized that use of NSAIDs, even in moderate dehydration in children, is 
hazardous(179,180). 
42BNSAIDs are drugs with the potential for causing significant renal toxicity including 
the nephrotic syndrome, interstitial nephritis, and renal failure even in children 
without obvious preceding renal disease. Children prescribed such drugs should be 
regularly monitored with urinalyses and plasma creatinine estimations. The possibility 
of toxicity to over-the-counter use of NSAIDs should be remembered(181). 
A substantial proportion of children receiving long term NSAID therapy may 
experience CNS effects, with headache being the most common. Less common 
symptoms include fatigue, sleep disturbance and hyperactivity. Ibuprofen has been 
reported to cause aseptic meningitis, particularly in patients with systemic lupus 
erythematosus(182). 
 Pharmacovigilance in India  
To be eternally vigilant to ensure that medicines, which are developed for treatment of 
diseases, actually do not do more harm than good, is one of the important pre-
requisites for the progress of medicine. Already, at least in the U.S.A., figures as high 
as 3 to 5% of hospital admissions have been attributed to Iatrogenic diseases, ie., 
those caused by drugs. The science and systems used for systematically identifying 
and correlating drugs and side-effects and taking corrective actions fall under the 
discipline of Pharmacovigilance(183). 
Need for Pharmacovigilance Systems 
The leading Indian companies realizing the compulsions of the new regime have 
already initiated investments of substantial resources for the discovery and 
development of new drugs needed for both Indian and International markets. For an 
effective Pharmacovigilance system to be functional and efficient all the stakeholders 
need to be alert and attentive through out the lifetime of the drug in the market. 
Approaches to Pharmacovigilance  
Maximum attention needs to be paid to assess the ADRs immediately following the 
launch of a new product. The Committee on Safety of Medicines (CSM) of U.K., the 
successor to the Dunlop Committee has set up a Yellow Card Scheme which is a 
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reporting system under which, all suspected adverse reactions, post- treatment with a 
drug is reported. Currently on an average, over 25000 reports are registered per year 
in U.K. These reports, could have many false positives, nevertheless, they still 
provide early warnings of drug hazards. Such warnings make it possible to further 
carry out prospective and systematic studies to validate the claims of drug - related 
adverse reactions. 
Existing system of pharmacovigilance in India  
In 1986, for the first time a formal drug safety monitoring system was proposed in 
India. The proposal of adverse drug reaction monitoring system of 1986 consisted of 
12 regional centres with each centre covering a population of 50 million. More 
concrete efforts of drug safety monitoring in India began in 1997, in cooperation with 
World Health Organization (WHO) Adverse Drug Reaction Monitoring Programme 
based in Uppsala, Sweden.  Under this programme, three ADR monitoring centres 
were identified, including a national pharmacovigilance centre at AIIMS, New Delhi 
and two WHO special centres at Mumbai and Aligarh. This programme could not 
succeed due to multiple reasons and it paved the way for the launch of more 
ambitious national pharmacovigilance programme (NPP) - central drugs standard 
control organization (CDSCO) - sponsored by WHO and funded by World bank on 
January 01, 2005. The objectives of NPP were to involve a large number of health 
care professionals in the process, inculcate the culture of reporting ADRs and to be a 
benchmark for global drug monitoring(184). 
The NPP particularly solicits reports of :  
1. All adverse events suspected to have been caused by new drugs and drugs of 
 current interest (List published by CDSCO from time to time) 
2. All suspected drug interactions 
3. Reactions to any other drugs, which are suspected of significantly affecting a 
 patient's management, including reactions suspected of causing: 
 - Death 
 - Life threatening reactions (real risk of dying) 
 - Hospitalization (initial or prolonged) 
 - Disability (significant, persistent or permanent) 
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 - Congenital anomaly 
 - Required intervention to prevent permanent impairment or damage 
The NPP consists of a pharmacovigilance advisory committee located at CDSCO, 
New Delhi and two zonal centres - South-West zonal centre (Department of Clinical 
Pharmacology, Seth GS Medical College and KEM Hospital, Mumbai) and North-
East zonal centre (Department of Pharmacology, AIIMS, New Delhi). The Mumbai 
zonal centre collects information from three regional centres, while New Delhi zonal 
centre collects information from two regional centres. Each regional centre in turn 
collects information from 24 peripheral centres. To further support the NPP, 
implementation of Schedule Y has made it mandatory to report all serious adverse 
events, including suspected unexpected serious adverse reactions from clinical trials. 
Despite the ongoing efforts, much needs to be done for the success of NPP in India, 
especially with regard to reporting ADRs from post marketed drugs. 
Problems & limitations of current system  
Since the need to raise the standards of internal pharmacovigilance system in India is 
becoming more and more pressing under the present circumstances, the limitations of 
the current system and associated problems are becoming a major concern for all the 
involved agencies. Some of the major issues are: 
1. As more and more medicines are approved for marketing without long term 
safety studies, lack of sufficient research on the enormity of the problem and 
incidence of ADRs and associated morbidity, mortality and financial cost is an 
important area of concern in India. Lack of adequate assessment of the 
magnitude of the problem is suspected to lead to failure of not only the planning 
and development but also arrangement of sufficient funds for effective 
implementation 
2.  At present, the system of collecting and forwarding information is poor. The 
health care professionals involved in pharmacovigilance work at peripheral 
hospitals and primary care centres are often unaware of exact methods of 
collecting data and thereby making it difficult to transfer the data to national 
database and interpret it correctly. An adequate sharing of information between 
health professionals and regulatory authorities is also poor. The important 
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information collected regarding ADRs at academic institutes and teaching 
hospitals as part of the thesis work of postgraduate students is often not 
communicated either to manufacturers or to regulatory and other concerned 
authorities. On the part of patients, who actually experience the ADRs, some 
effort is sometimes made to report information. But there is no system in place 
to check for the validity of such information 
3. Scarcity of people with adequate knowledge of science of pharmacovigilance is 
a pestering issue in India. Shortage of knowledgeable people to handle various 
aspects of pharmacovigilance at all levels and to train more and more people in 
this field, right from peripheral areas to the office of Drug Controller General of 
India (DCGI) is another important issue, which needs attention. Moreover, the 
ignorance on the part people, health professionals and government departments 
has made the situation even worse 
4. The pharmacovigilance system in India is currently handled by DCGI under the 
ministry of health & family welfare. The health ministry at present does not 
sanction any budget for pharmacovigilance programme and the entire program 
is working with the financial support from World Bank. Poor funding of this 
extremely important national programme is further posing limitations to its 
successful implementation. 
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MATERIAL AND METHOD 
Study design: A prospective, cross sectional study. 
Site: 
i) Shree Krishna Hospital (SKH) & Medical Research Centre, a 550 bedded 
 tertiary care rural based teaching hospital attached to Pramukh Swami Medical 
 College, Karamsad. 
ii) General practitioner (GPs) clinics from Anand district. 
Study duration : July 2007 to August 2010 
Sample Size  : Total 1000 patients of all age group. 
Quality assurance: 
The protocol was prepared and presented to Human Research Ethics Committee 
(HREC) for approval [Annex I]. After approval a pilot study was undertaken to test 
the designed proforma [Annex II (a)]. All the Patients/Parents participating in the 
study were explained clearly about the purpose and nature of the study in the language 
they can understand and written informed consent of the patients as well as parents (in 
case of paediatric patients) was taken before their enrolment in the study [Annex III]. 
Data Source: 
Totally 1000 patients were considered for the study, of which 900 patients were from 
SKH, who availed outpatient and inpatient services of various departments and 100 
patients were from general practitioners clinics, who attended the outpatient services. 
The source of data collection was from three specialities i.e. Orthopaedics, Paediatrics 
and Medicine including out patients clinics of GPs with reference to their age groups. 
Inclusion and Exclusion Criteria: 
Inclusion Criteria: 
Patients of all age and either sex, who were on non steroidal anti-inflammatory drugs 
(NSAIDs).  
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Exclusion Criteria: 
 H/O recent NSAIDs taken (i.e. last 30 days) 
 H/O kidney, liver and acid-peptic disease 
 H/O pregnancy and lactation 
 H/O Rheumatoid arthritis 
 H/O Cardiovascular and cerebrovascular disease in which Aspirin was 
prescribed 
Collection of Data: 
 Randomly selected 1000 patients, who were prescribed NSAIDs, while 
attending outpatient and inpatient departments of SKH and general 
practitioner were enrolled in the study. 
 On the 1st day of the visit of the patient at the hospital, information regarding 
the prescribing pattern of NSAIDs, medical condition and demographic data 
was collected. The demographic data included name, age, sex, weight, date of 
visit, address and telephone no. 
 Pattern of use of NSAIDs included name of drug (NSAIDs), dose, route, 
frequency of administration, duration of treatment. 
 A question was asked during the 1st visit at the hospital. 
i) Have you or your child had ever taken any NSAIDs with/without 
prescription? 
Follow up planning: 
All the patients were followed up at the interval of 3rd, 7th day and 1 month. 
 On 3rd day after receiving the NSAIDs, telephonically patient was asked a 
question. 
i) Have you or your child experienced any problem after taking prescribed 
drug? 
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If any new complaint was received, it was noted in the adverse drug reaction (ADR) 
proforma [Annex II (b)]. 
In the absence of the telephone number the same question was asked during their next 
visit to the hospital. 
 On 7th day or at the time of next visit at the hospital blood pressure was taken. 
Any new complaint or abnormal investigation was recorded. 
 After 1 month, patients were followed-up either telephonically or through 
personal contact at hospital or home.  
 For all the indoor patients medicines prescribed on discharge were recorded. 
On completion of one month they were followed up to check for any adverse 
event. 
 Any ADR reported in the medical notes of doctor or nurse for all inpatients 
were taken in to consideration.  
Format of analysis: 
Data of all 1000 patients were analyzed for following parameters. 
1. Patients’ details: Age and sex wise distribution, Frequency of outdoor and 
indoor patients according to the departments, Diseases or conditions prevalent 
in patients and Co-morbid conditions and history of Over the counter use of 
NSAIDs were analysed.  
2. Analysis of NSAIDs used: Total number of NSAIDs prescribed, Use of used 
FDCs of NSAIDs, Category wise distribution of drugs used( for this  NSAIDs 
were divided in COX-1, COX-2). ATC coding of NSAIDs are given according 
to WHO ATC/DDD system. DDD is calculated using the following formula.  
Number of DDD = Item used x Amount of drug per item/ WHO DDD measure 
3. Use of gastroprotective agents were calculated.  
4. ADR Analysis: 
 All the reported ADRs were analysed  for the following parameters: 
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 Frequency of patients developing ADRs 
 Age and Sex distribution of reported ADRs 
 System wise distribution of ADRs 
 Causality assessment by WHO-UMC scale and Naranjo’s probability score 
and comparison between the two score 
 Preventability of ADRs using criteria of Schumock and Thornton modified by 
Lau et al,2003 
 Severity of ADRs using Hartwing and Siegle 
Scale of causality assessment: 
The WHO-UMC causality categories with assessment criteria are as follows :  
[Annex IV] 
a) Certain    d)    Unlikely 
b) Probable     e)    Conditional/Unclassified 
c) Possible    f)    Unassessable/Unclassifiable 
The Naranjo’ probability scale for the assessment of the ADRs is based upon a set 
of questionnaire where answers are to be provided to each question in  yes, no or 
don’t know .Each answer is awarded certain points and the total score obtained  
predicts the probability of the ADR as given in [Annex V]. 
The ADR is given a probability category from the total score as follows: 
    >_9 = definite      5-8 = probable          1-4 = possible          <- 0 = doubtful 
Preventability of ADRs:  
The preventability of the ADRs was evaluated by using the  the criteria of Schumock 
and Thornton modified by Lau et al. They were categorized into definitely 
preventable , probably preventable and not preventable [Annex VI].     
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Severity of ADRs:  
The severity of ADRs was categorized in to mild, moderate and severe using ADR 
severity assessment scale of Hartwing and Siegle [Annex VII]. 
Outcome: 
All inform action on ADRs (probability, Severity, preventability) their causative drug 
and therapeutic consequences were noted. Outcome was assessed on all the follow-up 
days.  
a) According to doctor's assessment: 
 Clinically cured, when disease condition resolved completely. 
 Clinically improved/ relieved, when patient felt better but disease condition 
had not resolve completely. 
 No change/ same status, when there was no improvement in the disease 
condition seen during the therapy. 
 Worsen, if the condition deteriorated during the therapy. 
 Death, if patient died during the therapy. 
b) According to patient's assessment using 10 point visual analogue scale 
 10 point visual analogue scale (VAS) was given to the patient for evaluating 
their own feeling of wellbeing after the drug therapy. Marking of 0 to 10 were 
there on the VAS.0 indicating absolutely worse and 10 indicating fully 
recovered. Patient was asked to assign status of wellbeing on the day of 
discharge for the inpatients.  
Statistical analysis: 
Statistical analysis was done using Microsoft excel and SPSS software version 14.0. 
Chi square test and Odds ratio were used to determine correlation between dependent 
and independent variables. P-value <0.05 was considered as significant.  
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RESULTS 
Data of total 1000 patients were collected from various inpatient and outpatient 
departments of the Shree Krishna Hospital. Out of these 1000 patients, 500 were 
taken from different indoor departments and 500 from different outdoor departments. 
All the collected data were analyzed mainly for following major parameters: 
1. Utilization pattern of NSAIDs during 2008 from January to June.  
2. Patients’ details 
3. Analysis of non-steroidal anti-inflammatory drugs (NSAIDs) used 
4. Use of Gastroprotective agents  
5. Analysis of adverse drug reactions (ADRs).  
6. Analysis of outcome of ADRs 
A detailed analysis report has been given below. 
1. Utilization pattern of NSAIDs during 2008 from January to June.  
a) Most Common Pharmacological  Group of Drugs Prescribed   during  
 Jan - Jun -2008: 
 Data   was collected for the analysis of utilization pattern of drugs during the jan-
june 2008. It is observed   that in outdoor patients the most frequently prescribed 
drugs were from the cardiovascular group during that period. Non-steroidal Anti-
inflammatory Drugs (NSAIDs) were the second highest number of prescribed 
drugs.  In indoor patients maximum drugs were prescribed from the 
cardiovascular   drugs. Non-steroidal Anti-inflammatory Drugs (NSAIDs) were 
in the fourth rank of maximum prescribed drugs. [Table-1 (a)] 
b) Eight most commonly Prescribed NSAIDS and their ATC / DDD code. ( Jan-
June 2008): 
 Total eight NSAIDs are prescribed most commonly during the study period. 
Analysis of total number of these most commonly prescribed drugs and their 
DDD has been counted for the year 2008 from Jan-June. 
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  In Orthopaedic outdoor patients Diclofenac was the most frequently prescribed 
NSAID followed by Piroxicam , Paracetamol , Ibuprofen and Indomethacin in 
descending order. In Medicine outdoor patients the most common prescribed 
NSAID was Paracetamol followed by  Diclofenac , Etoricoxib , Ibuprofen and 
Indomethacin in descending order. Aceclofenac and Piroxicam were the almost in 
same quantity and  prescribed in less quantity compare to other NSAIDs. In 
Paediatric outdoor patients the highest number of prescribed NSAID was 
Paracetamol followed by Ibuprofen and Diclofenac. Other NSAIDs were not 
prescribed in paediatric patients. In outdoor patients of above three departments 
use of Nimesulide was nil. In indoor patients of Orthopedic department the most 
frequently prescribed drug was Diclofenac followed by Paracetamol , Ibuprofen , 
Etoricoxib , Nimesulide, Indomethacin and Aceclofenac in descending order. In 
Medicine indoor patient Paracetamol was the most commonly prescribed NSAID. 
Next to Paracetamol , Diclofenac, Piroxicam and  Indomethacin were other 
NSAIDs which is prescribed in descending order. In Pediatric indoor patients 
only Paracetamol was the maximum prescribed drug.  Ibuprofen, Diclofenac & 
Etoricoxib weree next three NSAIDs  which were prescribed in descending order. 
These eight drugs are given ATC code and their number of DDDS is calculated 
according to WHO formula mentioned in methodology. [ Table – 1 (b)] 
c)  Six most commonly prescribed combinations of  NSAIDs  during Jan-June 
2008: 
 Diclofenac + Paracetamol was the most commonly prescribed combination in 
orthopaedic outdoor patients followed by combination of Paracetamol + 
Chlorpheniramine maleate + Caffine.In Medicine outdoor patients the most 
commonly prescribed combination was Paracetamol + Chlorpheniramine maleate 
+ Caffine followed by Diclofenac and Paracetamol combinations. In Pediatric 
outpatients commonly prescribed combination was Paracetamol + 
Chlorpheniramine maleate + Caffine. In Pediatric indoor patients maximum 
number of prescribed combination was same as outdoor patients  
(i.e PCM+CPM+Caffine) followed by combination of Ibuprofen + Paracetamol 
and Diclofenac + Paracetamol in descending order. The number of their DDDs 
was calculated ccording to WHO formula as mentioned in  
methodology. [Table–1 (c)] 
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Table – 1 (a) : Most Common Pharmacological  Group of Drugs Prescribed    
  during Jan - Jun -2008 
OPD IPD 
Sr.No Group Number Sr.No Group Number
1. Cardiovascular Drugs 432679 1. Cardiovascular Drugs 62651 
2. NSAIDs 265694 2. H2 Blocker / PPI 52451 
3. Antidiabetics  132815 3. Antimicrobial 45140 
4. Antimicrobial 130738 4. NSAIDS  24841 
5. H2 Blocker/PPI 122650 5. Vitamins,& Minerals 23377 
6. Vitamins,& Minerals 121900 6. Drugs Acting on CNS 18623 
7. Drugs Acting on CNS 68423 7. Drugs Acting on RS 18020 
8. Drugs Acting on RS 60732 8. Hypolipidemics 7288 
9. Steroid 7642 9. Haematinics 4641 
10. Haematinics 2018 10. Antidiabetic  5405 
11. Hypolipidemics 2135 11. Steroid 5123 
12. Dermal Preparation 1018 12. Dermal Preparation 296 
 
               Table – 1 (b) : Eight most commonly Prescribed NSAIDS and their ATC / DDD code (Jan-June 2008) 
OPD :  January – June 2008 IPD : January – June 2008 
Drugs ATC 
Code 
WHO 
DDD 
Ortho 
DDD 
Med 
DDD 
Ped 
DDD 
Total 
DDD 
Ortho 
DDD 
Med 
DDD 
Ped 
DDD 
Total 
DDD 
Diclofenac  M01AB05 0.1 gm 17552.75 4465 82.75 22100.5 3058.5 560.5 48.75 3667.75
Paracetamol N02BE01 4 gm 4362.6 4952.23 1292.05 10606.88 669.33 1839.85 337.37 2846.55
Piroxicam M01AC01 20 mg 6481 181 0 6662 30 74 0 104
Etoricoxib M01AH05 60 mg 0 864.5 0 864.5 155.5 0 37.5 193
Ibuprofen M01AE01 1.2 gm 1931.17 620.33 166.33 2717.83 280.5 0 67.5 348
Indomethacin M01AB01 0.1 gm 292.25 443 0 735.25 49.5 53.25 0 102.75
Aceclofenac M01AB16 0.2 gm 0 181.5 0 181.5 19.5 0 0 19.5
Nimesulide M01AX17 0.2 mg 0 0 0 0 82 0 0 82
Total  30619.77 11707.57 1541.13 4344.83 2527.6 488.12
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Table – 1 (c) : Six most commonly prescribed combinations of NSAIDs  during Jan-June 2008 
OPD :  January – June 2008 IPD : January – June 2008 
Combinations Ortho 
DDD 
Med 
DDD 
Ped 
DDD
Total 
DDD 
Ortho 
DDD 
Med 
DDD 
Ped 
DDD
Total 
DDD 
Paracetamol + CPM + Cafine 927 8791 333 10051 74 511 73 658
Ibuprofen + Paracetamol 0 0 0 0 0 0 20 20
Diclofenac + Paracetamol 15343 1744 0 17087 513 98 17 628
Aceclofenac + Paracetamol 0 0 0 0 0 0 0 0
Diclofenac+Serratiopeptidase 0 0 0 0 0 0 0 0
Ibuprofen+PCM Susp 0 0 0 0 0 0 0 0
 
2.  PATIENT DETAILS: 
a) Age  and department  wise distribution of patients: 
Out of 1000 patients, 400 patients were taken from Orthopedics department (200 
patients from outdoor, 200 from indoor), 400 from Medicine department (200 patients 
from outdoor, 200 from indoor), and 200 from Pediatrics department (100 from 
outdoor, 100 from indoor). Majority of patients were in age group of 1-18 years (257, 
25.7%), followed by age group of 41-50 years (216, 21.6%), and lowest number of 
patients (88, 8.8%) were in the age group of 19-30 years.   [Table-2 (a)] 
b)  Sex and Department wise distribution of patients: 
Out of total 1000 patients 538 (53.8%) were female and 462(46.2%) were male. Out 
of 400 patients of orthopedic department 210(52.5%) were female and 190(47.5%) 
were male. Out of 400 patients of medicine department patient 222(55.5%) were 
females and178 (44.5%) were males. Total 200 patients of paediatric department 
106(53%) were female and 94(47%) were male.   [Table-2 (b) , Fig.1] 
c)  Age and sex wise distribution of patients: 
Table-2 (c) shows age and sex wise distribution of patients. Out of 1000 patients, the 
total number of male patients was 462 and female patients were 538.  
Out of 462 male patients; 131(28.4%) were in the age group of 1-18 years, 53 (11.5%) 
were in the age group of 19-30 years, 53 (11.5%) were in the age group of 31-40 
years, 115 (24.9%) were in the age group of 41-50 years, 80 (17.3%) were in the age 
group of 51-60 years and 30(6.5%) patients having more than 60 years of age.  
Out of 538 female patients; 126(23.4%) were in the age group of 1-18 years, 35 
(6.5%) were in the age group of 19-30 years,104 (19.3%) were in the age group of  
31-40 years, 101 (18.8%) were in the age group of 41-50 years, 93 (17.3%) were in 
the age group of 51- 60 years and 79(14.7%) patients having more than 60 years of 
age.   [Fig.2] 
d) Diseases/Conditions prevalence: 
Out of 1000 patients, 400 patients who were in orthopedics department were 
obviously suffering from musculoskeletal disorders. In medicine department the total 
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400 patients were taken for study of their disorder. Amongst them 100(25.0%) 
patients were suffering from musculoskeletal system related disorders, 39 (9.75%) 
were suffering from cardiovascular disorders and 261(62.25%) were suffering from 
various infections. In pediatrics department the total 200 patients were taken for study 
of their disorder. Amongst them 21(10.5%) patients were suffering from 
musculoskeletal system related disorders and 179(89.5%) were suffering from various 
infections. [Table-2(d) , Fig.3] 
e) Presence of Co-morbid conditions: 
Out of total 1000 patients 817(81.7%) were suffering from one disease, remains 
183(18.3%) patients were suffering from more than one diseases simultaneously.  
Co-morbid conditions are prevalent in 183(18.3%) patients.  [Table-2(e)] 
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 2BTable - 2(a) : Age and Department wise distribution 
Dept 
Age In Year 
Ortho n (%) Med n(%) PED n(%) 
Total 
n(%) 
1-18 29 (7.25) 28(7.0) 200(100.0) 257(25.7)
19-30 36(9.0) 52(13) 0(.0) 88(8.8)
31-40 76(19.0) 81(20.25) 0(.0) 157(15.7)
41-50 112(28.0) 104(26.0) 0(.0) 216(21.6)
51-60 94(23.5) 79(19.75) 0(.0) 173(17.3)
> 60 53(13.25) 56(14.0) 0(.0) 109(10.9)
Total 400(100) 400(100) 200(100) 1000(100)
 
3BTable-2(b) : Sex and Department wise distribution 
Department 
Male 
n (%) 
Female 
n (%) 
Total 
n (%) 
Ortho 190(47.5) 210(52.5) 400(100) 
Medicine 178(44.5) 222(55.5) 400(100) 
PED 94(47) 106(53) 200(100) 
Total 462 (46.2) 538 (53.8) 1000(100) 
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Table-2(c) : Age and Sex Distribution 
Age (in years) 
Male 
n (%) 
Female 
n (%) 
Total 
n (%) 
1-18 131(28.4) 126 (23.4) 257 (25.7)
19-30 53 (11.5) 35 (6.5) 88(8.8)
31-40 53 (11.5) 104 (19.3) 157 (15.7)
41-50 115 (24.9) 101(18.8) 216(21.6)
51-60 80 (17.3) 93 (17.3) 173 (17.3)
> 60 30(6.5) 79 (14.7) 109 (10.9)
Total 462 (100) 538 (100) 1000 (100)
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4BTable - 2(d) : Diseases/Conditions Prevalence 
Department 
Diagnosis Orthopaedics 
n (%) 
Medicine 
n (%) 
Paediatrics 
n (%) 
Total 
n (%) 
Musculoskeletal 400(100) 100(25) 21(10.5) 521(52.1)
CVS 0 (0) 39(9.75) 0 (0) 39(3.9)
Infection 0(0) 261(65.25) 179(89.5) 440(44)
Total 400(100) 400(100) 200(100) 1000(100)
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Table -2(e): Co-morbid Conditions 
No. of Diseases No. of Patient Percent 
One  817 81.7 
Two/more  183 18.3 
Total 1000 100.0 
 
3.       Analysis of NSAIDs used: 
a)       Pattern of use of NSAIDs: 
Total 1000 patients who received NSAIDs, 888 patients received different NSAIDs 
and 112 patients received fixed dose combinations. Out of 888 patients,802 patients 
received COX- 1 inbitors. Paracetamol was the highest number of prescribed drug 
(503, 56.65%). The second highest prescribed drug was Ibuprofen (102 patients), 
leaving Diclofenac (71) and Piroxicam (66) third and fourth number of frequently 
prescribed drugs respectively. Minimal prescriptions were found of Aceclofenac  and 
Indomethacin, 43 (4.84%) and 17 (1.91) respectively. During analysis Nimesulide 
was considered as COX-2 inhibitors with Etoricoxib. Total 86 patients received COX-
2 inhibitors, from that total number of prescriptions of Nimesulide and Etoricoxib was 
51 (5.74%) and 35(3.94) respectively [Table-3 (a)].  
(b) Age wise distribution of COX inhibitors: 
Out of 1000 patients 756 (75.6%) received COX-1 inhibitors, out of which 
233(30.8%) were in the age group of 1-18 years, 152(20.1%) in the age group of 41-
50 years, 122(16.1%) in the age group of 51-60 years, 111(14.7%) were in the age 
group of 31-40 years, 79 (10.4%) were in the age group of greater than 60 years, and 
59(7.8%) were in the age group of 19-30 years. 
In 70 (7.0%) patients COX 2 inhibitors were used, of which 36 patients were from the 
age grope of 41-50 years and 51-60 years (18 patients in each group) balance 34 
patients were from the remaining age groups. Forty six (4.6%) and 16(1.6%) patients 
received simultaneously two COX -1 inhibitors and COX 1 & 2 inhibitors 
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respectively. When these results were subjected to statistical analysis by applying chi-
square test of association, the p-value was found to be less than 0.0001  [Table-3 (b)] 
c) Sex wise distribution of COX inhibitors: 
Out of 462 male patients 352(76.2%) patients received  single COX-1 inhibitor, 
18(3.9%) patients received two COX -1 inhibitors in separate formulation, where as 
35(7.6%) received single COX 2 inhibitor and 5(1.1%) patients received both COX-1 
and COX-2 inhibitors individually.  
Out of the 538 female patients 404(74.7%) patients received  single COX-1 inhibitor,  
28(5.2%) patients received two COX -1 inhibitors in separate formulation, where as 
35(6.9%) received single COX 2 inhibitor and 11(2.0%) patients received both COX-
1 and COX-2 inhibitors individually. 
Among 112 patients, who received combinations, 60(11.2%) patients were females 
and 52(11.3%) patients were male. [Table-3 (c) , Fig.4] 
d) Age wise distribution of combinations of NSAIDs: 
The table-3(d) shows the data of combinations of different drugs prescribed in 
various age groups. Out of 112 patients maximum combinations (31 combinations) 
were prescribed in age group 41-50 years,  the second  highest (20 combinations) 
were  in age group of 31-40 years. Seventeen combinations each, have been 
prescribed in age group of 19-30 years, 51-60 years and more than 60 years. 
Minimum (10 combinations) were prescribed in age group of 1-18 years. Out of 112 
patients the most common combinations were Diclofenac + Paracetamol (49, 44%) 
followed by Ibuprofen + Paracetamol (42, 37%).  
As shown in table -3(C) more numbers of combinations (60 patients) were prescribed 
in female patients than male (52 patients.) 
e)  Age wise Distribution of Use of Over The Counter (OTC) NSAIDs: 
Out of 216 patients in age group of 41-50 years, 211(97.69%) used OTC drugs, whereas 
remaining 5 patients did not  use  OTC drug. Among the 173 patients of  51-60 years of age 
only 1 patient  did not use OTC drug and remaining all 172(99.42%) patients used OTC 
drugs. All 109(100%) patients of 60 years of age used OTC drugs. From the total of 157 
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patients,138 (87.90) have used OTC drugs and 19 (12.10%) patients did not use OTC drugs 
in the  age group of 31-40years. 
 Less number of uses of OTC was in the age group of 1-18 years and 19-30 years (i.e 62 
and 58 patients respectively). When these results were subjected to statistical analysis 
by applying chi-square test of association, the p-value was found to be less than 
0.0001  [Table-3 (e)] 
Table - 3(a) : Use of NSAIDs 
Sr.No. Name of Drug No. of Prescriptions percentage 
1 Aceclofenac 43 4.84 
2 Diclofenac 71 8.0 
3 Etoricoxib 35 3.94 
4 Ibuprofen 102 11.49 
5 Indomethacin 17 1.91 
6 Nimesulide 51 5.74 
7 Paracetamol 503 56.65 
8 Piroxicam 66 7.43 
TOTAL 888 100 
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5BTable - 3 (b) : Age wise distribution of Cox inhibitors 
COX Inhibitors 
Age 
(years) COX -1 
n (%) 
COX (1& 1) 
n (%) 
COX 2 
n (%) 
COX(1&2)
n (%) 
Combination 
n (%) 
Total 
n (%) 
1-18 233(30.8) 6 (13) 6 (8.6) 2 (12.5) 10(8.9) 257(25.7)
19-30 59 (7.8) 7(15.2) 4(5.7) 1(6.2) 17(15.2) 88 (8.8)
31-40 111(14.7) 9(19.6) 16(22.9) 1 (6.2) 20(17.9) 157(15.7)
41-50 152(20.1) 13(28.3) 18(25.7) 2(12.5) 31(27.7) 216(21.6)
51-60 122(16.1) 9(19.6) 18(25.7) 7(43.8) 17(15.2) 173(17.3)
> 60 79 (10.4) 2(4.3) 8 (11.4) 3(18.8) 17(15.2) 109(10.9)
Total 756(100) 46(100) 70(100) 16(100) 112(100) 1000(100)
6BChi  χ2 – 63.347, P value < 0.0001 
7BTable - 3 (C) : Sex wise distribution of Cox inhibitors 
COX Inhibitors 
Male 
n (%) 
Female 
n (%) 
Total 
n (%) 
COX -1 352 (76.2) 404 (74.7) 756 (75.4)
COX (1 & 1) 18 (3.9) 28 (5.2) 46 (4.6)
COX 2 35 (7.6) 35 (6.9) 70 (7)
COX (1 & 2) 5 (1.1) 11 (2.0) 16 (1.6)
Combination 52 (11.2) 60 (11.2) 112 (11.2)
Total 462 (100) 538 (100) 1000 (100)
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Fig – 4: Sex Wise distributi n of Cox inhibitors 
8BTable - 3 (d) : Age wise distribution of Combinations of NSAIDs 
Age in years 
Combinations 1-18 
n(%) 
19-30 
n(%) 
31-40 
n(%) 
41-50 
n(%) 
51-60 
n(%) 
> 60 
n(%) 
Total 
n(%) 
Acelofenac  +  
Paracetamol 0(0) 0(0) 2(10) 0(0) 3(18) 2(12) 7(6)
Paracetamol+ 
Ceterizine + 
Phenylpropalamine 
0(0) 0(0) 1(5) 0(0) 0(0) 0(0) 1(1)
Nimesulide + 
Paracetamol 1(10) 2(12) 2(10) 4(13) 1(6) 0(0) 10(9)
Diclofenac + 
Paracetamol 4(40) 7(41) 9(45) 12(39) 7(41) 10(59) 49(44)
Diclofenac + 
Paracetamol + 
Serratiopeptidase 
1(10) 0(0) 0(0) 1(3) 0(0) 0(0) 2(2)
Ibuprofen+ 
Paracetamol 4(40) 7(41) 6(30) 14(45) 6(35) 5(29) 42(37)
Diclofenac+ 
Dicyclomine 0 1(6) 0 0 0 0 1(1)
Total 10(100) 17(100) 20(100) 31(100) 17(100) 17(100) 112(100) 
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 Table - 3 (e) : Age wise distribution of use of over the counter (OTC) NSAIDs 
OTC Age 
NO (%) YES (%) 
Total (%) 
1-18 195 (75.88) 62(24.12) 257 (100) 
19-30 30 (34.10) 58(65.90) 88 (100) 
31-40 19 (12.10) 138(87.90) 157(100) 
41-50 5 (2.31) 211 (97.69) 216 (100) 
51-60 1 (0.58) 172 (99.42) 173 (100) 
> 60 0 (0) 109 (100) 109 (100) 
Total 250 (25) 750 (75) 1000 (100) 
  9BChi  χ2 – 523.229 , P value < 0.0001 
4. Use of gastroprotective agents: 
a)  Age wise distribution of Gastro protective agents: 
Out of 1000 patients 456 (45.6%) patients received gastro protective agents  while 
544(54.4%) did not received gastro protective agents. Out of 257 patients, 43 
(16.73%) received gastro protective agents in the age group of 1-18 years.  In the age 
group 19-30 years 47 (53.41%) received gastro protective agents out of 88 patients. 
Total 157 patients in the age group 31-40 years 91 (57.96%) patients received & 66 
(42.04%) did not received gastro protective agents. In the age group of 41-50 years of 
age 126(58.33%) patients received gastro protective agents while 90 (41.67%) 
patients did not received gastro protective agents from total of 216 patients. From the 
total of 173 patients 91(52.60%) received & 82(47.40%) did not received gastro 
protective agents .Out of 109 patients of age group more than 60 years, 58 (53.21%) 
patients received & 51(46.79%) did not received gastro protective agents. When these 
results were subjected to statistical analysis by applying chi-square test of association, 
the p-value was found to be less than 0.0001   [Table-4(a), Fig.5] 
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b) Sex wise distribution of Gastro protective agents: 
Out of 462 male patients, 211(45.67%) received and 251 (54.33%) did not received 
gastroprotective agents. Out of 538 female patients 245(45.54%) received and 
293(54.46%) patients did not received gastroprotective agents. When these results 
were subjected to statistical analysis by applying chi-square test of association, the p-
value was found to be less than 0.0001 [Table-4 (b), Fig.6] 
Table- 4 (a) : Age wise distribution of Gastro protective agents 
Gastro protective agents 
Age 
Not Prescribe (%) Prescribe (%) 
Total (%) 
1-18 214 (83.27) 43 (16.73) 257 (100)
19-30 41 (46.59) 47(53.41) 88(100)
31-40 66(42.04) 91(57.96) 157(100)
41-50 90(41.67) 126(58.33) 216(100)
51-60 82 (47.40) 91(52.60) 173(100)
> 60 51(46.79) 58(53.21) 109(100)
Total 544 (54.4) 456 (45.6) 1000 (100)
 10BChi  χ2 –118.258 , P value < 0.0001 
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Table - 4 (b) : Sex wise distribution of Gastro protective agents 
11BGastro protective agents  Sex 
  Not Prescribe(%) Prescribe(%) 
 
Total(%) 
Male 251( 54.33) 211(45.67) 462(100) 
Female 293(54.46) 245(45.54) 538(100) 
Total 544(54.4) 456(45.6) 1000(100) 
  12BChi  χ2 –0.002 , P value < 0.967 
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Fig-6 Sex wise distribution of Gastro protective agents 
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5. Analysis of Adverse Drug Reactions (ADRs): 
a) Frequency and distribution of ADRs: 
Out of 1000 patients, 192(19.2%) developed ADRs. A detailed analysis of these 
reports is given below.  
b) Department wise distribution of ADRs: 
Out of 400 Orthopedic patients 104 (26%) developed ADR & 296 (74%) patients did 
not suffer from any ADR. In Medicine department 81 (20.25%) patients observed 
ADR and 319 (79.75%) patients reflected no ADR. Out of 200 patients from 
Paediatric department only 7 (3.5%) experienced ADR & remaining 193 patients did 
not. When these results were subjected to statistical analysis by applying chi-square 
test of association, the p-value was found to be less than 0.0001.  [Table-5 (b), Fig.7] 
c-1) Age wise distribution of ADRs: 
Out of 257 patients in the age group of 1-18 years, ADRs occurred in  
20(7.78%)patients, rest of 237 patients did not experience ADR .In the age group of 
19-30 years 9 (10.23%)patients suffered  from ADR & 79 (89.77%) did not have 
ADR from  the total of 88 patients. From 157 patients, 27 (17.20%) patients developed 
ADR in the age group 31-40 years. The highest number of ADR was observed in the 
age group of above 60 years (i.e. 38.53%), the second highest in the age group of 41-
50 years (i.e. 25.93%). In the age group of 51-60 years 38(21.97%) patients developed 
ADR. When these results were subjected to statistical analysis by applying chi-square 
test of association, the p-value was found to be less than 0.0001. [Table-5(c-1), Fig-8] 
c-2) Sex wise distribution of ADRs: 
Out of 462 male patients 69(14.94%) suffered from ADR & the rest 393(85.06%) 
patients did not suffered. Total 538 female patients 123(22.86%) suffered from ADR 
& remaining of 450(77.14%) did not. When these results were subjected to statistical 
analysis by applying chi-square test of association, the p-value was found to be less 
than 0.0001.   [Table-5 (c-2), Fig-9] 
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d) ADRs and OTC medicine: 
Out of 1000 patients, 750 patients who consumed over the counter NSAIDs 
183(24.40%) patients developed ADR while rest of 567(75.60%) did not. From 250 
patients who did not take any over the counter NSAIDs, 9(3.60%) patients developed 
ADR. When these results were subjected to statistical analysis by applying chi-square 
test of association, the p-value was found to be less than 0.0001.  [Table-5(d), Fig-10] 
e) System wise distribution of ADRs: 
Majority of adverse drug reactions involved Gastrointestinal system. Out of 192 
ADRs, 52(27.0%) ADRs were from Gastrointestinal system followed by 
Cardiovascular system (48, 25.0 %). The other affected systems were Central Nervous 
System (32, 16.6 %) and Respiratory system (1, 0.5%). Liver, Kidney, Skin, 
Heamatological and Eye disorder were observed in 11, 12, 6, 10 and 9 patients 
respectively. Seven patients developed edema.       [Table-5(e)] 
13Bf) Age wise distribution of symptoms of ADRs: 
In age group of 1-18 years the major adverse effect was gastritis and decreased 
appetite, followed by headache and nausea. In age group of 19-30 years the major 
adverse effect was gastritis, anemia and urticaria. In age group of 31-40 years the 
most common adverse effect was again gastritis followed by palpitation and increased 
B.P. In age group of 41-50 years the most prevailing adverse effect was gastritis, 
followed by increased B.P., Palpitation and headache. In age group of 51-60 years the 
gastritis seen most likely adverse effect in patients. In age group more than 60 years 
again gastritis was the most prevailing adverse effect followed by blurred vision and 
decreased urination and heapatoxicity.  [Table-5 (f)] 
g-1) Non Steroidal Anti-inflammatory drug  (NSAIDs)and ADRs: 
Out of 192 patients who suffered from ADR, 150 patients suffered due to either single 
or parallel COX 1 and COX 2 inhibitors, remaining 42 patients suffered due to the 
combinations of NSIADS. Total 6 drugs were prescribed from the COX 1 inhibitors, 
out of which, it was observed that the maximum causative drug was Diclofenac 
(50.70%). The following sequences of causative COX 1 inhibitors were found to be 
Indomethacin (32.35 %), Ibuprofen (32.14 %), Piroxicam (30.30 %), Paracetamol 
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(5.77 %) and Aceclofenac (2.32 %). In the study COX 2 inhibitors represented 
Etoricoxib and Nimesulide having ADR of 21.57 % and 37.14% respectively. The 
combination of prescriptions represented ADR in 42 patients. [Table-5 (g-1)] 
g-2) Combinations and ADRs: 
Total 112 patients received different combination of NSAIDs from that 42 patients 
suffered from ADRs. It was observed that the maximum prescriptions (49) contained 
combinations of Diclofenac + Paracetamol constituting of 20 (40.81 %) patients, who 
suffered ADR. The descending order of the prescribed combinations were Iburpofen + 
Paracetamol (42), Nimesulide + Paracetamol (10) and Aceclofenac + Paracetamol (7) 
depicting 13 (30.95 %), 6 (60 %) and 1 (14.28%) patients suffered from ADR. 
Combinations of Diclofenac + Dicyclomin and Paracetamol + Cetrizine + 
Phenylpropalamine were prescribed to 1 patient each, having accounted of ADR 
(i.e. 100%).Two patients received combinations of Paracetamol + Diclofenac + 
Serratiopeptidase, none of them were observed to be suffering from  
ADR [Table - 5 (g-2)]. 
h-1) Causality Assessment of ADRs: 
The causality assessment of the ADRs was carried out using WHO scale. The analysis 
using WHO scale showed that in majority of the cases, a causality association was falling in 
the category of possible 137(71.4%) and probable 40(20.8%) while in no case it found to be 
certain. A causality association was falling in the category of unlikely 14(7.3%) and 
conditional 1(0.5%). Causality was also assessed using Naranjo’s algorithm. This is an 
objective questionnaire based method of evaluation. The common association was of 
possible (155, 80.72%) and probable (18, 9.37%) categories by this method. When these 
results were subjected to statistical analysis by applying chi-square test of association, 
the p-value was found to be less than 0.0001 [Table-5 (h-1), Fig-11] 
h-2) Assessment of agreement between Naranjo & WHO scale: 
Further analysis of the assessment of ADRs was carried out to compare the agreement of 
the Naranjo scale with the WHO scale. Out of 192 ADRs , two ADRs were eliminated (i.e. 
one from each scale) for the feasibility  of the performance of the test. One hundred and 
ninety ADRs were included. Observed agreement was not found good ( Kappa = 0.18, 
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weighted kappa = 0.21). It suggest that  the assessment of the ADRs by Naranjo scale is fair 
but not good. [Table-5 (h-2)] 
i) Onset of ADR: 
Amongst 192 patients ,102(53.0%) patients  developed  ADRs within 3 days of 
period, 62 (32.0%) developed after 4-7 days of period and 28 (15.0%) patients  
developed  after 8-30 days of period.   [Table-5 (i)] 
j) Severity of ADR: 
Out of 192 (19.2%) patients with adverse drug reactions, 169 (88.0%) were mild 
ADRs. In 23 (12.0%) cases it was moderate in nature. While there was no case of  
severe ADRs observed.  [Table-5 (j),Fig.12]  
14Bk)  Preventability of ADR: 
15BThe preventability assessment of ADRs was carried out using modified Schmock and 
Thornton scale. It is evident that majority of ADRs (170,88.54%) were probably 
preventable. Twenty (10.41%) ADRs were definitely preventable and 2 (1.05%) were 
found not preventable.   [Table-5(k), Fig.13] 
Table - 5 (b) : Department wise distribution of ADRs 
ADR Total 
Department No 
n (%) 
Yes 
n (%) 
No 
n (%) 
Ortho 296(74) 104(26) 400(100)
Med 319(79.75) 81(20.25) 400(100)
Ped 193(96.50) 7(3.50) 200(100)
Total 808(80.80) 192(19.20) 1000(100)
       16BChi  χ2 – 43.984 , P value < 0.0001 
 
 
65 
104
81
7
0
20
40
60
80
100
120
Ortho Med Ped
Ax
is 
Tit
le
Department
Fig 11 C: Department and ADRFig-7: Department wise distribution of AD s 
 
17BTable - 5 (c1) : Age wise distribution of ADRs 
ADR 
Age in years 
 
No 
n (%) 
Yes 
n (%) 
Total No 
n (%) 
1-18 237 (92.22) 20 (7.78) 257(100) 
19-30 79(89.77) 9(10.23) 88(100) 
31-40 130(82.80) 27(17.20) 157(100) 
41-50 160(74.08) 56(25.92) 216(100) 
51-60 135(78.04) 38(21.96) 173(100) 
> 60 67(61.47) 42(38.53) 109(100) 
Total 808(80.80) 192(19.20) 1000(100) 
  18BChi  χ2 – 59.980 , P value < 0.0001 
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19BTable - 5 (c2)  : Sex wise distribution of ADRs 
ADR 
Sex No 
n (%) 
Yes 
n (%) 
Total 
n (%) 
Male 393 (85.7) 69 (14.93) 462 (100)
Female 415 (77.14) 123 (22.86) 538 (100)
Total 808 (80.80) 192 (19.20) 1000 (100)
     20BChi  χ2 – 10.069 , P value < 0.002 
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Table - 5(d) : ADRs and OTC medicine 
ADR 
OTC No 
n (%) 
Yes 
n (%) 
Total 
n (%) 
No 241 (96.40) 9 (3.60) 250 (100)
Yes 567 (75.60) 183 (24.40) 750 (100)
Total 808 (80.80) 192 (19.20) 1000 (100)
  21BChi  χ2 – 52.290 , P value < 0.000 
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22BTable - 5 (e) : System wise distribution of ADRs 
Affected System Patients Percent 
Cardiovascular System 48  
Increased B.P. 34 17.7 
Palpitation 14 7.3 
Gastrointentestinal system 52  
Gastritis 29 15.1 
Diarrhoea 4 2.1 
Vomiting 7 3.6 
Constipation 1 .5 
Nausea 6 3.1 
Decresed appetite 9 4.7 
Respiratory System 1  
Breathlessness 1 .5 
Central nervous system 32  
Headache 15 7.8 
Confusion 3 1.6 
Giddiness 12 6.3 
Paresthesia 2 1.0 
Eye 9  
Blurred vision 9 4.7 
Electrolyte imbalance 7  
Edema 7 3.6 
Heamatology 10  
Anemia 6 3.1 
Decreased T.C. 4 2.1 
Liver 11  
Hepatotoxicity 11 5.7 
Kidney 12  
Increased creatinine 2 1.0 
Decrese Urination 10 5.2 
Skin 6  
Urticaria 6 3.1 
Total 192 100.0 
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23BTable - 5(f) : Age wise distribution of symptoms of ADRs 
Age 
Name 1-18 
n (%) 
19-30 
n (%) 
31-40 
n (%) 
41-50 
n (%) 
51-60 
n (%) 
> 60 
n (%) 
Total 
n (%) 
Increased B.P. 0(0) 0(0) 3(11.1) 5(8.9) 12(31.6) 14(33.3) 34(17.7)
Palpitation 1(5) 1(11.1) 4(14.8) 4(7.1) 3(7.9) 1(2.4) 14(7.3)
Gastritis 4(20) 2(22.2) 6(22.2) 10(17.9) 4(10.5) 3(7.1) 29(15.1)
Diarrhoea 0(0) 0(0) 1(3.7) 1(1.8) 1(2.6) 1(2.4) 4(2.1)
Vomiting 3(15) 0 (0) 1(3.7) 2(3.6) 1(2.6) 0(0) 7(3.6)
Constipation 0(0) 0(0) 0(0) 0(0) 0(0) 1(2.4) 1(0.5)
Nausea 3(15) 0(0) 1(3.7) 2(3.6) 0(0) 0(0) 6(3.1)
Decreased 
appetite 4(20) 0(0) 1(3.7) 1(1.8) 3(7.9) 0(0) 9(4.7)
Breathlessness 0(0) 0(0) 1(3.7) 0(0) 0(0) 0(0) 1(0.5)
Headache 3(15) 0(0) 3(11.1) 5(8.9) 3(7.9) 1(2.4) 15(7.8)
Confusion 0(0) 0(0) 0(0) 1(1.8) 1(2.6) 1(2.4) 3(1.6)
Giddiness 1(5) 1(11.1) 2(7.4) 3(5.4) 3(7.9) 2(4.8) 12(6.3)
Paresthesia 0(0) 0(0) 0(0) 0(0) 0(0) 2(4.8) 2(1)
Blurred vision 1(5) 0(0) 0(0) 2(3.6) 3(7.9) 3(7.1) 9(4.7)
Oedema 0(0) 0(0) 1(3.7) 4(7.1) 1(2.6) 1(2.4) 7(3.6)
Anaemia 0(0) 2(22.2) 1(3.7) 2(3.6) 1(2.6) 0(0) 6(3.1)
↓ed total count 0(0) 0(0) 1(3.7) 3(5.4) 0(0) 0(0) 4(2.1)
Heapatoxicity 0(0) 1(11.1) 1(3.7) 5(8.9) 1(2.6) 3(7.1) 11(5.7)
↑ed creatinine 0(0) 0(0) 0(0) 0(0) 0(0) 2(4.8) 2(1)
↓ed Urination 0(0) 0(0) 0(0) 4(7.1) 1(2.6) 5(11.9) 10(5.2)
Urticaria 0(0) 2(22.2) 0(0) 2(3.6) 0(0) 2(4.8) 6(3.1)
Total 20(100) 9(100) 27(100) 56(100) 38(100) 42(100) 192(100)
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24BTable - 5 (g-1) : Causal NSAIDs 
Drug Prescribe No. of ADR Percent 
Aceclofenac 43 1 2.32 
Diclofenac 71 36 50.70 
Etoricoxib 35 13 37.14 
Ibuprofen 102 33 32.35 
Indomethacin 17 7 41.18 
Nimesulide 51 11 21.57 
Paracetamol 503 29 5.77 
Piroxicam 66 20 30.30 
Combination 112 42 37.5 
Total 1000 192 19.20 
 
25BTable - 5 (g-2) : Causal Combinations 
Combinations Prescribed No. of ADR Percentage 
Ibuprofen + Paracetamol 42 13 30.95 
Diclofenac + Paracetamol 49 20 40.81 
Nimesulide + Paracetamol 10 6 60 
Diclofenac + Dicyclomine 1 1 100 
Paracetamol + Cetrizine + 
Phenylpropalamine 
1 1 100 
Aceclofenac + Paracetamol 7 1 14.28 
Diclofenac + Paracetamol 
+ Serratiopeptidase 
2 0 0 
Total 112 42 37.5 
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26BTable - 5(h-1) : Causality Assessment of ADRs 
Causality category 
WHO Scale 
Number of ADRs 
n (%) 
Naranjo Scale 
Number of ADRs 
n (%) 
Certain/Definite 0(0) 1(0.52) 
Probable 40(21) 18(9.37) 
Possible 137(71) 155(80.72) 
Unlikely/Doubtful 14(7) 18(9.37) 
Conditional 1(1) NA 
Total 192(100) 192(100.0) 
  27BChi  χ2 – 3.393 , P value < 0.494 
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Table - 5(h-2) : WHO – UMC scale 
WHO – UMC scale 
Naranjo 
scale 
Probable Possible Doubtful 
 
Total 
Probable 9  9  1  19 
Possible  29  115  9 153 
Doubtful 2  12  4 18 
TOTAL  40  136  14 190 
 Kappa = 0.175, Weighted kappa with quadratic weights = 0.21  
28BTable - 5(i) : Onset of ADR 
Day Total 
1-3 Days 102(53.00%) 
4-7 Days 62(32.00%) 
8-30 Days 28(15.00%) 
Total 192(100.0%) 
 
29BTable - 5(j) : Severity of ADR 
Severity 
Total 
n (%) 
Mild 169(88) 
Moderate 23(12) 
Sever 0 
Total 192(100) 
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Fig-12: Severity of ADR 
  
                                    30BTable - 5(k) : Preventability of ADR 
Preventability 
Total 
n (%) 
Definitely 20(10.41) 
Probably 170(88.54) 
Not Preventive 2(1.05) 
Total 192(100) 
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6) Outcome of ADR 
It shows 50 (26.2%) patients have been cured, 119 (61.9%) patients have been relived and 
in 23 (11.9%) patient  the condition remains same. [Table-6, Fig.14] 
Table - 6 : Outcome of ADR 
Outcome Total 
Cured 50(26.2%)
Relived 119(61.9%)
Same 23(11.9%)
Total 192(100.0%)
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75 
31BTable - 7 : Univariate analysis of significant factors associated with ADR  
ADR 
No Yes 
Pearson 
Chi-Square Tests 
Study 
Parameters 
Variables 
Categories Number N % Number N % 
Chi-
square df Sig. 
Ortho 296 74 104 26 
Med  319 79.75 81 20.25 Dept 
PED  193 96.5 7 3.5 
43.98 2 0.0001
1-18 237 92.22 20 7.78 
19-30 79 89.77 9 10.23 
31-40 130 82.80 27 17.20 
41-50 160 74.08 56 25.92 
51-60 135 78.03 38 21.97 
Age 
> 60 67 61.47 42 38.53 
59.98 5 0.0001
Male 393 85.06 69 14.94 
Sex 
Female 415 77.14 123 22.86 
10.07 1 0.0015
Cox (1 & 1) 26 56.52 20 43.48 
Cox 1 650 85.98 106 14.02 
Cox 2 50 71.43 20 28.57 
Cox (1 & 2) 12 75 4 25 
Cox 
Combination 70 62.5 42 37.5 
58.27 4 0.0001
Not Prescribe 406 74.63 138 25.37 Gastro 
Protective 
agents Prescribe 402 88.16 54 11.84 
29.25 4 0.0001
No 241 96.40 9 3.60 
OTC 
Yes 567 75.60 183 24.40 
52.29 1 0.0001
One Disease 681 83.35 136 16.65 
Co Morbid 
Conditions Two or more 
diseases 127 69.40 56 30.60 
18.76 1 0.0001
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Table -7 shows the univariate analysis of significant factors associated with ADRs. 
The analysis related to the different department shows that total 400 patients from the 
orthopedic department, 296(74%)  patients did not suffered from ADRs, while  in 
104(26%) patients ADRs were observed. It was further observed that 81(20.25%) 
patients suffered from ADRs from the total of 400 patients from medicine department, 
while among the Pediatrics patients only 7 patients observed ADRs from the total of 
200 patients. When the results were subjected to statistical analysis by  
applying chi-square test of association, the p- value found to be less than  
0.0001 (χ2 = 43.98 , p < 0.0001). 
The second variable studied was Age. While analyzing association between age and 
ADRs, it was found that in the age group of 1-18 years, 20(7.78%) patients developed 
ADRs. In the age group of 19-30 years, 9(10.23%) patients found with ADRs. Twenty 
seven (17.20%) patients in the age group of 31-40 years, developed ADRs. In the age 
group of 41 – 50 years, 56(25.92%) patients suffered from ADRs. Thirty eight 
(21.97%) patients of ADRs were from the age group of 51-60 years. Though  number 
of patients who received NSAIDs were less in the age grope of  more than a 60 years ( 
109 patients) the number of ADRs were more  (42 patients,38.53%). When the results 
were subjected to statistical analysis by applying chi-square test of association, the p- 
value found to be less than 0.0001 (χ2 = 59.98 , p < 0.0001). 
Gender was taken as another dependent variable to see the effect of ADRs. In the 
study, total 462 male patients received NSAIDs, from that 69(14.94%) patients  
developed  ADRs. Females patient who received NSAIDs were more than male 
patients who received NSAIDs. Out of 538 female patients, 123(22.86%) developed 
ADRs. When the results were subjected to statistical analysis by applying chi-square 
test of association, the p- value found to be less than 0.001 (χ2 = 10.07 , p < 0.001). 
In the study, to observe the association between cyclo-oxygenase inhibitors and 
ADRs, four groups were made for the analysis. The first group was the patients who 
received single Cyclo-oxygenase-1(COX-1) inhibitors. Total 756 patients included in 
this group, from those, 106 (14.06%) patients developed ADRs. The second group 
consisting of 46 patients who received two individual COX-1 in same prescription 
(i.e. COX-1 & COX-1) from those 20 (43.48%) patients developed ADRs.  During 
analysis Nimesulide was considered as COX-2 inhibitor. It was observed that two 
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drugs (i.e. Nimesulide and Etirocoxib) were frequently prescribed as COX-2 
inhibitors. Total 86 (70+16), COX-2 inhibitors were prescribed in the study which 
included the patients from the third group who received single COX-2 inhibitors as 
well as those patients who received both(i.e.COX-1 and COX-2) simultaneously in 
same prescription. The total number of patients who received single COX-2 inhibitors 
was 70. Out of those 70 patients 20 (28.57%) patients developed ADRs. The fourth 
group of the patients was those who received COX-1 and COX-2 inhibitors both 
simultaneously in same prescription. Only 16 patients fall in this group for analysis of 
those 4(25%) of them developed ADRs. The patients who received fixed dose 
combination of NSAIDs were taken into separate group. Total 112 patients received 
NSAIDs combinations, from that 42(37.50%) patients developed ADRs. When the 
results were subjected to statistical analysis by applying chi-square test of association, 
the p- value found to be less than 0.0001 (χ2 = 58.27 , p < 0.0001). 
Out of 544 patients, 138(25.37%) developed ADRs, who did not received gastro 
protective agents. Among 456 patients who received gastro protective agents 54 
(11.84%) patients developed symptoms of ADRs. When the results were subjected to 
statistical analysis by applying chi-square test of association, the p- value found to be 
less than 0.0001 (χ2 = 29.25 , p < 0.0001). 
Majority of the patients (750 patients) used some or other over the counter NSAIDs. 
From that 183(24.40%) patients developed ADRs. Out of 250 patients who did not 
take any over the counter NSAIDs, only 9(3.6%) patients developed ADRs. When the 
results were subjected to statistical analysis by applying chi-square test of association, 
the p- value found to be less than 0.0001 (χ2 = 52.29 , p < 0.0001). 
Out of 1000 patients, maximum (817 patients) were suffering from one disease, rest 
of them (183 patients) were suffering from either two or more co-morbid conditions. 
Among 817 patients, 136 (16.65%) developed ADRs. Among 183 patients who 
suffered from two or more co-morbid conditions, 56 (30.60%) of them developed 
ADRs. When the results were subjected to statistical analysis by applying chi-square 
test of association, the p- value found to be less than 0.0001 (χ2 = 18.76 , p < 0.0001). 
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Table : 8 (i) - Classification   table    
Predicted 
ADR Observed 
No Yes 
Percentage 
No 804 4 99.5 
Yes 100 92 47.9 ADR 
Total 904 96 89.6 
The above table shows the classification table for the sensitivity & specificity of 
variables determined ADRs. In this table 804 and 92 have been taken as concordant 
pair and 100 and 4 have been taken as discordant pairs. It suggests that 89.6% ADRs 
have correctly classified. (i.e. the predictive value is 89.6% ). It suggests more 
specificity & less sensitivity.  
Table - 8 (ii)  : Multivariate analysis of significant factors associated with ADR 
      by logistic  regression 
95% CI  
Variable 
Adjusted 
Odd ratio 
 
P Value Lower Upper 
Age 1.03 0.001 1.01 1.04
Sex  
Male 1 ( Reference )  
Female 1.51 0.054 1.0 2.30
Cox inhibitors  
Cox 1 1 ( Reference )  
Cox 2 2.91 0.0001 1.61 3.93
Gastroprotective 
t
 
Yes 1 ( Reference )  
No 71.47 0.0001 31.90 160.10
OTC  
No 1 ( Reference )  
Yes 2.35 0.063 0.95 5.38
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Age is taken as continuous variable. For each unit increase in age (i.e. 1 year) the odd 
of getting ADR increased. It suggests that odds of getting ADR are 1.03 times more 
as the age increases. (Adjusted  odd ratio = 1.03, 95% CI = 1.01 – 1.04,  
p value < 0.001). 
While analyzing the gender, male has taken as a reference & the female has taken as 
continuous variable. It shows the odds of getting ADR 1.67 times more in female as 
compared to male. (Adjusted odd ratio = 1.51, 95% CI = 1.0 – 2.30, p value< 0.054)  
For the comparison of Cox inhibitors & its influence on ADR , the patients who received 
single Cox -1 inhibitor as well as two simultaneous receiving of Cox- 1 inhibitors had 
taken as  reference & the patients who received single Cox –2 inhibitor as well as two 
simultaneous receiving of Cox- 2 inhibitors was  considered as continuous variable. It 
shows that the odds of getting ADR by the Cox-2 inhibitors are 1.90 times more than 
Cox-1 inhibitors.(Adjusted odd ratio = 2.91, 95% CI = 1.61 – 3.93, p value< 0.0001). 
While analyzing influence of  gastro-protective agents on ADRs, results shows that  
odds of getting ADRs due to  not taking these agents are maximum (i.e.71.47) times 
more than taking these agents.( Adjusted odd ratio = 71.47, 95% CI = 31.90 – 160.10, 
p value< 0.0001). 
 Further analysis of the OTC drug & its influence on ADR the patients who had not 
taken any over the counter  NSAIDs is taken as reference & the patients who had 
taken over the counter NSIADs is taken as a continuous variable. The result showed 
that the odds of getting ADR in patients with OTC drugs are 2.89 times more as 
compared to the patients who did not taken over the counter NSAIDs.( Adjusted odd 
ratio = 2.35, 95% CI = 0.95 – 5.38, p value< 0.063). 
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DISCUSSION 
The present study was conducted with aims and objectives of evaluating drug 
utilization pattern of Non steroidal anti-inflammatory drugs (NSAIDs) and adverse 
drug reactions (ADRs) faced during therapeutic interventions in a rural based tertiary 
care teaching hospital and Medical Research Centre. 
Utilization pattern of NSAIDs 
With variety of NSAIDs that are presently available, it is difficult at times to select a 
particular NSAID on a rationale basis. Currently NSAIDs are being increasingly used 
with or without prescriptions for variety of indications. Keeping this scenario in mind, 
to observe the utilization pattern of NISADs, data was collected & analysed from the 
department of pharmacy of a Shree Krishna Hospital (SKH) and Medical Research 
centre, a tertiary care teaching hospital, Karamsad during January to June 2008. The 
data consisted of outdoor and indoor patients from the department of Orthopaedics, 
Medicine and Paediatrics. All pharmacological groups of drugs as well as the pattern 
of use of NSAIDs was analysed for the indoor and outdoor patients of these 
departments. The data reflects that NSAIDs are second most frequently prescribed 
drugs in outdoor patients and fourth most commonly prescribed drugs in indoor 
patients of all the departments. It shows that the use of NSAIDs is higher compare to 
other groups. The analysis of the data from the period January to June 2008 found that 
eight NSAIDs were commonly prescribed, this included Diclofenac, Paracetamol, 
Piroxicam, Etoricoxib, Ibuprofen, Indomethacin, Aceclofenac and Nimesulide.  
Another finding was use of combinations of NSAIDs namely Diclofenac + 
Paracetamol followed by Paracetamol + Chlorphenaremine maleate + Caffeine. 
According to the Italian study(185) in 2004, NSAIDs were widely used in the general 
population of Italy.  To describe nationwide pattern of use of NSAIDs, a study 
conducted in Danish population(186) in 2008 showed that NSAIDs are commonly used 
in the Danish population. An Indian study conducted by Paul AD(13) has shown that 
usage pattern and preferences of NSAIDs among different practice categories in India 
is high and  there is a need for awareness programmes on rational prescribing of 
NSAIDs towards optimal therapeutics and improved patient care in India . All these 
studies signify the importance of research in utilization pattern of NSAIDs.  
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Use of NSAIDs in relation with Gender and Age  
After analyzing demographic data, it is observed that more number of female patients 
(538, 53.8%) is suffering with the kind illnesses, which requires NSAIDs as compared 
to male patients (462, 46.2%).  Donna K et al(187)   have   stated   that there is a gender 
differences in frequency and intensity of pain. Women often report lower pain 
thresholds, higher pain ratings, and lower tolerance for pain. In addition, Curhan GC 
et al(188) also stated that women in the highest category of use of any of the analgesics. 
Both the statements favours’ the study result showing more use of NSAIDs in 
females. 
The study reflects that NSIADs were frequently prescribed to age groups of 1-18,  
41-50 and 51-60 years. Though, the higher numbers are found in the age group  
1-18 years, the reason behind that is all the patients up to the age of 18 years, which 
were treated by the General Practitioners, have been incorporated in this group with 
history of trauma and fever. The results of the study by Fosbol EL(186) found that 
female sex and increasing age are associated with increased use of NSAID.  Also 
Johnson A(161), found in his study that usage of NSAIDs was higher between 45 and 
64 years, and females, the result of these studies coincides with the present study. In 
the contradictory, a study conducted in Nigeria(11) revealed that there is no significant 
difference in the distribution of female to male ratio that employs NSAIDs on a daily, 
weekly or occasional basis. 
Morbidity pattern and use of NSAIDs 
In the present study, conditions related to musculoskeletal systems appear more than 
other two systems i.e. CVS and Infectious diseases. Musculoskeletal diseases are 
prevalent in 52% and 44% in infectious disease. Infections are the second most 
common encountered condition where NSAIDS were prescribed either as antipyretic 
or analgesics. Cardiovascular diseases are considered as separate grope of morbidity 
pattern. In the study all patients of cardiovascular diseases have been included except 
those who were prescribed Aspirin. It means that NSAIDs were prescribed as anti-
inflammatory, antipyretic or analgesics in cardiovascular conditions of patients. 
Totally 39 patients fall in this group.  
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Co-morbidities (more than one disease simultaneously) increase complexities of drug 
therapy, as multiple drug groups are required to be given together in patient having 
co-morbid conditions, and thus increasing the chances of development of adverse 
drug reactions and drug interactions. In the current study co-morbidity is prevalent in 
18.3% of the patients and 81.7% patients suffered from single disease. A Korean 
study(189) showed 46% prevalence rate of co-morbid disease (cardiovascular, renal, 
liver, diabetes, hypertension) in patients taking NSAIDs for the treatment of 
orthopaedic problems. 
Patter of use of NSAIDs 
Out of 1000 patients, 888 patients receive either single formulation or two 
formulations of different NSAIDs (i.e. COX-1 or COX-2); remaining 112 patients 
receive different combination of NSAIDs. A use of tNSAIDs topped the list of 
various selective COX-2 inhibitors in the present study. Selective COX-2 inhibitors 
were developed with assumption of better safety profile (renal and GI) than non-
selective NSAIDs and became very popular few years back. However, the results of 
present study points towards the reversal of trends back to the use of conventional 
NSAIDs. This shift might have come with the reported CVS toxicity with the use of 
selective COX-2 inhibitors. Initial trials showed superiority of COX-2 selective drugs 
over non-selective drugs but clinical experience has put their safety in question. The 
withdrawal of rofecoxib and valdecoxib by the manufacturing companies, in lieu of 
causing cardiovascular side effects, has probably changed the prescribing pattern of 
NSAIDs. Paracetamol, Ibuprofen, Diclofenac, Piroxicam, Aceclofenac, Indomethacin 
are found to be the top six tNSAIDs COX-1 inhibitors. Though, Nimesulide is comes 
under the classification of preferential COX-2 inhibitors it has been counted as 
selective COX-2 inhibitors in the study, so Nimesulide and Etoricoxib are found to be 
top two COX-2 inhibitors. Total 86 patients received above two drugs. A study by  
Shi W et al(190) found similar result. The only difference in that study was 
Nabumetone and Meloxicam, were  also used which  are not used in this study. Sung-
Hun Lee et al (189) stated that the COX-2 selective NSAID showed a propensity to be 
prescribed more commonly for high/very high GI risk groups, but the rate is still as 
low as 51%. Jhonson A(161)   found  that use of selective COX-2 inhibitors were more 
common in  elderly patients  with musculoskeletal diseases and those with prior 
gastrointestinal hospitalizations. 
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 Fries JF(191) stated that prior to market release of the first COX-2 inhibitor (celecoxib), 
northern California health maintenance organization (HMO) developed a treatment 
guideline for the use of NSAIDs based on the Standardized Calculator of Risk for 
Events (SCORE) program developed at Stanford University, Division of Immunology 
and Rheumatology. The SCORE tool stratifies patients by risk of developing serious 
GI complications using patient characteristics that have assigned points. After May 
1999, different NSAIDs were recommended for patients depending on the total 
number of points assigned by the SCORE tool. The study by Craig(192) supports the 
statement that the rate of GI events can be predicted by a defined set of easily 
assessed patient criteria using the SCORE. Stratification of patients by risk score can 
guide the physician to appropriate therapeutic options, with the potential of protecting 
patients at greatest risk for GI events.  Bull SA et al(155) also suggested that, it is 
desirable that physicians consider each patient's clinical factors before prescribing 
NSAIDs. In the study by Paul AD(13) found that Ibuprofen and Diclofenac are the 
most commonly proscribed drugs. The study was conducted in Mumbai city and its 
suburbs, involving 1,916 doctors from general practice to specialist practice.  
Combination products, also known as fixed dose drug combinations (FDCs), are 
combinations of two or more active drugs in a single dosage form. Fixed dose 
combinations increases risk of drug interactions and ADRs. Moreover, they cause 
difficulty in titration of dose of particular drug as it is not possible to increase or 
decrease the dose of single ingredient. Use of FDC can improve compliance to 
therapy partly by decreasing number of formulations to be taken, but their benefit risk 
ratio should be judged. In the present study FDC are also prescribed, in the Outdoor 
and indoor patients. Total 112 patients received FDC with seven different 
combinations of NSAIDs. Diclofenac + Paracetamol is the topmost combination and 
Ibuprofen + Paracetamol is the second most frequently prescribed combination in the 
present study. M Gupta(193) showed that combination of Ibuprofen + Paracetamol was 
the most common FDC used in Orthopaedic outpatient clinic of a north Indian tertiary 
care hospital, which is coincides with the present study. A study conducted in 
Uttarnchal(194) found that Diclofenac, Ibuprofen and Piroxicam were the commonly 
used NSAIDs and Valdecoxib and Rofecoxib were commonly prescribed selective 
COX-2 inhibitors. Out of 487 NSAID’s, 277(56.8%) were used as monotherapy and 
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210 (43.12%) were used as FDC in that study. In comparison to above stated study, 
the present study shows less use of FDC. In favour of the present study Burke A(195) 
stated that combining two NSAIDs does not and cannot improve the efficacy of 
treatment. It only adds to the cost of therapy and more importantly, to the adverse 
effects and the ‘muscle relaxants’ in some of these combinations are of questionable 
efficacy. 
Use of Gastroprotective agents with NSAIDs 
Non steroidal anti-inflammatory drugs (NSAIDs) have many adverse effects, 
especially gastrointestinal toxicity, which is the reason for their frequent co-
prescription with gastro-protective agents. The study shows 45.6 %  patients have 
received either H2 blockers or Proton  pump inhibitors(PPI).  Ranitidine, 
Pantoprazole and Omeprazole are commonly used gastro-protective agents. A 
prospective study conducted in the orthopaedic outpatient unit of an urban, tertiary 
care, teaching hospital, for six months, found that 32.58% patients have been co-
prescribed with gastro-protective agents.  In that study the most common gastro-
protective agents were PPI (81.19%). H2 blockers were a distant second (17.81%), 
while Misoprostol was not used at all(196). To prevent NSAIDs induced gastropathy, 
three strategies are followed in clinical routine: (i) coprescription of a gastro 
protective drug, (ii) use of selective COX-2 inhibitors, and (iii) eradication of 
Helicobacter pylori. Proton pump inhibitors are the comedication of choice as they 
effectively reduce gastrointestinal adverse events of NSAIDs and are safe even in 
long-term use (197). In present study also PPIs are more co-prescribed than H2 blockers   
which are justifiable. Choice of NSAIDs and gastroprotective agents should be guided 
by risk/benefit and effectiveness assessment. 
Misoprostol: Misoprostol is a prostaglandin analogue used to locally replace 
prostaglandins the formation of which is inhibited by NSAIDs. According to a meta-
analysis performed by Koch(198) misoprostol prevents NSAID-induced GI damage. 
Gastric ulceration was found to be significantly reduced in both acute and chronic 
NSAID treatment, whereas duodenal ulceration was significantly reduced only in 
chronic treatment. In the MUCOSA study co-application of 200 µg misoprostol four 
times a day was shown to reduce the overall rate of NSAID-induced complications by 
about 40%(199). Unfortunately, its use is limited by a high rate of GI adverse  
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events(199, 200).  Furthermore, misoprostol use was not associated with a reduction of 
dyspeptic symptoms(201). In the present study Misoprostol is not prescribed which 
justify the above statements. 
H2-receptor antagonists: H2-receptor antagonists presented the standard of ulcer 
treatment up to the development of PPIs. They were the first drugs effectively to heal 
reflux oesophagitis as well as peptic ulcers. However, in the prevention of NSAID-
induced gastric ulceration, H2-receptor blockers, at standard doses are not only 
ineffective but might also increase the risk of ulcer bleeding, perhaps because of 
masking warning symptoms(202).  Formation of duodenal ulcers on the other hand can 
be prevented and upper GI symptoms improved by H2-receptor antagonists(197). Taken 
together, nowadays H2-receptor antagonists can no longer be recommended to prevent 
NSAID gastropathy. 
Proton-pump inhibitors (PPI): Acid suppression by PPI is more effective compared 
with H2-receptor antagonists and is now standard therapy for the treatment of both 
peptic ulcers and gastro-oesophageal reflux-disease (GERD). Omeprazole (20 mg 
once a day) has been demonstrated to be significantly more effective in the prevention 
of gastroduodenal ulcers than ranitidine (150 mg twice daily)(203) or misoprostol (200 
µg bid)(204). In both studies, the PPI provided greater symptomatic relief of dyspepsia 
associated with NSAID; omeprazole was tolerated better than misoprostol(204). 
Graham and co-workers(200) showed in a double-blind, randomized, multicentre study 
that lansoprazole is superior to placebo in the prevention of NSAID-induced gastric 
ulcers in H. pylori-negative subjects but not superior to full-dose misoprostol (200 µg 
four times daily). Taking into account the poor compliance associated with 
misoprostol (due to adverse effects and the requirement of four doses), lansoprazole 
and full-dose misoprostol are clinically equivalent(200). Due to the selectivity of their 
target enzyme the rate of adverse events associated with PPIs is low. Long-term use 
of PPIs is safe(205). Prior to long-term use of PPIs, H. pylori should be eradicated. A 
disadvantage of PPIs may be that they are unlikely to protect against mucosal injury 
in more distal parts of the intestine. 
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History over the counter use of NSAIDs 
NSAIDs are commonly used as prescription medicines as well as over the counter 
(OTC) medicines in India. A variety of NSAID combinations are also available 
without prescription.  
 In India, the import, manufacture, distribution and sale of drugs and cosmetics are 
regulated by the Drugs and Cosmetics Act, 1940 (DCA), the Drugs and Cosmetics 
Rules, 1945 (DCR)(206). 
India currently ranks 11th in the global OTC market size. It is estimated that it will 
reach 9th position within five years. Currently the Indian OTC market is estimated to 
represent approximately USD 1,813 million (euro 1362 million) with an annual 
growth rate of 10.7% at the end of calendar year 2009(207). The phrase “OTC” has no 
legal recognition in India; all the drugs not included in the list of prescription-only 
drugs are considered to be non-prescription drugs (or OTC drugs). Hence, "OTC" 
Drugs means drugs legally allowed to be sold. Prescription-only drugs are those 
medicines that are listed in Schedules H and X of the Drug and Cosmetics Rules. 
Currently, non drug-licensed stores (e.g. non-pharmacists) can sell a few medicines 
classified as “Household Remedies” listed in Schedule K and D. There is doubt that 
which drugs to be consumed as non-prescription medicines because of nonavailibility 
of national list of OTC medicine. NSAIDs are one of the medications which are 
mostly misused or self medicated. Bansal Vidhu stated that users are generally 
unaware of the potential of adverse side effects.  It must be noted that these findings 
were derived from prescription-strength NSAID use; a completely safe NSAID is yet 
to be discovered(208). In this study 75% patients have a history of use of over the 
counter NSAIDs. All 109 patients from the age group of above 60 years have history 
of use of NSAIDs without prescription. Out of173 patients, 172 patients have history 
of use of NSAIDs without prescription in the age group of 51-60 years. The least use 
of OTC drugs by the age group of 1-18 years. It shows that as age increases the 
chances of taking OTC drugs is also increases. There are multiple factors for use of 
NSAIDs without prescription like co-morbid conditions, cost and easily availability of 
drugs leads to more use of OTC drugs. 
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Adverse Drug Reactions of NSAIDs 
Medicine can cure or control the disease on one hand but on the other hand they can 
also cause disease by producing adverse drug reactions (ADRs). Although, many 
ADRs are mild and disappear when the drug is stopped or the dose is reduced, others 
are more serious and require frequent hospital visits or hospitalization.  
Non Steroidal Anti Inflammatory Drugs are implicated in 21%- 25% of all adverse 
drug reactions, with the most commonly reported effects being GI irritation(209). 
NSAIDs increase the relative risk of gastrointestinal haemorrhage by approximately 
3-fold, although estimations as high as 10-fold have been reported in the 
literature(209).  In this study, the incidence rate of ADR is 19.2%. A study conducted in 
Delhi, found 12% incidence rate of ADR due to NSAIDs(210).  An observational study 
in Chhattisgarh showed 9.74% incidence rate of ADRs due to NSAIDs(211).  In the 
UK, NSAIDs account for approximately 25% of all reported drug adverse events(212). 
In the study conducted in Italy 23.5% incidence rate of ADR due to NSAIDs(213). It 
shows that in India the NSAIDs induced ADR rate is between 10-20 % which is low 
compare to international studies. 
Inter-individual variability in drug metabolism is a major cause of adverse drug 
effects. In many cases, such variability is linked to polymorphisms in genes coding 
for drug-metabolising enzymes. Individuals carrying enzyme-inactivating mutations 
display impaired drug metabolism. Higher plasma drug concentrations and lower 
clearance rates occur in carriers of inactivating mutations when treated at standard 
doses. 
 The study shows the high incidence rate in elderly patients followed by the age grope 
of 41-50 years of age. There are multiple reasons why the elderly are more liable to 
ADRs. The elderly receive more drugs, drug interactions occur due to polypharmacy, 
poor compliance, altered pharmacokinetics and pharmacodynamics. 
The study shows higher incidence of ADR in Female.  It is correlated with the study 
by Ramesh M et al(214). Similar result was found in the study conducted by Chau Tran 
et al(215). This result is coinciding with the statement by Anderson GD(216). He stated 
that female has been shown to be a risk factor for clinically relevant adverse drug 
reactions because of the increased risk is differences in pharmacokinetics, in 
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pharmacodynamics, and/or more medications or higher mg/kg doses than males.  
Generally, males weigh more than females, yet few drugs are dosed based on body 
weight. Drug concentrations are dependent on the volume of distribution (Vd) and 
clearance (Cl). Both parameters are dependent on body weight for most drugs 
independent of sex differences. Females have a higher percent body fat than males, 
which can affect the Vd of certain drugs. Renal clearance of unchanged drug is 
decreased in females due to a lower glomerular filtration. Gender differences in 
activity of the cytochrome P450 (CYP) and uridine diphosphate 
glucuronosyltransferase (UGT) enzymes and renal excretion will result in differences 
in Cl. There is evidence for females having lower activity of CYP1A2, CYP2E1, and 
UGT; higher activity of CYP3A4, CYP2A6, and CYP2B6; and no differences in 
CPY2C9 and CYP2D6 activity. Pharmacodynamic changes can affect both the 
desired therapeutic effect of a drug as well as its adverse effect profile. Anderson GD 
also stated that females also have a higher incidence of drug-induced liver toxicity, 
gastrointestinal adverse events due to NSAIDs, and allergic skin rashes.  
 In the contradictory to above statement HShi WH(190) stated that different NSAIDs might 
have different risk factors and that there is no single risk factor universally applicable 
to all NSAIDs. This could be probably because of social & family systems which 
allow main focus on health of men as compared to women. He stared that there are 
multiple factors causing ADRs. They could be polypharmacy, age, gender, race, 
genetics, multiple, and inter-current diseases can cause morbidity and mortality. 
Over the counter (OTC) drugs are one of the most irrationally used and its irrational 
use has contributed to rise of ADRs. There is a history of use of NSAIDs without 
prescription in 183 (95.3%) patients, who developed ADR out of 192 patients.  It 
suggests that history of use of NSAIDs without prescription could be one of the 
factors for causing ADRs. A survey conducted to ascertain basic knowledge about the 
use of OTC pain medications among patients seen in the emergency department, there 
was an increased potential exists for inappropriate use and adverse effects and patients 
were unaware of the risks. The study reported that significant gaps existed in patients’ 
knowledge about OTC pain medications. More than 40% of the patients did not know 
about potentially significant drug interactions or possible GI side effects. More than 
60% did not know about the relationship between the use of these agents and hepatic 
and renal disease(217). A case reports by A Whelton(218) has  shown that over-the-
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counter (OTC) analgesics, which are generally considered to be a safe treatment for 
minor aches and pains and fever, may cause adverse renal effects. 
On April 29, 2009, the FDA issued a final ruling that the manufacturers of OTC 
analgesics and antipyretics will have revise their labelling, which includes warnings 
about potential adverse effects (e.g. internal bleeding, liver damage, concomitant 
warfarin therapy) associated with the use of these agents and also prominently display 
the active ingredients on the labels of both the packages and bottles. This labelling 
mandate is intended to assist patients in easily identifying the active ingredients and 
decrease the possibility of a patient inadvertently taking multiple products containing 
these analgesics concurrently. Although these products are considered to be safe and 
effective when used appropriately, the FDA believes that patients need to be aware 
that these products have the potential to cause serious adverse effects, such as 
hepatotoxicity and GI bleeding, when used improperly(219). This FDA action applies 
to all products that contain acetaminophen and NSAIDs.  All OTC manufacturers of 
NSAID and acetaminophen products must comply with labelling requirements by 
April 29, 2010 which may reduce the burden of ADRs due to frequently use of 
NSAIDs without prescription. Stewart R stated that older adults living independently 
often self-medicate with OTC agents for common problems such as fever, mild pain, 
colds, allergies, indigestion and gas, constipation, and insomnia and he found that 
about 50% of adults over 65 regularly use OTC pain relievers(220). In U.K., hospital 
admissions due to ADRs are much comparable to the other parts of Europe(221).  
The overall risk OTC analgesic appears to be low, but given the accessibility and vast 
number of persons taking these agents, the absolute number of patients affected may 
be substantial. Therefore, it is important that healthcare providers recognize the risk 
factors for adverse analgesic-related effects.  
Symptoms of ADRs 
Gstrointestinal 
Gastrointestinal toxicities are at the top with highest number (52 patients, 27 %). GI 
toxic effects induced by NSAIDs are common. Pharmacoepidemiologial study of 
NSAID induced ADRs in Shangahi patients accounted for 57.8% GI related ADRs 
due to NSAIDs(190), which is higher in compare to present study.  Studies and 
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quantitative systematic reviews, comparing NSAID users against well-matched 
controls, shows that NSAIDs are associated with a 1.5 to 7.2-fold increase in serious 
adverse GI events across various agents and risk profiles(52,59). Food and Drug 
Administration Arthritis Advisory Committee notes that symptomatic ulcers and 
potentially life-threatening complications have been found in up to 4% of patients per 
year(222).  
Minor GI side effects are common and affect 10 - 60% of NSAID users(214). 
Abdominal pain, nausea, constipation, diarrhoea, indigestion of food, and burning 
sensation in abdomen are classed as minor GI events. Duodenal, gastric or intestinal 
ulcers, bleeding, perforation, hospitalization and related death are classed as major GI 
events(48). 
NSAID-associated dyspepsia is common and has been reported in up to 25–50% of 
patients(223,50). Dyspepsia is the most common reason for stopping use of NSAIDs. 
However, the presence of dyspepsia does not predict the presence of mucosal lesions 
in patients taking NSAIDs(223). Dyspepsia may include indigestion of food, upper 
abdominal pain, belching, nausea, abdominal burning, and loss of appetite, flatulence 
and upset of stomach. In this study symptoms of GI side effect are gastritis, diarrhoea, 
vomiting, nausea and constipation which all are minor GI side effects. Piroxicam has 
higher risk Diclofenac and Indomethacin have intermediate risk and Ibuprofen has 
lower risk in developing GI toxicity. In this study almost all prescribed drugs are 
culprit for developing GI related side effect, either individually or in FDC with other 
NSAIDs.  
The risks of upper GI toxicity associated with non-selective NSAIDs have been 
extensively studied. Case-control studies and meta-analyses have shown that the risk 
of upper GI complications is increased in NSAID users, compared with  
non-users(52, 224). The risk is highest during the first month of treatment and then 
remains elevated afterwards. The risk of bleeding depends on the individual NSAIDs. 
Various studies have shown that the upper GI symptoms associated with regular 
NSAIDs use can have a considerable impact on the quality of life, productivity at 
work and routine daily activities of patients who need to take these agents on a regular 
basis(225, 226, 227). Laine L(209) stated that after a single dose of a non-selective NSAID, 
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almost all patients develops some degree of gastric erosion, and  
approximately 10–30% of chronic users will develop a peptic ulcer.  
Cardiovascular risks of NSAIDs 
Cardiovascular events (increasing blood pressure and palpitation) developed in 48 
patients.   Out of 48 patients, in 34 patients there is increased blood pressure within 
one month after taking NSAIDs. In all 34 patients systolic blood pressure rises 
between 3-5 mm hg and diastolic blood pressure rises between 2-4 mm hg .It is more 
frequently seen (14 patients) in elderly, followed by the age group of 51-60 years (12 
patients) and 41-50 years of patients (5 patients). Warner TD stated that all NSAIDs 
in doses adequate to reduce inflammation and pain and it can increase blood pressure 
in both normotensive and hypertensive individuals(104). The average rise in blood 
pressure is 3/2 mmHg but varies considerably(105). A comprehensive review of the 
extensive body of literature surrounding the adverse cardiorenal effects of nsNSAIDs 
and selective COX-2 agents stated that nsNSAIDs and COX-2 inhibitors, lead to 
variable degrees of fluid retention and blood pressure effects(228).  In continuation of 
above statement, the result of present study shows that blood pressure found to be 
increase in 34 patients and 14 patients developed palpitation. Oedema developed in 7 
patients. Piroxicam, Diclofenac and Ibuprofen are the causal drugs for development of 
oedema. In this study culprit drugs which increases the blood pressure are Diclofenac, 
Ibuprofen, Piroxicam, paracetamol, indometacin and Etirocoxib. This shows that both 
tNSAIDs and COX-2 inhibitors, lead to variable degrees of fluid retention and blood 
pressure effects. A case control study showed that all NSADs increase blood pressure 
and that Piroxicam, Indomethacin and Ibuprofen produced the most marked increase 
from the nNSAIDs(229). 
HCurhan GCH(188) concluded in his study that women who take higher dose of 
paracetamol and ibuprofen on a regular basis are significantly more likely to develop 
hypertension. Because of the widespread availability of NSAIDs without a 
prescription, many patients with hypertension may be at risk for aggravated blood 
pressure effects caused by these drugs.  The magnitude of the adverse cardiovascular 
effects associated with NSAIDs is also modulated by the underlying disease process 
such as rheumatoid arthritis, presence of traditional cardiovascular risk factors, 
concomitant drug therapy, and the dosage and duration of exposure.  A cross section 
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study involving younger adults has revealed that NSAID use produces a clinically 
significant increment in mean BP of 5.0 mm Hg, which is most marked in patients 
with controlled hypertension(161). 
Liver and NSAIDs 
NSAIDs are among the most common drugs causing idiosyncratic hepatotoxicity in 
several case series published since 2001. A 2004 systematic review found that the 
incidence of serious liver injury resulting in hospitalization in current users of 
NSAIDs ranged from 3.1 to 23.4 per 100,000 patient years. The excess risk 
attributable to current use of NSAID ranged from 4.8 to 8.6 per 100,000 patient years 
of exposure, compared with past NSAID use(230). Serious liver injuries have been 
described with several NSAIDs, either in isolated reports or case series(230, 231). 
Hepatotoxicity from NSAIDs can occur at any time after drug administration, but like 
most adverse drug reactions, most commonly occurs within 6–12 weeks of initiation 
of therapy(232).  
In the presence study hepatotoxicity is define as deranged liver function tests. In eight 
patients elevation of liver enzymes has been found during routine laboratory analysis. 
Three patients are diagnosed having jaundice after the three weeks of NSAIDs 
therapy. Elevation of trasaminases found within one month. Hepatic reactions are 
more often reported with pyrazolone, indole and propionic acid group of compound 
than the fenamate and oxicam classes(8). Australian agencies have drawn attention to 
an apparently higher frequency of liver reaction with Saulindac and Diclofenac.  
Three weeks use of Piroxicam cause acute hepatitis(8). In this study Diclofenac, 
Ibuprofen Paracetamole Nimesulide and Piroxicam are the culprit for the hepatotoxic 
reaction. In one series of 180 patients with diclofenac related hepatotoxicity, 33% 
were detected as a result of routine laboratory analysis and 67% were detected by 
symptoms; 79% were female and 71% were over 60 years of age(233) and hepatic 
injury was apparent by 1 month after starting the drug in 24% of patients. In the study 
the follow was carried out for a month so it can be stated that there are chances of 
hepatotoxic reactions can occur within a month with the history of OTC drug so it 
shows that continuous monitoring of hepatotoxic reaction is necessary in the patients 
who take NSAIDs frequently.  Merlani G(234) stated that acute liver failure occurs in a 
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tiny proportion of individuals exposed and is often not recognized as a possible 
adverse event until the post-marketing stage.  
Renal failure and NSAIDs  
Drug-induced acute renal failure (ARF) accounted for 20% of all ARF in an Indian 
study(235). One review article stated that overall incidence of NSAID-induced renal 
diseases is 3% but over-the-counter availability of these drugs puts a large population 
at risk. Conditions causing NSAID induced hemodynamic deterioration of renal 
function are higher than usual dose, volume depletion due to flow loss diarrhoea, 
congestive heart failure, nephrotic syndrome, cirrhosis particularly with ascites, pre-
existing renal disease, third space fluid sequestration, diuretic therapy, age > 65 years. 
In this study the incidence is 6% and maximum sufferer age grope is above 60 years 
of age(137). Numerous well documented cases of acute NSAID induced renal disease 
in patients with prior normal renal function have been documented.  Acute kidney 
injury requiring hospitalization is a relatively rare adverse event.  A study by 
Wolfgang C(236) observed acute renal failure approximately 1 in 200 new users within 
45 days after initiation of nonselective NSAIDs or COX-2 inhibitor treatment. The 
culprit drugs in study were or indomethacin, ibuprofen, and rofecoxib(236). 
The present   study, kidney function abnormalities found in 12 patients, among them 
only, 2 patients developed increase creatinine level and in 10 patients developed 
oliguria within 30 days. One study compared NSAID users with non-NSAID users 
and found a dose-dependent risk of acute kidney injury among NSAID users 
compared with nonusers(237). The actual risk of NSAIDs associated acute renal 
dysfunction to be the subject of controversy. It is still not known whether old age is a 
risk factor, whether the risk of renal impairment varies with   different NSAIDs or 
whether renal function continues to deteriorate or stabilize. These all studies shows 
that there is need to monitor kidney function for the patients who takes NSAIDs on 
regular basis. 
Adverse effect of NSAIDs on Central Nervous System and Skin 
Symptoms of Headache, Giddiness, confusion, and Paresthesia are observed in 
15,12,3 and 2 patients respectively who were considered to be CNS related events.  
Paracetamol and Indomethacin is the responsible drug for headache. Diclofenac and 
94 
Ibuprofen are responsible in developing confusion and giddiness. Paresthesia 
developed mainly in the age group of above 60 years of patients in whom Diclofenac 
and Ibuprofen were prescribed. Photosensitivity is a commonly overlooked adverse 
effect of many of the NSAIDs. Out of 192 patients, 6 patients developed urticaria.  
Blurred vision observed in the age group of 41-50 years and above which may be due 
to age or the disease itself. 
Suspected drug 
Total 8 NSAIDs are responsible for development of ADRs in this study. Diclofenac, 
Ibuprofen, Paracetamol, Piroxicam, Nimesulide, Etoricoxib, Indomethacin,and 
Aceclofenac were found to be top eight causal  NSAIDs. Shi W et al 2004(190) survey 
found Diclofenac, Ibuprofen, Indomethacin, Nimesulide, Meloxicam and Naumetone 
were the top six orally taken NSAIDs among shanghai patients. In the study by Ivan 
Ferraz-Amaro et al(237), Diclofenac and Ibuprofen was used widely and associated 
largely to developing ADRs related to gastrointestinal system. These studies suggest 
that regular monitoring of ADR is required in the patients who are regularly taking 
Diclofenac, Paracetamol and Ibuprofen.  
Causality assessment 
Adverse Drug Reactions usually do not present with unique clinical and laboratory 
findings making it difficult to demarcate them from the concurrent illness. For the 
estimation of the probability that a drug caused an adverse event, several methods 
have been developed namely, the WHO-UMC criteria, the Naranjo probability scale, 
the Kramer scale and the Karch and Lasagna scale. But none of the available 
assessment methods have been shown to produce a precise and reliable quantitative 
estimation of relationship likelihood. A variety of scales, algorithms, and nomograms 
have been published to improve the accuracy and decrease variability among 
assessors. Despite these efforts, the precision and accuracy of assessing the 
relationship between drug administration and an adverse drug event remain uncertain. 
Very few studies have been reported in showing causality assessment of   NSAIDs 
induced ADRs by both WHO-UMC score and Naranjo’s scale. The present study was 
planned to compare the WHO-UMC causality assessment criteria and the Naranjo 
probability scale for determining causal relationship between the drug and the event.  
Total 192 ADRs were assessed first by the WHO-UMC criteria and then by using 
Naranjo probability scale. Findings by both scales are, almost same. Majority of 
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ADRs belonged to “possible”  followed by “probable” categories. A total 190 ADRs 
were generated. Between-observed agreement was 45% with a kappa(w) value of 
0.175 for Naanjo scale. This result is similar with the study by Garacia et al conducted 
in 2008(238). It suggests that Naranjo scale had low sensitivity. For comparison 
between two scale, a comparative study of causality assessment scales used in the 
analysis of spontaneously reported events, showed that there is no difference between 
the two scales but Naranjo’s scale is more time consuming(239).  It is also experienced 
that with the inbuilt stringencies in both the scales it becomes very difficult to 
describe the category of ‘certain’ or ‘definite’ to an observed ADR. Lack of data with 
regard to dechallenge or rechallenge, polypharmacy, use of fixed dose combinations 
and simultaneous stopping of more than one drug at a time make it a nearly 
impossible proposition. It revealed that the basic nature of observations remain the 
same in both the WHO-UMC criteria and the Naranjo’s scale.  
Onset, Severity, Preventability and Outcome of ADRs 
Fifty three percent of ADRs developed within 1-3 days. It shows that monitoring of 
ADRs during the initial stage of treatment may prevent the severe as well as serious 
ADRs. Mainly hepototoxic reaction and kidney related ADRs developed between 15-
30 days of period. It was not possible in present study to do follow up after one month 
of developing ADRs. Most of the ADRs are mild in nature which can be reversible. 
Rechallenge has not been done in any cases. No serious or severe effects developed 
during the treatment or after the treatment. In this study, 88% of the ADRs are 
probably preventable and 20 % are definitely preventable rest of ADRs are not 
curable, which is coincides with the broad range of figures 30-70% suggested in 
literatures(240,241). Establishing the preventability status of the ADRs is essential to 
adopt appropriate strategies to prevent the occurrence of similar ADRs in the future. 
Given the considerable burden of ADRs, there is a need to put into place preventive 
strategies. Prevention is likely to require complex multi-faceted intervention 
strategies. The study shows that88% of patients have been either cured or relived from 
their ADRs , while only 12% of the patients have found with the same adverse events 
after  the treatment of ADRs.  Twelve percent of patients in which the same adverse 
event observed after treatment may be due to lack of follow up to observe the 
progression of the ADRs. A similar study found that 98.3% patients can get fully 
recovered or improved and a few left sequel or death,  which shows the  outcome of 
ADR of common used NSAIDs was good  in that study(142). 
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CONCLUSION 
 Non steroidal   anti-inflammatory drugs (NSAIDs) are widely prescribed 
drugs. Monitoring of Adverse drug  reaction  is an important tool to prevent 
the  damage to a system like Gastrointestinal, Cardiovascular and derangement 
of Kidney and Liver functions. 
 Use of selective COX-2 inhibitors is less compare to non-selective NSAIDs 
which shows that prescribers are conscious about the ADRs  by  selective 
COX-2inhibitors. 
 Fixed dose combinations of NSAIDs are  used  less which goes in favour of 
rational prescribing practice 
 Elderly patients, forty to sixty years of age , Female sex, history of use of 
NSAIDs without prescription are the main risk factors for causing ADRs 
 In more than fifty percent of the patients gastro protective agents have been 
used   and rest of the patients in whom gastro protective agents are not used 
,they have suffered from the gastrointestinal symptoms. It suggest that 
guideline for prescribing NSAIDs  is necessary to follow. 
 Maximum ADRs are mild to moderate in nature and no serious or severe 
reaction developed after prescribing NSAIDs which is the positive point . 
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Adverse Drug Reactions (ADR) in the in Patients of Medicine Department of a 
Rural Tertiary Care Teaching Hospital and Influence of Pharmacovigilance in 
Reporting ADR published in Indian Journal of Pharmacology in 2008  
Jan-Feb;40(1)37-40 
                                                         Abstract 
Objectives:(i) To find the incidence and study various aspects of Adverse Drug 
Reactions (ADR) in the inpatients of medicine department of Shree Krishna Hospital, 
a rural tertiary care teaching hospital. (ii) To test the impact of pharmacovigilance in 
reporting ADR. 
Material & Methods : A prospective study involving 600 patients admitted to the 
medical wards and TB & Chest diseases ward over a period of six months and a 
retrospective analysis of 600 case files for the corresponding period of the previous 
year were carried out to find the incidence rate of ADR, study various aspects of ADR 
like causality assessment, drugs frequently causing ADR etc. Suitably structured and 
pre-tested format was used for compiling the data. Results:In the prospective study, 
18 of the 600 patients (3%) developed ADR. A significant number (77.78%) of 
patients developed ADR between the 3rd and 10th days of administering the drug/s. As 
the number of drugs increased, the incidence of ADR also increased. Majority of 
ADR (72.22%) occurred due to chemotherapeutic agents. 66.67% of ADR involved 
the gastrointestinal tract. None of the ADR was fatal. Sex of the patients did not 
influence the incidence rate of ADR. On the other hand, in the retrospective analysis, 
only ADR were reported in just 6 out of 600 patients (1%). Conclusion : The 
incidence rate of ADR is found to be much lower (3%) than the reported rate (10%-
20%). Pharmacovigilance certainly contributes to picking up ADR. 
Key words : Adverse drug reactions, ADR monitoring, Pharmacovigilance 
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Adverse drug reactions of nonsteroidal anti-inflammatory drugs in orthopedic 
patients published in Journal of Pharmacology and Pharmacotherapetics in 
2011  Jan-Feb ;2(1) 26-29 
                                                             Abstract 
Objectives: To identify the ADRs due to NSAIDs and to know how to monitor the 
drug's effect. Materials and Methods: A descriptive study was undertaken in the 
Orthopedic Outpatients Department of a tertiary care teaching hospital. Hundred 
patients were enrolled in this study to observe the risk of adverse drug reactions 
(ADRs) due to NSAIDs. All the ADRs were further analyzed in relation to age and 
sex, type of drug and its pattern. Probability scale was used for the causality 
assessment of the ADRs. Results: 26% of the 100 patients developed ADR due to 
NSAIDs. There was not much of a difference in the number of the ADRs in relation 
to the gender. Diclofenac was the highest prescribed drug (65 patients), followed by 
paracetamol (12), nimesulide (10), ibuprofen (6), piroxicam (5) and Etoricoxib (2). 
Diclofenac accounted for the maximum number (73%) of ADRs, followed by 
nimesulide (16%), paracetamol (7%), and Etoricoxib (4%). Conclusion: 
Pharmacovigilance improves recognition of ADRs by the medical students. It allows 
the treating physician to identify the ADR associated with drugs, in particular, with 
the ones considered relatively safe and with those commonly prescribed by the 
medical and non-health professionals. 
Key words: Adverse drug reaction, pharmacovigilance, nonsteroidal anti-
inflammatory drug 
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 Human Research Ethics Committee 
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ANNEX II (a) 
Proforma 
 
 Serial No.  
 Name      Date: 
 Age, Weight and Sex    Reg. No. 
 Address & Phone No. 
 Medical Condition for the use of 
 Secondary or associated diseases 
 Drug Treatment Record 
 
            1st VISIT (Details of NSAIDs)   BP =                mm/hg 
 
 
Name of the Drug  
Sr.No. 
Brand /Generic Generic if 
Brand Name 
 
Dose/route
Frequency of 
Administration 
Duration of 
Treatment  
      
      
 
       Date : _____________ 
2nd VISIT (Details of NSAIDs)    BP =                 mm/hg 
 
Name of the Drug  
Sr.No. 
Brand /Generic Generic if 
Brand Name 
 
Dose/route
Frequency of 
Administration 
Duration of 
Treatment  
      
      
  
      Date:__________ 
 
 3rd VISIT (Details of NSAIDs)   BP =                 mm/hg 
 
Name of the Drug  
Sr.No. 
Brand /Generic Generic if 
Brand Name 
 
Dose/route
Frequency of 
Administration 
Duration of 
Treatment  
      
      
 
  
 Investigation if any : 
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ANNEX II (b) 
 
PROTOCOL FOR ADR REPORTING  
(To be filled for a drug causing / suspected to have ADR) 
 
 NSAIDs related ADR is suspected ?   Yes /  No 
 Date of onset of reaction : 
 Date when reaction stopped : 
 Description of ADR : 
 Details of the suspected drug(s) leading to ADR : 
 
No. 
Drug Name When the drug 
started 
Route Total Daily 
Dose 
Duration 
      
      
 
 Investigations carried out (including biopsy) for confirming ADR, if any:  
No. Investigation Results 
   
   
 
 Treatment of reaction : 
 Date of start of treatment of ADR : 
 Date of end of treatment of ADR : 
 Treatment with suspected drug : 
a. Continued 
b. Discontinued  
c. Dose reduced 
 Did the reaction end after stopping the drug ? Yes  /  No 
 Did the reaction reappear after reintroduction of the drug ?   Yes  /  No 
 Outcome of ADR management : 
a.   Alive with sequelae 
b.   Recovered  
c.   Still under treatment  
d.   Died 
e.   Lost of follow up 
 Final assessment : 
a.   Definite 
b.   Probable 
c.   Possible  
d.   Conditional  
e.   Doubtful  
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1BANNEX  III  
 
2BDEPARTMENT OF PHARMACOLOGY 
3BPRAMUKH SWAMI MEDIACAL COLLEGE 
0BKARAMSAD 
 
4BINFORMED CONSENT FORM  
 
 
STUDY TITLE: "Study of adverse event in patients receiving  non-steroidal                       
anti-inflammatory drugs (NSAIDs) and influence of  pharmacovigilance in reporting 
adverse event”  
 
PATIENT’S NAME:       
 
SEX:   MALE/FEMALE                            AGE        
 
IF IPD   :WARD                                      REG.NO  
 
IF OPD ADDRESS: 
 
 
I have been explained regarding the research project to be conducted by Dr. Alpa Gor in the 
Department of Pharmacology, P.S.M.C., Karamsad. 
 
I understand that my / my ward participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason.  
 
I understand that my / my ward identity will not be revealed in any information released to 
third parties or published.  
 
I agree to take part in the above study. 
 
SIGNATURE / THUMB IMPRESSION of the participant / parent.            Date :      /       / 
 
 
Signatory’s name:_____________________________________ 
 
 
Signature of the Investigator:____________________________                 Date:      /      /   
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ANNEX III 
V[RPV[DP58[, ;[g8Z OMZ D[0LS, S[Z V[g0 V[HI]S[XG4 SZD;Nv#((#Z5 
           
;lJUT ;\DlT5+ 
VeIF;GF lJQFIG]\ DYF/]\ o “Study of adverse event in patients receiving  non-steroidal      
anti-inflammatory drugs (NSAIDs) and influence of  pharmacovigilance in reporting 
adverse event”  
    
10BNNL"G]\ GFD      o  PPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPP     
5BHFlT                o   5]Z]QFq :+L                                p\DZ      o PPPPPPPPPPPPPPPPPP 
HM V\NZGF NZNL CMI TM JM0" PPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPP           ZHLPG\AZ  PPPPPPPPPPPPPPPP 
HM ACFZGF NZNL CMI TM    ;ZGFD] o PPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPP 
               PPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPP 
;\XMWG VeIF; DF8[GF lJQFI  “Study of adverse event in patients receiving  non-steroidal anti-
inflammatory drugs (NSAIDs) and influence of  pharmacovigilance in reporting adverse 
event” lJQF[ DG[ 0F"PV<5F UMZ4 OFD["SM,MHL lJEFU4 5LPV[;PD[0LS, SM,[H4  SZD;N ;DHFjI]\\ K[P                                   
 
6BC\] ;DH\] K]\ S[ VF VeIF;DF\ DFZ\] q DFZF ;\A\WLG\] EFU ,[JFG\] :J{lrKS K[ VG[ SM.56 SFZ6 VF%IF l;JFI 
V[DF\YL C\] q DFZF ;\A\WL DFZL q T[GL ;FD[,lUZL 5FKL B[\RL XS\] K]\P VFD SZTF\ DFZFq DFZF ;\A\WLGF TALAL S[ 
SFINFSLI lCTG[ 56 SM. V;Z YX[ GCL\\P 
 
7BC]\ V[ 56 ;DH\] K]\ S[ DFZF q DFZF ;\A\WL lJX[GL DFlClT 5|l;wW SZTL JBT[ DFZL q DFZF ;\A\WLGL VM/B 
SIF\I KTL SZJFDF\ GCL\ VFJ[P 
 
8BNZNL VYJF T[GF SFIN[;ZGF 5|lTlGlWGL  ;CL q V\U}9FG\] lGXFG PPPPPPPPPPPPPPPPPPPPPPPP   TFZLBo PPPPPPPPPPPPPPPPPPPPPPP 
 
9B;\XMWS sT5F;STF"fGL ;CL PPPPPPPPPPPPPPPPPPPPPPPPPPPPP                                       TFZLBo PPPPPPPPPPPPPPPPPPPPPPPPPP 
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ANNEX  IV 
Causality Assessment: 
UWHO PROBABILITY SCALE 
 
 
 
 
 
 
 
 
 
Certain 
Event or laboratory test abnormality, with 
plausible time relationship to drug intake cannot 
be explained by disease or other drugs. 
Response to withdrawal plausible 
(pharmacologically, pathologically) 
Event definitive pharmacologically or 
phenomenologically (an objective and specific 
medical disorders or recognized 
pharmacological phenomenon) Rechallenge (if 
necessary) 
Unassessable / unclassifiable 
 
A report suggesting an adverse reaction 
Can’t be judged because of insufficient 
or contradictory information 
Report can’t supplemented or verified 
 
 
 
 
 
 
 
 
 
 
Probable  
 
Event or lab abnormality, with reasonable time 
relationship during intake 
Unlikely to be attributed to disease or other 
drugs 
Response to withdrawal clinically reasonable 
Rechallenge not necessary 
 
Unlikely 
 
Event or laboratory abnormality with a 
time to drug makes a relationship 
improbable(but not impossible) 
Disease or other drugs provide plausible 
explanation 
 
Possible  
 
Event or laboratory test abnormality, with 
reasonable time relationship to drug intake 
Could also be explained by disease or other 
drugs 
Information on drug withdrawal lacking or 
unclear 
 
Conditional / Unclassified 
 
Event or laboratory test abnormality 
More data for proper assessment needed 
Or additional data under examination 
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ANNEX V 
NARANJO’S ADR PROBABILITY SCORE 
(Naranjo CA, Busto U et at., 1981) 
 Yes No Don’t 
know 
1.    Are there previous conclusive reports on this reaction? +1 0 0 
2.  Did the adverse event appear after the suspected drug was 
given? 
+2 -1 0 
3.  Did the adverse reaction improve when the drug was 
discontinued or a specific antagonist was given? 
+1 0 0 
4. Did the adverse reaction appear when the drug was 
readministered? 
+2 -1 0 
5.  Are there alternative causes (other than the drug) that could 
have caused the reaction? 
-1 +2 0 
6.   Did the reaction reappear when a placebo was given? -1 +1 0 
7.  Was the drug detected in the blood (or other fluids) in toxic 
concentrations? 
+1 0 0 
8.  Was the reaction more severe when the dose was increased, or 
less severe when the dose was decreased? 
+1 0 0 
9.  Did the patient have a similar reaction to the same or similar 
drugs in any previous exposure? 
+1 0 0 
10.  Was the adverse event confirmed by any objective evidence? +1 0 0 
       Total score    
 
 The total score calculated from this table defines the category as: 
 POSSIBLY (total score 1-4) 
 PROBABLY (total score 5-8) 
 DEFINITELY (total score >9) 
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ANNEX VI 
 
Modified Schumock and Thornton criteria for preventability of an ADR 
 
Section A 
____________________________________________________________________________ 
 
Answering “yes” to one or more of the following implies that an ADR is DEFINITELY
preventable. 
 
1. Was there a history of allergy or previous reactions to the drug? 
2. Was the drug involved inappropriate for the patient's clinical condition? 
3. Was the does, route, or frequency of administration inappropriate for the patient's age,  
    weight, or disease state? 
 
If answers are all negative to the above, then proceed to Section B.  
 
Section B 
____________________________________________________________________________ 
 
Answering “yes” to one or more of the following implies that an ADR is PROBABLY 
preventable. 
 
1. Was required therapeutic drug monitoring or other necessary laboratory tests not performed? 
2. Was a documented drug interaction involved in the ADR?  
3. Was poor compliance involved in the ADR? 
4. Was a preventative measure not administered to the patient? 
5. If a preventive measure was administered, was it inadequate and / or inappropriate? 
Answer 'no' if this question is non-applicable.  
If answers are all negative to the above, then proceed to Section C. 
 
 
 
 
 
 
Section C 
____________________________________________________________________________ 
The ADR is NOT preventable. 
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ANNEX VII 
ADR SEVERITY ASSESSMENT SCALE 
(Hartwing SC, Siegel J et al.,1992) 
 
MILD  
Level 1 : The ADR requires no change in treatment with the suspected drug. 
OR 
Level 2 : The ADR requires that the suspected drug is withheld, discontinued otherwise 
changed. 
No antidote or other treatment is required and there is no increase in length of stay. 
 
OR 
MODERATE 
Level 3 : The ADR requires that the suspected drug is withheld, discontinued otherwise 
changed, 
and / or an antidote or other treatment is required. There is no increase in length stay. 
 
OR 
Level 4 (a) : Any level 3 ADR that increase in length of stay by at least one day. 
 
OR 
Level 4 (b): The ADR is the reason for admission. 
 
SEVERE 
Level 5 :  Any level 4 ADR that requires intensive medical care. 
 
OR 
Level 6 : The ADR causes permanent harm to the patient. 
 
OR 
Level 7 : The ADR either directly or indirectly leads to the death of the patient.  
  
Sr. No Dept Age Sex Cox 1 Inhibitor
Cox 1 
Inhibitor
Cox 2 
Inhibitor
Combin
ation Diagno
Co 
morbid -
1
Co 
morbid -
2
OTC
Gastro 
protective 
agents
1 1 40 F 0 0 27 0 5 0 1
2 1 58 M 10 0 0 0 5 1 0
3 1 52 M 3 0 0 0 5 1 1
4 1 60 M 0 0 27 0 5 1 1
5 1 24 M 3 0 0 0 5 0 1
6 1 52 F 0 0 0 (8+20) 5 1 1
7 1 42 F 0 0 0 (8+20) 5 0 1
8 1 25 F 8 0 0 0 5 0 1
9 1 17 M 8 0 0 0 5 0 1
10 1 65 F 0 0 25 0 5 1 0
11 1 35 M 0 0 27 0 5 1 1
12 1 43 F 0 0 0 0 5 1 1
13 1 52 M 0 0 25 0 5 1 0
14 1 38 F 10 20 0 0 5 1 1
15 1 38 F 0 0 0 (3+20) 5 0 1
16 1 45 M 3 0 0 0 5 1 1
17 1 20 M 8 0 0 0 5 1 1
18 1 15 M 8 0 0 0 5 0 1
19 1 21 M 3 0 0 0 5 1 1
20 1 50 F 3 0 0 0 5 1 1 1
21 1 50 M 19 0 0 0 5 1 0
22 1 18 M 3 0 0 0 5 0 1
23 1 23 F 0 0 25 0 5 1 1
24 1 50 F 3 20 0 0 5 1 0
25 1 43 F 0 0 25 0 5 1 1
26 1 50 M 0 0 25 0 5 1 1
27 1 24 M 8 0 0 0 5 1 1
28 1 51 M 19 0 0 0 5 1 1
29 1 52 M 3 0 0 0 5 1 1
30 1 36 M 0 0 25 0 5 1 1
31 1 51 M 0 0 25 0 5 1 1
32 1 33 F 3 0 0 0 5 1 1
33 1 64 F 19 0 27 0 5 1 1 0
34 1 61 F 3 0 0 0 1 3 5 1 0
35 1 46 F 0 0 25 0 5 1 0
36 1 56 M 3 0 0 0 5 1 0
37 1 49 M 0 0 25 0 5 1 1
38 1 51 F 0 0 27 0 5 3 1 0
39 1 49 M 0 0 25 0 5 1 0
40 1 20 M 20 0 0 0 5 1 1
41 1 60 M 0 0 27 0 5 1 1
42 1 63 M 0 0 25 0 5 1 1
43 1 33 M 3 0 0 0 5 1 1
44 1 34 M 3 0 0 0 5 1 0
45 1 31 F 19 0 0 0 5 1 1
46 1 35 F 0 0 0 (3+20) 5 1 1
47 1 46 F 3 0 0 0 5 1 1
48 1 51 F 3 0 0 0 5 1 1
49 1 52 F 3 0 0 0 5 1 0
50 1 47 M 20 0 0 0 5 1 1
51 1 46 M 19 0 0 0 5 1 0
52 1 46 M 0 0 0 (8+20) 5 1 1
53 1 32 F 19 0 0 0 5 1 0
54 1 31 F 19 0 0 0 5 1 1
Pattern of use of NSAIDs
0B
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Sr. No Dept Age Sex Cox 1 Inhibitor
Cox 1 
Inhibitor
Cox 2 
Inhibitor
Combin
ation Diagno
Co 
morbid -
1
Co 
morbid -
2
OTC
Gastro 
protective 
agents
Pattern of use of NSAIDs
0B
55 1 52 F 19 0 0 0 1 5 1 0
56 1 57 M 0 0 25 0 5 1 1
57 1 59 F 8 0 0 0 1 5 1 0
58 1 61 M 0 0 27 0 3 5 1 1
59 1 64 M 0 0 25 0 5 1 0
60 1 63 F 0 0 25 0 5 1 0
61 1 15 M 19 0 0 0 5 0 1
62 1 14 F 19 0 0 0 5 0 1
63 1 16 F 20 0 0 0 5 0 0
64 1 25 M 3 0 0 0 5 1 1
65 1 16 M 20 0 0 0 5 0 0
66 1 35 M 20 0 0 0 5 1 0
67 1 34 M 3 0 0 0 5 1 1
68 1 62 F 19 0 0 0 5 1 1
69 1 64 F 3 0 0 0 5 1 0
70 1 34 F 20 0 0 0 5 1 1
71 1 34 F 19 0 0 0 5 1 0
72 1 67 F 19 0 0 0 5 1 0
73 1 69 F 0 0 25 0 3 5 1 0
74 1 54 F 0 0 0 (8+20) 5 1 1
75 1 53 F 0 0 25 0 5 1 0
76 1 36 F 0 0 25 0 5 1 0
77 1 33 F 3 0 0 0 5 1 1
78 1 26 F 3 0 0 0 5 1 1
79 1 31 F 3 0 0 0 5 1 1
80 1 48 F 19 0 0 0 5 1 1
81 1 54 M 3 0 0 0 5 1 1
82 1 46 M 3 0 0 0 5 1 0
83 1 47 M 0 0 25 0 5 1 0
84 1 42 F 19 0 0 0 5 1 1
85 1 43 F 20 0 0 0 5 1 0
86 1 41 F 19 0 0 0 3 5 1 0
87 1 45 F 0 0 27 0 5 1 0
88 1 56 M 3 0 0 0 1 5 1 0
89 1 55 F 19 0 0 0 5 1 1
90 1 52 F 19 0 0 0 5 1 1
91 1 51 F 19 0 0 0 5 1 1
92 1 48 M 3 0 0 0 5 1 1
93 1 47 M 8 0 0 0 5 1 1
94 1 49 M 3 0 0 0 5 1 1
95 1 42 M 3 0 0 0 5 1 1
96 1 45 M 8 0 0 0 1 5 1 0
97 1 62 F 0 0 0 (8+20) 5 1 1
98 1 63 F 20 0 0 0 5 1 0
99 1 51 F 10 0 0 0 3 5 1 1
100 1 41 F 10 0 0 0 5 1 1
101 1 40 F 3 0 0 0 5 1 0
102 1 58 M 10 0 0 0 5 1 0
103 1 52 M 0 0 25 0 5 1 0
104 1 6 M 8 0 0 0 5 0 1
105 1 24 M 19 0 0 0 5 1 1
106 1 52 F 0 0 27 0 5 1 0
107 1 42 F 20 0 0 0 5 1 0
108 1 25 F 0 0 0 (8+20) 5 1 1
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Sr. No Dept Age Sex Cox 1 Inhibitor
Cox 1 
Inhibitor
Cox 2 
Inhibitor
Combin
ation Diagno
Co 
morbid -
1
Co 
morbid -
2
OTC
Gastro 
protective 
agents
Pattern of use of NSAIDs
0B
109 1 17 M 0 0 25 0 5 0 0
110 1 65 F 20 0 0 0 1 5 1 0
111 1 35 M 0 0 0 (8+20) 5 1 1
112 1 43 F 20 0 0 0 5 1 0
113 1 52 M 3 19 0 0 5 1 0
114 1 38 F 19 0 0 0 5 1 1
115 1 38 F 20 0 0 0 5 1 0
116 1 45 M 19 0 0 0 5 1 1
117 1 20 M 3 0 0 0 5 1 1
118 1 15 M 8 0 0 0 5 0 0
119 1 21 M 19 0 0 0 5 1 1
120 1 50 F 20 0 0 0 5 1 0
121 1 50 M 3 0 0 0 5 1 1
122 1 18 M 20 0 0 0 5 0 0
123 1 23 F 20 0 0 0 5 1 1
124 1 50 F 3 0 0 0 5 1 1
125 1 43 F 0 0 0 (8+20) 5 1 1
126 1 50 M 0 0 25 0 5 1 0
127 1 24 M 0 0 27 0 5 1 0
128 1 51 M 20 0 0 0 5 1 0
129 1 52 M 0 0 25 0 5 1 0
130 1 36 M 0 0 27 0 5 1 0
131 1 51 M 0 0 0 (8+20) 5 1 1
132 1 33 F 19 0 0 0 5 1 1
133 1 64 F 0 0 0 (3+20) 1 5 1 0
134 1 61 F 8 0 0 0 5 1 1
135 1 46 F 3 0 0 0 5 1 0
136 1 56 M 3 0 0 0 5 1 1
137 1 49 M 19 0 0 5 1 1
138 1 51 F 3 19 0 (3+19) 5 1 0
139 1 49 M 8 20 0 0 5 1 0
140 1 20 M 3 20 0 0 5 1 1
141 1 60 M 3 20 0 0 5 1 0
142 1 63 M 19 0 0 0 5 1 1
143 1 33 M 19 0 0 0 5 1 1
144 1 34 M 19 20 0 0 5 1 1
145 1 31 F 8 0 0 0 5 0 1
146 1 35 F 19 0 0 0 5 1 1
147 1 46 F 0 0 25 0 5 1 0
148 1 51 F 19 0 0 0 5 1 1
149 1 52 F 3 0 0 0 5 1 1
150 1 47 M 20 0 0 0 5 1 1
151 1 46 M 19 0 0 0 5 1 1
152 1 46 M 20 0 0 0 5 1 0
153 1 32 F 3 0 0 0 5 1 1
154 1 31 F 19 0 0 0 5 1 1
155 1 52 F 20 0 0 0 5 1 1
156 1 57 M 3 0 0 0 5 1 1
157 1 59 F 19 0 0 0 1 5 1 1
158 1 61 M 3 0 0 0 3 5 1 0
159 1 64 M 8 0 0 0 5 1 0
160 1 63 F 3 0 0 0 5 1 1
161 1 15 M 3 0 0 0 5 0 1
162 1 14 F 0 0 25 0 5 0 0
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Sr. No Dept Age Sex Cox 1 Inhibitor
Cox 1 
Inhibitor
Cox 2 
Inhibitor
Combin
ation Diagno
Co 
morbid -
1
Co 
morbid -
2
OTC
Gastro 
protective 
agents
Pattern of use of NSAIDs
0B
163 1 16 F 20 0 0 0 5 0 0
164 1 25 M 3 0 0 0 5 1 1
165 1 16 M 8 0 0 0 5 0 1
166 1 35 M 19 0 0 0 5 3 1 1
167 1 34 M 8 0 0 0 5 1 1
168 1 62 F 0 0 25 0 5 1 0
169 1 64 F 0 0 25 0 5 3 1 0
170 1 34 F 20 0 0 0 5 0 0
171 1 34 F 0 0 27 0 5 1 0
172 1 67 F 3 0 0 0 5 1 1
173 1 69 F 10 0 0 0 5 1 1
174 1 54 F 10 0 0 0 5 1 1
175 1 53 F 3 19 0 0 5 1 0
176 1 36 F 3 0 0 0 5 1 1
177 1 33 F 20 0 0 0 5 1 1
178 1 26 F 20 0 0 0 5 1 1
179 1 31 F 0 0 25 0 5 1 1
180 1 48 F 0 0 27 0 5 0 0
181 1 54 M 0 0 0 (8+20) 5 1 1
182 1 46 M 0 0 27 0 5 1 0
183 1 47 M 19 0 0 0 5 1 1
184 1 42 F 19 0 0 0 3 5 1 1
185 1 43 F 8 0 0 0 3 5 1 1
186 1 41 F 19 0 0 0 5 1 1
187 1 45 F 19 0 0 0 5 1 1
188 1 56 M 0 0 25 0 5 1 0
189 1 55 F 0 0 27 0 5 1 1
190 1 52 F 0 0 0 (8+20) 5 1 1
191 1 51 F 8 0 0 0 5 1 1
192 1 48 M 3 0 0 0 1 5 1 1
193 1 47 M 0 0 25 0 5 1 0
194 1 49 M 3 0 0 0 5 0 1
195 1 42 M 20 0 0 0 1 5 1 0
196 1 45 M 20 0 0 0 1 5 1 0
197 1 62 F 19 0 0 0 1 5 1 1
198 1 63 F 20 0 0 0 5 1 0
199 1 51 F 19 0 0 0 5 1 1
200 1 41 F 8 0 0 0 1 5 1 0
201 2 40 F 20 0 25 0 5 1 0
202 2 58 M 8 0 0 0 3 5 1 1
203 2 52 M 0 0 0 (3+20) 5 1 1
204 2 60 M 8 20 0 0 1 5 1 1
205 2 24 M 3 0 0 0 5 1 0
206 2 52 F 3 0 0 0 5 1 0
207 2 42 F 0 0 0 (3+20) 5 0 1
208 2 25 F 3 0 0 0 5 1 1
209 2 17 M 8 0 0 0 5 0 0
210 2 65 F 8 0 0 0 1 5 1 1
211 2 35 M 8 0 0 0 5 0 1
212 2 43 F 20 10 0 0 5 1 0
213 2 52 M 3 0 0 0 5 1 1
214 2 38 F 20 8 0 0 5 1 1
215 2 38 F 0 0 0 (3+20) 5 1 1
216 2 45 M 8 0 0 0 5 1 1
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Sr. No Dept Age Sex Cox 1 Inhibitor
Cox 1 
Inhibitor
Cox 2 
Inhibitor
Combin
ation Diagno
Co 
morbid -
1
Co 
morbid -
2
OTC
Gastro 
protective 
agents
Pattern of use of NSAIDs
0B
217 2 20 M 8 0 0 0 5 1 1
218 2 15 M 3 0 0 0 5 0 1
219 2 21 M 3 0 0 0 5 1 1
220 2 50 F 20 3 0 0 5 1 1
221 2 50 M 20 19 0 0 5 1 1
222 2 18 M 0 0 0 (3+20) 5 0 1
223 2 23 F 0 0 0 (3+20) 5 1 1
224 2 50 F 8 0 0 0 5 1 1
225 2 43 F 0 0 0 (8+20) 5 1 1
226 2 50 M 0 0 0 (8+20) 5 1 1
227 2 24 M 8 0 0 0 5 1 0
228 2 51 M 3 0 0 0 5 1 1
229 2 52 M 0 0 0 (3+20) 5 1 1
230 2 36 M 20 3 0 0 5 1 1
231 2 51 M 8 0 0 0 5 1 1
232 2 33 F 0 0 0 (3+20) 5 0 1
233 2 64 F 0 0 0 (3+20) 5 1 1
234 2 61 F 8 0 0 0 5 1 1
235 2 46 F 3 0 0 0 5 1 0
236 2 56 M 0 0 25 0 5 1 1
237 2 49 M 20 0 25 0 5 1 0
238 2 51 F 3 0 0 0 5 1 1
239 2 49 M 20 0 0 0 5 1 1
240 2 20 M 3 0 0 0 5 1 1
241 2 60 M 3 0 0 0 5 1 0
242 2 63 M 3 0 0 0 5 1 1
243 2 33 M 20 8 0 0 5 0 1
244 2 34 M 8 0 0 0 5 1 1
245 2 31 F 20 8 0 0 5 1 0
246 2 35 F 3 0 0 0 5 1 1
247 2 46 F 0 0 0 (27+20) 5 1 0
248 2 51 F 20 3 0 0 5 0 1
249 2 52 F 3 0 0 0 5 1 1
250 2 47 M 3 0 0 0 5 1 1
251 2 46 M 20 3 0 0 5 1 1
252 2 46 M 20 0 0 0 5 0 1
253 2 32 F 8 0 0 0 5 1 1
254 2 31 F 3 0 0 0 5 1 1
255 2 52 F 19 0 0 0 5 1 1
256 2 57 M 8 0 0 0 5 1 1
257 2 59 F 0 0 0 (3+20) 5 1 1
258 2 61 M 3 0 0 0 5 1 1
259 2 64 M 3 0 0 0 5 1 1
260 2 63 F 3 0 0 0 5 1 1
261 2 15 M 3 0 0 0 5 0 1
262 2 14 F 20 8 0 0 5 0 0
263 2 16 F 8 0 0 0 5 0 0
264 2 25 M 20 3 0 0 5 1 1
265 2 16 M 0 0 0 (3+20) 5 0 1
266 2 35 M 8 0 0 0 5 1 0
267 2 34 M 20 0 25 0 5 1 1
268 2 62 F 3 0 0 0 3 5 1 0
269 2 64 F 3 0 0 0 3 5 1 1
270 2 34 F 3 0 0 0 5 1 1
137
Sr. No Dept Age Sex Cox 1 Inhibitor
Cox 1 
Inhibitor
Cox 2 
Inhibitor
Combin
ation Diagno
Co 
morbid -
1
Co 
morbid -
2
OTC
Gastro 
protective 
agents
Pattern of use of NSAIDs
0B
271 2 34 F 20 0 0 0 5 0 1
272 2 67 F 8 0 0 0 5 1 1
273 2 69 F 3 0 0 0 5 1 1
274 2 54 F 3 0 0 0 5 1 1
275 2 53 F 8 0 0 0 5 1 1
276 2 36 F 0 0 25 0 5 1 1
277 2 33 F 3 0 0 0 5 1 1
278 2 26 F 8 0 0 0 5 1 1
279 2 31 F 20 3 0 0 5 0 1
280 2 48 F 20 8 0 0 5 1 1
281 2 54 M 3 0 0 0 5 1 1
282 2 46 M 3 0 0 0 5 1 1
283 2 47 M 0 0 0 (8+20) 5 1 1
284 2 42 F 20 3 0 0 5 1 1
285 2 43 F 20 8 0 0 5 1 1
286 2 41 F 19 0 0 0 5 1 1
287 2 45 F 0 0 0 (3+20) 5 1 1
288 2 56 M 0 0 0 (3+20) 5 1 1
289 2 55 F 8 0 0 0 5 1 1
290 2 52 F 8 0 0 0 5 1 1
291 2 51 F 25 0 0 0 5 1 1
292 2 48 M 3 0 0 0 5 1 1
293 2 47 M 8 0 0 0 5 1 1
294 2 49 M 0 0 0 (8+20) 5 1 1
295 2 42 M 20 3 0 0 5 1 1
296 2 45 M 27 0 0 0 5 1 1
297 2 62 F 3 0 0 0 5 1 0
298 2 63 F 20 0 0 0 5 1 1
299 2 51 F 10 0 0 0 5 1 1
300 2 41 F 20 0 25 0 5 1 0
301 2 40 F 20 8 0 0 5 0 1
302 2 58 M 20 0 0 0 5 1 1
303 2 52 M 20 0 27 0 5 1 1
304 2 61 M 0 0 0 (3+20) 5 1 1
305 2 24 M 3 0 0 0 5 1 1
306 2 52 F 20 8 0 0 5 1 1
307 2 42 F 3 0 0 0 5 1 1
308 2 25 F 19 20 0 0 5 1 0
309 2 17 M 20 0 0 0 5 1 1
310 2 65 F 0 0 0 (3+20) 5 0 1
311 2 35 M 19 0 0 0 5 1 0
312 2 43 F 19 0 0 0 5 1 0
313 2 52 M 20 0 0 0 5 1 1
314 2 38 F 10 0 0 0 5 1 1
315 2 38 F 20 0 0 0 5 0 0
316 2 45 M 20 0 0 0 5 1 1
317 2 20 M 0 0 0 (8+20) 5 1 1
318 2 15 M 20 8 0 0 5 0 1
319 2 21 M 20 3 0 0 5 1 1
320 2 50 F 20 0 0 0 5 1 1
321 2 50 M 20 0 0 0 5 1 1
322 2 18 M 0 0 0 (3+20) 5 0 0
323 2 23 F 10 20 0 0 5 1 1
324 2 50 F 10 20 0 0 5 1 1
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325 2 43 F 20 0 0 0 5 1 0
326 2 50 M 20 0 0 0 5 1 1
327 2 24 M 20 3 0 0 5 1 1
328 2 51 M 20 0 0 0 5 1 0
329 2 52 M 20 0 0 0 5 1 1
330 2 36 M 20 0 0 0 5 0 1
331 2 51 M 0 0 0 (3+20) 5 1 1
332 2 33 F 20 0 0 0 5 1 1
333 2 64 F 20 0 0 0 5 1 1
334 2 61 F 20 0 0 0 5 1 1
335 2 46 F 20 0 0 0 5 1 1
336 2 56 M 20 19 0 0 5 1 1
337 2 49 M 20 0 0 0 5 1 1
338 2 51 F 20 0 0 0 5 1 1
339 2 49 M 20 19 0 0 5 1 1
340 2 20 M 20 0 0 0 5 0 1
341 2 60 M 20 0 0 0 5 1 1
342 2 63 M 20 0 0 0 5 1 1
343 2 33 M 20 0 0 0 5 1 1
344 2 34 M 20 0 0 0 5 1 1
345 2 31 F 20 0 0 0 5 0 0
346 2 35 F 20 0 27 0 5 0 1
347 2 46 F 20 0 0 0 5 1 1
348 2 51 F 20 0 0 0 5 1 0
349 2 52 F 20 0 27 0 5 1 1
350 2 47 M 0 0 0 (8+20) 5 1 1
351 2 46 M 20 0 0 0 5 1 0
352 2 46 M 20 0 0 0 5 1 1
353 2 32 F 0 0 0 (3+20) 5 1 1
354 2 31 F 20 0 0 0 5 1 1
355 2 52 F 20 0 0 0 5 1 1
356 2 57 M 20 0 0 0 5 1 0
357 2 59 F 20 0 27 0 5 1 1
358 2 61 M 20 0 0 0 5 1 1
359 2 64 M 20 0 0 0 5 1 0
360 2 63 F 20 0 0 0 5 1 0
361 2 15 M 20 0 25 0 5 0 0
362 2 14 F 20 0 27 0 5 0 1
363 2 16 F 20 3 0 0 5 0 1
364 2 25 M 20 0 0 0 5 1 1
365 2 18 M 0 0 0 (3+20) 5 1 1
366 2 35 M 20 0 0 0 5 0 1
367 2 34 M 20 0 0 0 5 0 0
368 2 62 F 20 0 27 0 5 1 1
369 2 64 F 20 0 27 0 5 1 0
370 2 34 F 0 0 0 (8+20) 5 1 1
371 2 34 F 20 0 0 0 5 1 1
372 2 67 F 20 0 0 0 5 1 1
373 2 69 F 20 0 0 0 5 1 0
374 2 54 M 20 0 0 0 5 1 0
375 2 53 F 20 0 0 0 5 1 1
376 2 36 F 20 0 0 0 5 1 1
377 2 33 F 20 0 0 0 5 1 1
378 2 26 M 20 0 0 0 5 0 1
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379 2 31 F 20 0 0 0 5 1 0
380 2 48 F 3 20 0 0 5 1 1
381 2 54 M 20 0 0 0 5 1 0
382 2 46 M 20 0 0 0 5 1 0
383 2 47 M 19 0 0 0 5 1 1
384 2 42 F 20 0 0 0 5 1 1
385 2 43 F 20 0 0 0 5 1 1
386 2 41 F 20 0 0 0 5 1 1
387 2 45 F 20 0 25 0 5 1 1
388 2 56 M 20 0 0 0 5 1 0
389 2 55 F 20 0 0 0 5 1 1 0
390 2 52 F 20 0 0 0 5 1 1
391 2 51 F 20 0 0 0 5 1 1
392 2 48 M 20 0 0 0 5 1 1
393 2 47 M 19 0 0 0 5 1 1
394 2 49 M 20 0 0 0 5 1 1
395 2 42 M 20 0 0 0 5 1 1
396 2 45 M 20 0 0 0 5 1 1
397 2 62 F 20 0 0 0 5 1 0
398 2 63 F 20 0 0 0 5 1 1
399 2 51 F 20 0 0 0 5 1 1
400 2 41 F 20 0 0 0 5 1 0
401 3 40 F 0 0 0 (8+20) 5 0 1
402 3 58 M 3 0 0 0 7 1 1
403 3 52 M 0 0 27 0 5 4 1 0
404 3 60 M 0 0 0 (27+20) 5 1 0 1
405 3 24 M 8 0 0 0 6 1 1
406 3 52 F 20 0 0 0 2 1 1
407 3 42 F 3 0 0 0 5 1 1
408 3 25 F 0 0 0 (8+20) 5 4 1 1
409 3 17 M 20 0 0 0 2 1 0
410 3 65 F 0 0 0 (8+20) 6 4 1 1
411 3 35 M 0 0 0 (8+20) 2 1 1
412 3 43 F 0 0 0 (3+20) 5 4 1 1
413 3 52 M 0 0 0 (8+20) 1 5 1 1
414 3 38 F 20 8 0 0 2 1 0
415 3 38 F 8 0 0 0 5 1 1
416 3 45 M 20 0 0 0 7 4 1 0
417 3 20 M 8 0 0 0 6 1 0
418 3 15 M 2 0 0 0 4 1 0
419 3 21 M 3 0 0 0 4 1 1
420 3 50 F 0 0 27 0 2 3 1 0
421 3 50 M 20 0 0 0 2 1 1
422 3 18 M 2 0 0 0 2 1 1
423 3 23 F 0 0 0 (3+20) 5 0 1
424 3 50 F 3 0 0 0 4 1 1
425 3 43 F 0 0 0 (3+20) 5 1 1
426 3 50 M 0 0 27 0 2 1 0
427 3 44 M 19 0 0 0 5 1 1 0
428 3 51 M 0 0 0 (2+20) 2 4 1 1
429 3 52 M 3 0 0 0 5 1 1
430 3 36 M 0 0 0 (2+20) 2 0 0
431 3 51 M 20 0 0 0 7 1 0
432 3 33 F 0 0 0 (27+20) 4 2 1 1
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433 3 64 F 2 0 0 0 1 2 4 1 0
434 3 61 F 0 0 0 (2+20) 5 3 1 1
435 3 46 F 0 0 0 (8+20) 5 1 1
436 3 56 M 20 0 0 0 2 1 0
437 3 49 M 20 0 0 0 4 1 0
438 3 51 F 2 0 27 0 4 2 1 0
439 3 49 M 0 0 0 (8+20) 5 1 1
440 3 20 M 2 0 0 0 7 2 0 0
441 3 60 M 0 0 0 (2+20) 1 3 4 1 1
442 3 63 M 0 0 0 (2+20) 1 3 4 1 1
443 3 33 M 19 0 0 0 5 1 1
444 3 34 M 8 0 0 0 5 6 1 1
445 3 31 F 8 0 0 0 4 1 1
446 3 35 F 0 0 0 (2+20) 4 5 1 1
447 3 46 F 0 0 0 (3+20) 2 6 1 1
448 3 51 F 0 0 27 0 5 2 1 0
449 3 52 F 0 0 0 (3+20) 5 4 1 0
450 3 47 M 0 0 0 (3+20) 5 4 1 1
451 3 46 M 20 0 0 0 4 1 0
452 3 46 M 20 0 0 0 4 1 0
453 3 32 F 2 0 0 0 4 1 0
454 3 31 F 8 0 0 0 5 1 1
455 3 52 F 2 0 0 0 7 4 1 0
456 3 57 M 8 0 0 0 2 1 1
457 3 59 F 2 0 0 0 2 4 1 0
458 3 61 M 0 0 0 (3+20) 3 4 1 1
459 3 64 M 0 0 0 (3+20) 4 1 0
460 3 63 F 20 0 0 0 2 1 0
461 3 15 M 3 0 0 0 5 1 1
462 3 14 F 20 0 0 0 4 1 0
463 3 16 F 0 0 0 (27+20) 4 2 1 1
464 3 25 M 20 0 0 0 7 0 0
465 3 16 M 20 0 27 0 2 4 1 0
466 3 35 M 0 0 27 0 4 1 1
467 3 34 M 2 0 0 0 2 1 1
468 3 62 F 20 0 0 (3+20) 2 8 1 1
469 3 64 F 20 0 0 0 2 1 0
470 3 34 F 2 0 0 0 2 1 0
471 3 34 F 20 0 0 0 2 1 0
472 3 67 F 2 0 0 0 2 5 1 0
473 3 69 F 20 0 0 0 4 1 0
474 3 54 F 20 0 0 0 4 5 1 1
475 3 53 F 0 0 0 (2+20) 4 2 1 0
476 3 36 F 20 0 0 0 2 1 0
477 3 33 F 20 0 0 0 2 0 0
478 3 26 F 20 0 0 0 2 1 1
479 3 31 F 20 8 0 0 4 1 0
480 3 48 F 3 0 0 0 5 1 1
481 3 54 M 8 0 0 0 5 2 1 1
482 3 46 M 8 0 0 0 5 2 1 1
483 3 47 M 8 0 0 0 3 2 1 1
484 3 42 F 8 0 0 0 5 3 1 1
485 3 43 F 8 0 0 0 1 5 1 0
486 3 41 F 8 0 0 0 1 4 1 0
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487 3 45 F 8 0 0 0 1 3 1 1
488 3 56 M 8 0 0 0 2 1 1
489 3 55 F 8 0 0 0 4 1 0
490 3 52 F 8 0 0 0 2 1 1
491 3 51 F 3 0 0 0 5 3 1 0
492 3 48 M 3 0 0 0 5 4 1 1
493 3 47 M 3 0 0 0 5 4 1 1
494 3 49 M 3 0 0 0 5 4 1 0
495 3 42 M 3 0 0 0 2 1 1
496 3 45 M 3 0 0 0 2 1 0
497 3 62 F 3 0 0 0 2 1 1
498 3 63 F 3 0 0 0 4 1 0
499 3 51 F 3 0 0 0 4 1 0
500 3 41 F 3 0 0 0 4 1 1
501 3 57 F 0 0 27 0 5 1 1
502 3 28 F 3 0 0 0 5 1 0
503 3 62 M 19 0 0 0 4 1 1
504 3 27 F 3 0 0 0 4 1 1
505 3 32 M 20 0 0 0 2 1 0
506 3 25 M 20 0 0 0 2 0 0
507 3 34 F 3 0 0 0 5 1 1
508 3 30 F 0 0 0 (27+20) 5 1 0
509 3 24 M 20 0 27 0 4 1 1
510 3 51 F 3 0 27 0 2 5 1 0
511 3 18 M 0 0 0 (8+20) 5 1 1
512 3 33 F 0 0 0 (3+20) 6 1 0
513 3 25 M 0 0 0 (8+20) 7 0 0 1
514 3 18 F 20 0 0 0 4 1 0
515 3 18 F 8 0 0 0 5 1 0
516 3 38 F 20 0 0 0 4 1 0
517 3 18 F 8 0 0 0 5 1 1
518 3 50 F 3 0 0 0 3 1 1
519 3 27 F 0 0 0 (3+20) 7 1 1
520 3 24 M 0 0 27 0 2 1 0
521 3 35 F 20 0 0 0 4 1 1
522 3 47 M 3 0 0 0 1 1 1
523 3 40 F 0 0 0 (3+20) 4 1 0
524 3 45 F 3 0 0 0 5 1 1
525 3 40 F 0 0 0 (3+20) 1 1 1
526 3 26 F 0 0 27 0 4 0 0
527 3 50 F 19 0 0 0 5 1 0
528 3 32 M 3 0 0 0 4 1 1
529 3 38 M 3 0 0 0 5 1 1
530 3 18 M 0 0 0 (3+20+S 6 1 1
531 3 32 M 20 0 0 0 4 1 1
532 3 36 F 0 0 0 (27+20) 4 1 0
533 3 30 F 0 0 0 (3+D) 7 0 0
534 3 42 F 0 0 0 (3+20+S 4 1 1
535 3 18 F 0 0 0 (8+20) 5 1 0
536 3 34 M 0 0 0 (8+20) 5 1 1
537 3 40 M 0 0 0 20+C+P 2 1 1
538 3 20 M 3 0 0 0 5 4 1 1
539 3 44 F 0 0 0 (27+20) 4 1 0
540 3 38 F 3 0 0 0 5 1 1
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541 3 42 M 0 0 0 (27+20) 4 1 1
542 3 22 F 20 0 0 (27+20) 4 1 0
543 3 35 F 19 0 0 0 5 1 1
544 3 30 F 8 0 0 0 2 1 1
545 3 23 F 8 0 0 0 5 1 0
546 3 47 F 0 0 0 (27+20) 4 1 0
547 3 40 M 20 0 0 (3+20) 3 5 1 0
548 3 18 F 0 0 27 0 2 1 0
549 3 20 F 0 0 0 (3+20) 4 1 1
550 3 20 F 0 0 0 (3+20) 2 0 1
551 3 46 M 0 0 0 (8+20) 2 1 0
552 3 55 M 20 0 0 0 7 1 0
553 3 70 F 20 0 0 0 3 7 1 1
554 3 48 M 0 0 0 (3+20) 1 4 1 0
555 3 38 F 20 0 0 0 4 1 0
556 3 44 M 20 0 0 0 2 1 0
557 3 59 F 20 0 0 0 5 1 0
558 3 61 M 3 0 0 0 5 1 1
559 3 64 M 8 0 0 0 1 5 1 1
560 3 63 F 20 0 0 0 1 4 1 0
561 3 15 M 20 0 0 0 5 1 0
562 3 22 F 0 0 0 (3+20) 5 0 0 1
563 3 16 F 20 0 0 0 5 1 0
564 3 25 M 20 0 0 0 2 1 0
565 3 26 M 20 0 0 0 2 0 0
566 3 35 M 3 0 0 0 4 1 1
567 3 34 M 20 0 0 0 5 1 0
568 3 62 F 20 0 0 0 4 1 0
569 3 64 F 20 0 0 0 5 1 0
570 3 34 F 0 0 27 0 2 1 0
571 3 35 M 2 0 0 0 2 1 0
572 3 67 F 20 0 0 0 2 3 1 1 0
573 3 65 F 20 0 0 0 2 1 0
574 3 54 F 20 0 0 0 5 1 0
575 3 53 F 20 0 0 0 4 1 0
576 3 36 F 2 0 0 0 2 3 1 0
577 3 33 F 20 0 0 0 2 4 1 0
578 3 26 F 2 0 0 0 5 1 0
579 3 31 F 0 0 27 0 2 1 0
580 3 48 F 20 0 0 0 2 1 0
581 3 54 M 20 0 0 0 2 1 0
582 3 46 M 0 0 0 (8+20) 5 1 0
583 3 47 M 20 0 0 0 7 1 0
584 3 42 F 0 0 0 (3+20) 5 1 0
585 3 43 F 20 0 0 0 4 1 0
586 3 41 F 3 0 0 0 2 5 1 0
587 3 45 F 20 0 0 0 1 5 1 0
588 3 56 M 3 0 0 0 5 4 1 1
589 3 55 F 20 0 0 0 6 1 0
590 3 52 F 20 0 0 0 7 1 0
591 3 51 F 20 0 0 0 1 3 1 0
592 3 48 M 20 0 0 0 2 1 0
593 3 47 M 0 0 0 (8+20) 5 1 1
594 3 49 M 20 0 0 0 7 1 0
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595 3 42 M 20 0 0 0 1 5 1 0
596 3 25 M 20 0 0 0 4 0 0
597 3 62 F 20 0 0 0 1 7 1 0
598 3 63 F 20 0 0 0 5 1 1 0
599 3 51 F 20 0 0 0 4 1 0
600 3 41 F 0 0 27 0 5 1 0
601 4 45 M 20 0 0 0 4 1 0
602 4 43 F 20 0 0 0 5 1 0
603 4 58 F 20 0 0 0 5 1 0
604 4 60 F 2 0 0 0 4 1 1
605 4 37 F 10 0 0 0 4 1 0
606 4 30 F 2 0 0 0 1 5 1 0
607 4 70 M 20 0 0 0 2 1 0
608 4 27 M 20 0 0 0 4 1 0
609 4 45 F 2 0 0 0 4 1 0
610 4 60 M 2 0 0 0 4 1 1
611 4 40 F 2 0 0 0 3 4 1 1
612 4 63 F 0 0 0 (8+20) 5 1 1 0
613 4 20 F 0 0 0 (8+20) 8 4 0 0
614 4 65 M 0 0 0 (8+20) 2 1 0
615 4 32 F 3 0 0 0 8 5 1 0
616 4 68 F 20 0 0 0 4 1 0
617 4 47 F 0 0 0 (3+20) 3 5 8 1 0
618 4 62 F 0 0 0 (3+20) 8 5 1 1
619 4 37 F 20 0 0 0 4 1 0
620 4 24 M 0 0 0 (8+20) 2 0 0
621 4 19 F 20 0 0 0 2 1 0
622 4 18 M 2 0 0 0 2 1 0
623 4 65 F 20 0 0 0 2 1 1
624 4 21 M 2 0 0 0 4 1 0
625 4 30 M 2 0 0 0 4 1 1
626 4 65 M 2 0 0 0 7 1 0
627 4 19 F 2 0 0 0 4 0 0
628 4 65 F 20 0 0 0 4 1 1
629 4 40 M 20 0 0 0 4 1 0
630 4 26 M 20 0 0 0 4 0 0
631 4 50 M 20 0 0 0 4 1 1
632 4 33 F 20 0 0 0 2 1 0
633 4 26 F 20 0 0 0 2 0 0
634 4 69 F 20 0 0 0 2 1 0
635 4 46 F 20 0 0 0 2 1 0
636 4 28 M 8 0 0 0 5 1 1
637 4 49 M 20 0 0 0 7 1 0
638 4 51 F 20 0 0 0 1 4 1 0
639 4 49 M 3 0 0 0 1 2 1 1
640 4 20 M 0 0 0 (3+20) 4 1 1
641 4 60 M 27 0 0 0 4 1 0
642 4 63 M 20 0 0 0 6 1 1 0
643 4 33 M 8 0 0 0 5 4 1 1
644 4 34 M 0 0 0 (8+20) 5 1 1
645 4 31 F 20 0 0 0 4 1 0
646 4 35 F 20 0 0 0 2 1 0
647 4 46 F 20 0 0 0 4 1 0
648 4 51 F 3 20 0 0 5 1 1 0
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649 4 52 F 20 0 0 0 1 5 1 0
650 4 47 M 20 0 0 0 4 1 1
651 4 46 M 20 0 0 0 4 1 0
652 4 60 M 20 0 0 0 5 2 1 0
653 4 32 F 20 0 0 0 4 1 1
654 4 31 F 8 20 0 0 5 1 1
655 4 52 F 20 0 0 0 1 5 1 0
656 4 57 M 0 0 27 0 4 5 1 0
657 4 59 F 20 0 0 0 4 1 0
658 4 61 M 20 0 0 0 1 3 4 1 0
659 4 64 M 20 0 0 0 1 7 1 0
660 4 63 F 20 3 0 0 5 1 1 1
661 4 17 M 20 0 0 0 4 1 0
662 4 18 F 20 0 0 0 4 1 0
663 4 16 F 20 0 0 0 4 1 0
664 4 25 M 20 0 0 0 4 0 0
665 4 16 M 20 0 0 0 4 1 0
666 4 35 M 8 0 0 0 5 2 1 1
667 4 34 M 3 0 0 0 5 6 1 1
668 4 62 F 0 0 0 (8+20) 1 5 1 1
669 4 64 F 20 0 0 0 1 3 2 1 0
670 4 34 F 20 0 0 0 4 1 0
671 4 39 M 8 0 0 0 4 1 1
672 4 67 M 20 0 0 0 1 5 1 0
673 4 69 F 20 0 0 0 4 2 1 0
674 4 54 F 20 0 0 0 6 1 0
675 4 53 F 20 0 0 0 5 4 1 0
676 4 36 F 8 0 0 0 5 1 0
677 4 33 F 20 0 0 0 5 1 0
678 4 26 M 20 0 0 0 2 0 1
679 4 31 M 20 0 0 0 2 1 0
680 4 48 F 10 0 0 0 5 1 0
681 4 54 M 20 0 0 0 2 1 0
682 4 46 M 10 0 0 0 5 1 1
683 4 47 M 0 0 0 (3+20) 2 5 1 1
684 4 42 F 0 0 0 (8+20) 4 7 1 0
685 4 43 F 20 0 0 0 4 1 0
686 4 41 F 20 0 0 0 1 4 1 0
687 4 45 F 20 0 0 0 7 1 0
688 4 56 M 3 0 0 0 4 1 1
689 4 55 F 20 0 0 0 8 7 1 0
690 4 52 F 20 0 0 0 2 1 1 0
691 4 51 F 0 0 0 0 2 1 1 0
692 4 48 M 20 0 0 (3+20) 5 1 1
693 4 47 M 20 0 0 0 4 1 0
694 4 49 M 20 0 0 0 4 1 0
695 4 42 M 20 0 0 0 2 1 0
696 4 45 M 8 0 0 0 5 1 1
697 4 62 F 20 0 0 0 4 1 1 0
698 4 63 M 20 0 0 0 2 1 1 0
699 4 51 F 20 0 0 0 2 1 0
700 4 41 F 0 0 27 0 4 1 0
701 4 40 F 20 8 0 0 6 5 1 1
702 4 58 M 0 0 0 (3+20) 5 1 0
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703 4 52 M 20 0 0 0 1 2 1 1
704 4 60 M 20 0 0 0 3 1 4 1 0
705 4 24 M 0 0 0 (8+20) 4 5 0 1
706 4 52 F 20 0 0 0 4 1 0
707 4 42 F 3 0 0 0 1 5 1 0
708 4 25 F 20 0 0 0 4 0 0
709 4 17 M 20 0 0 0 6 4 1 1
710 4 65 F 20 3 0 0 1 4 1 0
711 4 35 M 20 0 0 0 2 1 0
712 4 43 F 20 0 0 0 2 1 0
713 4 52 M 20 0 0 0 2 1 0
714 4 38 F 20 0 0 0 4 1 0
715 4 38 F 20 0 0 0 3 4 1 0
716 4 45 M 20 0 0 0 3 4 1 0
717 4 20 M 20 0 0 0 2 1 1
718 4 15 M 20 0 0 0 2 1 0
719 4 21 M 20 0 0 0 4 1 1
720 4 50 F 20 0 0 0 7 4 1 0
721 4 50 M 8 0 0 0 5 4 1 0
722 4 18 M 20 0 0 0 2 1 0
723 4 23 F 20 0 0 0 2 0 0
724 4 50 F 20 8 0 0 1 5 1 1
725 4 43 F 8 0 0 0 5 1 1
726 4 50 M 20 0 0 0 4 1 0
727 4 24 M 20 0 0 0 4 0 0
728 4 51 M 19 0 0 0 5 1 1
729 4 52 M 2 0 0 0 4 1 0
730 4 36 M 20 0 0 0 2 1 0
731 4 51 M 20 0 0 0 2 1 0
732 4 33 F 0 0 27 0 4 1 0
733 4 64 F 2 0 0 0 1 3 4 1 0
734 4 61 F 2 0 0 0 1 7 1 0
735 4 46 F 2 0 0 0 5 4 1 0
736 4 56 M 20 0 0 0 4 1 0
737 4 49 M 2 0 0 0 7 2 1 0
738 4 51 F 20 0 0 0 4 1 0
739 4 49 M 20 0 0 0 2 1 0
740 4 20 M 8 0 0 0 5 1 0 1
741 4 60 M 20 0 0 0 4 1 1
742 4 63 M 0 0 0 (3+20) 5 1 4 1 0
743 4 33 M 2 0 0 0 1 4 1 0
744 4 34 M 2 0 0 0 4 1 0
745 4 31 F 20 0 0 0 4 1 0
746 4 35 F 20 0 0 0 2 1 0
747 4 46 F 20 0 0 0 7 4 1 0
748 4 51 F 20 0 0 0 1 4 1 0
749 4 52 F 20 0 0 0 6 2 1 0
750 4 47 M 8 0 0 0 5 2 1 1
751 4 46 M 20 0 0 0 1 3 2 1 0
752 4 46 M 20 0 0 0 2 1 0
753 4 32 F 8 0 0 0 5 1 1
754 4 31 F 20 0 0 0 2 6 1 0
755 4 52 F 20 3 0 0 8 5 1 1
756 4 57 M 0 0 27 0 4 1 1
146
Sr. No Dept Age Sex Cox 1 Inhibitor
Cox 1 
Inhibitor
Cox 2 
Inhibitor
Combin
ation Diagno
Co 
morbid -
1
Co 
morbid -
2
OTC
Gastro 
protective 
agents
Pattern of use of NSAIDs
0B
757 4 59 F 20 0 0 0 3 2 1 0
758 4 61 M 3 0 0 0 4 1 1
759 4 64 M 20 0 0 0 5 1 1 0
760 4 63 F 2 0 0 0 1 7 1 0
761 4 15 M 2 0 0 0 2 1 0
762 4 14 F 20 0 0 0 4 1 0
763 4 16 F 20 0 0 0 2 1 1
764 4 25 M 2 0 0 0 4 0 0
765 4 16 M 20 0 0 0 4 1 0
766 4 35 M 0 0 25 0 5 1 1
767 4 34 M 20 0 0 0 2 1 0
768 4 62 F 20 0 0 (3+20) 2 5 1 1
769 4 64 F 20 0 0 0 1 3 4 1 0
770 4 34 F 3 0 0 0 5 1 1
771 4 34 F 0 0 27 0 5 1 0
772 4 67 F 3 0 0 0 5 1 1
773 4 69 F 20 0 0 0 2 1 0
774 4 54 F 2 0 0 0 5 4 1 0
775 4 53 F 20 0 0 0 1 4 1 0
776 4 36 F 2 0 0 0 2 1 0
777 4 33 F 20 0 0 0 4 1 0
778 4 26 F 8 0 0 0 5 4 1 1
779 4 31 F 2 0 0 0 5 2 1 0
780 4 48 F 20 0 0 0 4 1 0
781 4 54 M 20 0 0 0 7 1 1
782 4 46 M 20 0 0 0 4 1 0
783 4 47 M 2 0 0 0 2 7 1 0
784 4 42 F 20 0 0 0 2 1 0
785 4 43 F 2 0 0 0 4 2 1 0
786 4 41 F 20 0 0 0 2 1 1
787 4 45 F 20 0 0 0 2 1 0
788 4 56 M 2 0 0 0 2 1 0
789 4 55 F 0 0 25 0 5 4 1 0
790 4 52 F 20 0 0 0 4 1 0
791 4 51 F 19 0 0 0 5 1 1 0
792 4 48 M 20 0 0 0 2 1 1
793 4 47 M 0 0 0 (3+20) 4 1 1
794 4 49 M 20 0 0 0 7 1 0
795 4 42 M 19 0 0 0 5 1 1 0
796 4 45 M 0 0 27 0 2 5 1 0
797 4 62 F 20 0 0 0 4 1 0
798 4 63 F 2 0 0 0 2 1 0
799 4 51 F 0 0 27 0 2 5 1 0
800 4 41 F 20 0 0 0 7 1 0
801 5 4 F 20 0 0 0 4 1 1
802 5 8 M 8 0 0 0 5 0 0
803 5 2 M 20 0 0 0 2 1 0
804 5 6 M 20 0 0 0 7 1 0
805 5 4 M 20 0 0 0 2 1 1
806 5 2 F 20 0 0 0 2 1 0
807 5 4 F 20 0 0 0 2 1 0
808 5 2 F 20 0 0 0 2 1 1
809 5 7 M 8 0 0 0 5 1 0
810 5 6 F 20 0 0 0 7 0 0
147
Sr. No Dept Age Sex Cox 1 Inhibitor
Cox 1 
Inhibitor
Cox 2 
Inhibitor
Combin
ation Diagno
Co 
morbid -
1
Co 
morbid -
2
OTC
Gastro 
protective 
agents
Pattern of use of NSAIDs
0B
811 5 3 M 20 0 0 0 7 1 0
812 5 3 F 20 0 0 0 7 1 0
813 5 5 M 20 0 0 0 7 1 0
814 5 8 F 20 0 0 0 4 1 0
815 5 8 F 20 0 0 0 4 1 0
816 5 5 M 20 0 0 0 4 1 0
817 5 2 M 20 0 0 0 4 1 0
818 5 5 M 20 0 0 0 4 1 0
819 5 2 M 20 0 0 0 6 1 1
820 5 5 F 20 0 0 0 6 1 0
821 5 5 M 20 0 0 0 6 1 0
822 5 8 M 8 0 0 0 6 1 0
823 5 3 F 20 0 0 0 6 1 1
824 5 5 F 20 0 0 0 2 1 0
825 5 4 F 20 0 0 0 2 1 0
826 5 5 M 20 0 0 0 2 1 0
827 5 2 M 20 0 0 0 4 1 0
828 5 9 M 0 0 0 (8+20) 8 1 1
829 5 5 M 20 0 0 0 5 1 0
830 5 6 M 20 0 0 0 5 1 0
831 5 5 M 20 0 0 0 5 1 1
832 5 3 F 20 0 0 0 7 1 0
833 5 6 F 20 0 0 0 7 1 0
834 5 9 F 20 0 0 0 2 1 0
835 5 6 F 20 0 0 0 4 0 0
836 5 6 M 20 0 0 0 7 0 0
837 5 9 M 8 0 0 0 6 0 0
838 5 5 F 20 0 0 0 6 0 0
839 5 9 M 20 0 0 0 4 0 0
840 5 2 M 20 0 0 0 2 0 0
841 5 6 M 20 0 0 0 6 0 0
842 5 3 M 20 0 0 0 4 0 0
843 5 3 M 20 0 0 0 6 0 0
844 5 4 M 20 0 0 0 2 0 0
845 5 3 F 20 0 0 0 2 0 0
846 5 5 F 20 0 0 0 2 0 0
847 5 6 F 20 0 0 0 2 0 0
848 5 5 F 20 0 0 0 4 0 1
849 5 2 F 20 0 0 0 7 0 0
850 5 7 M 8 0 0 0 6 0 1
851 5 6 M 20 0 0 0 6 0 0
852 5 4 M 20 0 0 0 7 0 0
853 5 2 F 20 0 0 0 4 0 0
854 5 3 F 20 0 0 0 4 0 1
855 5 2 F 20 0 0 0 4 0 0
856 5 7 M 20 0 0 0 4 0 0
857 5 9 F 20 0 0 0 2 0 1
858 5 6 M 0 0 0 (8+20) 5 0 1
859 5 6 M 20 0 0 0 2 0 0
860 5 3 F 20 0 0 0 5 0 0
861 5 5 M 20 0 0 0 4 0 0
862 5 4 F 20 0 0 0 2 0 0
863 5 6 F 20 0 0 0 2 0 0
864 5 5 M 20 0 0 0 4 0 1
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865 5 6 M 20 0 0 0 5 0 0
866 5 3 M 20 0 0 0 7 0 0
867 5 4 M 20 0 0 0 6 0 0
868 5 2 F 20 0 0 0 2 0 1
869 5 6 F 20 0 0 0 2 0 0
870 5 3 F 20 0 0 0 2 0 0
871 5 4 F 20 0 0 0 4 0 0
872 5 7 F 20 0 0 0 4 0 0
873 5 6 F 20 0 0 0 6 0 0
874 5 4 F 20 0 0 0 6 0 0
875 5 3 F 20 0 0 0 5 0 0
876 5 6 F 8 0 0 0 5 0 1
877 5 3 F 20 0 0 0 4 0 0
878 5 6 F 20 0 0 0 4 0 1
879 5 1 F 20 0 0 0 2 0 0
880 5 8 F 20 0 0 0 2 0 0
881 5 4 M 20 0 0 0 5 0 0
882 5 6 M 20 0 0 0 5 0 0
883 5 7 M 20 0 0 0 2 0 0
884 5 2 F 20 0 0 0 2 0 0
885 5 3 F 20 0 0 0 4 0 0
886 5 1 F 20 0 0 0 2 0 1
887 5 5 F 20 0 0 0 6 0 0
888 5 6 M 20 0 0 0 4 0 0
889 5 5 F 20 0 0 0 4 0 0
890 5 2 F 20 0 0 0 4 0 0
891 5 1 F 20 0 0 0 4 0 1
892 5 8 M 20 8 0 0 7 0 0
893 5 7 M 20 0 0 0 2 0 0
894 5 9 M 8 0 0 0 7 0 1
895 5 4 M 20 0 0 0 7 0 0
896 5 5 M 8 0 0 0 2 0 1
897 5 2 F 20 0 0 0 6 0 1
898 5 3 F 20 0 0 0 4 0 0
899 5 1 F 20 0 0 0 2 0 0
900 5 4 F 20 0 0 0 2 0 0
901 6 4 F 8 0 0 0 5 4 0 0
902 6 5 M 8 0 0 0 5 2 0 0
903 6 2 M 8 0 0 0 5 4 0 0
904 6 6 M 8 0 0 0 5 7 0 0
905 6 4 M 8 0 0 0 4 0 0
906 6 5 F 0 0 27 0 2 0 1
907 6 4 F 0 0 27 0 5 0 0
908 6 5 F 20 0 0 0 2 0 0
909 6 1 M 20 0 0 0 4 0 0
910 6 5 F 20 0 0 0 2 0 0
911 6 3 M 20 0 0 0 7 2 0 0
912 6 3 F 20 0 0 0 7 4 0 0
913 6 5 M 20 0 0 0 6 2 0 0
914 6 3 F 20 0 0 0 8 4 0 0
915 6 8 F 20 8 0 0 5 2 0 1
916 6 5 M 20 0 0 0 4 0 0
917 6 2 M 20 0 0 0 4 0 0
918 6 1 M 20 0 0 0 2 0 0
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919 6 1 M 20 0 0 0 2 0 0
920 6 5 F 20 0 0 0 7 0 0
921 6 5 M 20 0 0 0 6 7 0 0
922 6 8 M 20 8 0 0 5 2 0 1
923 6 3 F 20 0 0 0 4 0 0
924 6 5 F 20 0 0 0 4 0 0
925 6 4 F 20 0 0 0 2 0 0
926 6 5 M 20 0 0 0 2 0 0
927 6 4 M 20 0 0 0 2 0 0
928 6 5 M 20 0 0 0 2 0 0
929 6 5 M 20 0 0 0 2 0 0
930 6 6 M 20 0 0 0 4 0 0
931 6 5 M 20 0 0 0 4 0 0
932 6 3 F 20 0 0 0 4 0 0
933 6 4 F 20 0 0 0 4 0 0
934 6 6 F 20 0 0 0 6 0 0
935 6 6 F 8 0 0 0 7 0 1
936 6 5 M 20 0 0 0 4 0 0
937 6 9 M 20 0 0 0 2 0 0
938 6 5 F 20 0 0 0 4 0 0
939 6 9 M 8 0 0 0 8 4 0 1
940 6 2 M 20 0 0 0 2 0 0
941 6 6 M 20 0 0 0 4 0 0
942 6 6 M 20 0 0 0 6 0 0
943 6 3 M 20 0 0 0 7 0 0
944 6 4 M 20 0 0 0 2 0 0
945 6 1 F 20 0 0 0 4 0 0
946 6 5 F 8 0 0 0 8 2 0 1
947 6 4 F 20 0 0 0 2 0 0
948 6 5 F 20 0 0 0 4 0 0
949 6 5 F 20 0 0 0 2 0 0
950 6 4 M 20 0 0 0 4 0 0
951 6 6 M 20 0 0 0 4 0 0
952 6 4 M 20 0 0 0 6 0 0
953 6 3 F 20 0 0 0 6 0 0
954 6 3 F 20 0 0 0 6 0 0
955 6 5 F 20 0 0 0 7 0 0
956 6 5 M 20 0 0 0 7 0 0
957 6 9 F 8 0 0 0 4 0 1
958 6 1 M 20 0 0 0 4 0 0
959 6 6 M 20 0 0 0 2 0 0
960 6 3 F 20 0 0 0 5 0 0
961 6 5 M 20 0 0 0 2 0 0
962 6 4 F 20 0 0 0 2 0 0
963 6 6 F 8 0 0 0 8 2 0 1
964 6 5 M 20 0 0 0 4 0 0
965 6 6 M 20 0 0 0 4 0 0
966 6 5 M 20 0 0 0 4 0 0
967 6 10 M 20 0 0 0 2 0 0
968 6 12 F 20 0 0 0 2 0 0
969 6 6 F 20 0 0 0 6 0 0
970 6 4 F 20 0 0 0 7 0 0
971 6 3 F 20 0 0 0 2 0 0
972 6 7 F 20 0 0 0 4 0 0
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973 6 6 F 20 0 0 0 4 0 0
974 6 5 F 20 0 0 0 6 0 0
975 6 3 F 20 0 0 0 2 0 0
976 6 6 F 8 0 0 0 6 0 1
977 6 3 F 20 0 0 0 2 0 0
978 6 6 F 20 0 0 0 4 0 0
979 6 3 F 20 0 0 0 4 0 0
980 6 8 F 8 0 0 0 5 0 1
981 6 5 M 20 0 0 0 2 0 0
982 6 4 M 20 0 0 0 2 0 0
983 6 7 M 20 0 0 0 2 0 0
984 6 2 F 8 0 0 0 4 0 0
985 6 4 F 20 0 0 0 4 0 0
986 6 11 F 20 0 0 0 2 0 0
987 6 5 F 20 0 0 0 2 0 0
988 6 6 M 20 0 0 0 6 0 0
989 6 5 F 20 0 0 0 6 0 0
990 6 5 F 20 0 0 0 6 0 0
991 6 1 F 20 0 0 0 6 0 0
992 6 10 M 20 0 0 0 4 0 0
993 6 7 M 20 0 0 0 4 0 0
994 6 9 M 20 0 0 0 7 0 1
995 6 4 M 20 0 0 0 2 0 0
996 6 5 M 20 0 0 0 2 0 0
997 6 6 F 20 0 0 0 4 0 1
998 6 3 F 20 0 0 0 4 0 0
999 6 1 F 20 0 0 0 2 0 0
1000 6 1 F 20 0 0 0 2 0 0
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1 1 40 F N
2 1 58 M Y 15 10 1 1 2 2 2 2
3 1 52 M N
4 1 60 M N
5 1 24 M N
6 1 52 F N
7 1 42 F N
8 1 25 F N
9 1 17 M N
10 1 65 F Y 3 25 2 2 2 3 2 2
11 1 35 M N
12 1 43 F N
13 1 52 M Y 10 25 1 1 2 3 4 1
14 1 38 F N
15 1 38 F N
16 1 45 M N
17 1 20 M N
18 1 15 M N
19 1 21 M N
20 1 50 F N
21 1 50 M Y 21 19 2 1 2 2 3 2
22 1 18 M N
23 1 23 F N
24 1 50 F Y 16 3 1 1 2 3 3 1
25 1 43 F N
26 1 50 M N
27 1 24 M N
28 1 51 M N
29 1 52 M N
30 1 36 M N
31 1 51 M N
32 1 33 F N
33 1 64 F Y 1 19 2 2 1 2 2 2
34 1 61 F Y 1 9 3 2 1 2 2 3 2
35 1 46 F N
36 1 56 M N
37 1 49 M N
38 1 51 F N
39 1 49 M N
40 1 20 M N
41 1 60 M N
42 1 63 M N
43 1 33 M N
44 1 34 M Y 4 3 1 1 2 3 3 1
45 1 31 F N
46 1 35 F N
47 1 46 F N
48 1 51 F N
49 1 52 F Y 19 3 1 1 2 3 3 1
50 1 47 M N
51 1 46 M Y 4 19 1 2 1 2 2 2
52 1 46 M N
53 1 32 F Y 7 19 1 1 1 4 2 2
54 1 31 F N
55 1 52 F Y 1 19 2 1 1 3 3 1
56 1 57 M N
57 1 59 F Y 4 8 1 1 2 3 3 2
58 1 61 M N
ADR Monitoring of NSAIDs 
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59 1 64 M Y 27 25 3 1 1 3 3 2
60 1 63 F N
61 1 15 M N
62 1 14 F N
63 1 16 F N
64 1 25 M N
65 1 16 M N
66 1 35 M N
67 1 34 M N
68 1 62 F N
69 1 64 F N
70 1 34 F N
71 1 34 F Y 1 19 2 1 1 2 3 1
72 1 67 F Y 4 19 1 1 2 2 3 1
73 1 69 F N
74 1 54 F N
75 1 53 F Y 17 25 1 1 2 3 3 2
76 1 36 F N
77 1 33 F N
78 1 26 F N
79 1 31 F N
80 1 48 F N
81 1 54 M N
82 1 46 M N
83 1 47 M N
84 1 42 F N
85 1 43 F N
86 1 41 F Y 4 19 1 1 1 3 3 1
87 1 45 F Y 9 27 3 1 2 3 3 1
88 1 56 M N
89 1 55 F N
90 1 52 F N
91 1 51 F N
92 1 48 M N
93 1 47 M N
94 1 49 M N
95 1 42 M N
96 1 45 M Y 15 8 1 1 2 3 3 2
97 1 62 F N
98 1 63 F N
99 1 51 F N
100 1 41 F N
101 1 40 F Y 3 3 2 1 2 3 3 2
102 1 58 M Y 15 10 1 1 1 2 2 2
103 1 52 M N
104 1 6 M N
105 1 24 M N
106 1 52 F N
107 1 42 F N
108 1 25 F N
109 1 17 M N
110 1 65 F N
111 1 35 M N
112 1 43 F N
113 1 52 M Y 1 4 19 2 2 1 3 2 2
114 1 38 F N
115 1 38 F N
116 1 45 M N
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117 1 20 M N
118 1 15 M Y 7 8 1 1 2 3 3 2
119 1 21 M N
120 1 50 F N
121 1 50 M N
122 1 18 M N
123 1 23 F N
124 1 50 F N
125 1 43 F N
126 1 50 M N
127 1 24 M N
128 1 51 M N
129 1 52 M N
130 1 36 M N
131 1 51 M N
132 1 33 F N
133 1 64 F Y 4 1 3 2 2 1 3 3 3
134 1 61 F N
135 1 46 F Y 27 3 2 1 2 2 3 2
136 1 56 M N
137 1 49 M N
138 1 51 F Y 19 3 1 2 2 3 3 2
139 1 49 M Y 4 8 1 2 1 4 3 1
140 1 20 M N
141 1 60 M Y 17 3 1 1 2 3 3 2
142 1 63 M N
143 1 33 M N
144 1 34 M Y 10 19 1 1 2 3 3 2
145 1 31 F Y 15 8 1 1 2 5 3 2
146 1 35 F N
147 1 46 F Y 3 25 2 1 2 3 3 1
148 1 51 F N
149 1 52 F N
150 1 47 M N
151 1 46 M Y 28 19 2 1 2 2 3 1
152 1 46 M N
153 1 32 F Y 4 28 3 2 1 2 2 3 2
154 1 31 F N
155 1 52 F N
156 1 57 M N
157 1 59 F Y 1 19 3 1 2 3 3 2
158 1 61 M Y 19 3 1 1 2 3 3 2
159 1 64 M Y 8 8 2 1 2 3 3 2
160 1 63 F Y 28 3 1 1 2 2 3 1
161 1 15 M N
162 1 14 F Y 19 25 1 1 2 3 4 1
163 1 16 F N
164 1 25 M N
165 1 16 M N
166 1 35 M N
167 1 34 M N
168 1 62 F Y 17 25 2 1 2 3 3 2
169 1 64 F Y 18 25 3 1 2 3 3 2
170 1 34 F N
171 1 34 F Y 9 27 1 1 2 3 3 1
172 1 67 F N
173 1 69 F Y 15 10 1 1 2 2 3 2
174 1 54 F N
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175 1 53 F Y 3 19 2 1 1 2 2 2
176 1 36 F N
177 1 33 F N
178 1 26 F N
179 1 31 F N
180 1 48 F Y 19 27 1 1 2 3 3 2
181 1 54 M N
182 1 46 M N
183 1 47 M Y 4 9 27 1 1 1 3 3 2
184 1 42 F N
185 1 43 F Y 15 8 2 1 2 3 3 1
186 1 41 F N
187 1 45 F N
188 1 56 M Y 10 25 2 1 2 3 3 2
189 1 55 F N
190 1 52 F Y 4 7 8 1 1 1 3 3 2
191 1 51 F N
192 1 48 M Y 4 27 3 2 2 1 3 2 1
193 1 47 M Y 21 25 2 1 2 3 3 2
194 1 49 M Y 21 3 3 1 2 3 3 2
195 1 42 M N
196 1 45 M N
197 1 62 F Y 1 4 19 3 1 2 3 3 2
198 1 63 F N
199 1 51 F N
200 1 41 F Y 17 8 1 1 2 3 3 2
201 2 40 F Y 3 25 2 1 2 3 3 2
202 2 58 M N
203 2 52 M N
204 2 60 M Y 1 21 8 3 1 2 3 3 3
205 2 24 M Y 24 3 3 2 2 3 3 1
206 2 52 F Y 4 3 1 1 2 3 3 2
207 2 42 F N
208 2 25 F N
209 2 17 M Y 10 8 2 1 2 3 3 2
210 2 65 F Y 1 15 8 2 2 2 3 1 2
211 2 35 M Y 22 8 3 1 2 3 3 3
212 2 43 F Y 15 10 1 1 2 2 3 2
213 2 52 M N
214 2 38 F N
215 2 38 F N
216 2 45 M N
217 2 20 M N
218 2 15 M N
219 2 21 M N
220 2 50 F N
221 2 50 M N
222 2 18 M N
223 2 23 F N
224 2 50 F N
225 2 43 F Y 22 4 8 1 1 2 2 3 2
226 2 50 M N
227 2 24 M Y 22 8 3 1 2 3 3 3
228 2 51 M N
229 2 52 M N
230 2 36 M N
231 2 51 M N
232 2 33 F N
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233 2 64 F Y 1 21 3 3 1 2 3 3 2
234 2 61 F N
235 2 46 F Y 3 7 3 1 1 2 3 3 2
236 2 56 M N
237 2 49 M Y 24 25 3 2 1 2 2 2
238 2 51 F N
239 2 49 M N
240 2 20 M N
241 2 60 M Y 19 3 1 1 2 3 3 2
242 2 63 M Y 16 3 1 1 2 3 3 3
243 2 33 M Y 13 8 1 1 2 3 3 3
244 2 34 M N
245 2 31 F Y 3 17 8 2 1 2 3 3 2
246 2 35 F N
247 2 46 F Y 24 20 3 2 1 3 2 2
248 2 51 F N
249 2 52 F N
250 2 47 M N
251 2 46 M N
252 2 46 M N
253 2 32 F N
254 2 31 F Y 4 3 1 1 2 3 3 1
255 2 52 F N
256 2 57 M N
257 2 59 F Y 1 3 2 1 2 2 3 2
258 2 61 M N
259 2 64 M N
260 2 63 F N
261 2 15 M N
262 2 14 F Y 4 8 1 1 2 3 3 2
263 2 16 F Y 15 8 2 1 2 2 3 2
264 2 25 M N
265 2 16 M Y 9 3 2 1 2 3 3 2
266 2 35 M Y 4 8 1 1 2 3 3 2
267 2 34 M N
268 2 62 F Y 18 3 3 3 1 2 3 3 3
269 2 64 F N
270 2 34 F N
271 2 34 F N
272 2 67 F N
273 2 69 F N
274 2 54 F N
275 2 53 F N
276 2 36 F N
277 2 33 F N
278 2 26 F N
279 2 31 F N
280 2 48 F N
281 2 54 M N
282 2 46 M N
283 2 47 M N
284 2 42 F N
285 2 43 F N
286 2 41 F N
287 2 45 F N
288 2 56 M N
289 2 55 F N
290 2 52 F N
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291 2 51 F N
292 2 48 M N
293 2 47 M N
294 2 49 M N
295 2 42 M N
296 2 45 M N
297 2 62 F Y 19 3 1 1 2 3 3 3
298 2 63 F N
299 2 51 F Y 15 10 1 1 2 2 3 3
300 2 41 F N
301 2 40 F N
302 2 58 M N
303 2 52 M N
304 2 61 M N
305 2 24 M N
306 2 52 F Y 5 8 1 1 2 3 3 3
307 2 42 F N
308 2 25 F Y 3 17 19 1 1 2 2 3 1
309 2 17 M N
310 2 65 F Y 21 3 2 1 2 3 3 2
311 2 35 M Y 4 19 1 1 2 3 3 1
312 2 43 F Y 3 19 2 2 2 3 3 2
313 2 52 M N
314 2 38 F N
315 2 38 F Y 3 20 1 1 2 3 4 1
316 2 45 M N
317 2 20 M N
318 2 15 M Y 9 4 8 1 1 2 3 3 1
319 2 21 M Y 28 3 2 1 2 3 3 2
320 2 50 F N
321 2 50 M N
322 2 18 M Y 10 4 3 1 1 2 3 3 3
323 2 23 F N
324 2 50 F Y 15 10 1 1 2 2 3 3
325 2 43 F N
326 2 50 M N
327 2 24 M N
328 2 51 M N
329 2 52 M N
330 2 36 M N
331 2 51 M N
332 2 33 F N
333 2 64 F N
334 2 61 F N
335 2 46 F N
336 2 56 M N
337 2 49 M N
338 2 51 F N
339 2 49 M N
340 2 20 M N
341 2 60 M N
342 2 63 M N
343 2 33 M N
344 2 34 M N
345 2 31 F Y 1 3 27 2 1 2 3 3 1
346 2 35 F N
347 2 46 F N
348 2 51 F Y 1 20 3 1 2 3 3 3
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349 2 52 F N
350 2 47 M N
351 2 46 M N
352 2 46 M N
353 2 32 F N
354 2 31 F N
355 2 52 F N
356 2 57 M N
357 2 59 F N
358 2 61 M N
359 2 64 M N
360 2 63 F N
361 2 15 M N
362 2 14 F N
363 2 16 F Y 3 3 1 1 2 2 4 2
364 2 25 M N
365 2 18 M Y 17 3 2 1 2 3 3 2
366 2 35 M N
367 2 34 M N
368 2 62 F N
369 2 64 F Y 27 7 27 3 2 1 3 2 3
370 2 34 F Y 24 20 3 1 2 2 3 1
371 2 34 F N
372 2 67 F Y 1 20 2 1 2 4 3 3
373 2 69 F Y 17 20 1 1 2 3 3 2
374 2 54 M N
375 2 53 F N
376 2 36 F N
377 2 33 F N
378 2 26 M N
379 2 31 F N
380 2 48 F Y 17 3 3 1 1 2 3 3 2
381 2 54 M N
382 2 46 M Y 24 20 3 1 2 2 3 2
383 2 47 M N
384 2 42 F N
385 2 43 F N
386 2 41 F N
387 2 45 F N
388 2 56 M N
389 2 55 F Y 1 10 20 2 1 2 3 3 3
390 2 52 F N
391 2 51 F N
392 2 48 M N
393 2 47 M N
394 2 49 M N
395 2 42 M N
396 2 45 M N
397 2 62 F Y 1 3 20 3 1 2 3 3 2
398 2 63 F N
399 2 51 F N
400 2 41 F Y 1 3 20 2 1 2 3 3 2
401 3 40 F Y 4 8 1 1 2 2 3 2
402 3 58 M Y 4 3 2 1 2 3 3 2
403 3 52 M N
404 3 60 M Y 24 27 2 1 2 2 4 2
405 3 24 M N
406 3 52 F N
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407 3 42 F N
408 3 25 F Y 22 10 8 1 1 2 3 3 1
409 3 17 M N
410 3 65 F N
411 3 35 M N
412 3 43 F N
413 3 52 M N
414 3 38 F N
415 3 38 F N
416 3 45 M N
417 3 20 M Y 4 15 8 3 2 2 2 2 2
418 3 15 M N
419 3 21 M N
420 3 50 F Y 24 27 2 1 2 3 3 2
421 3 50 M N
422 3 18 M N
423 3 23 F N
424 3 50 F Y 3 1 3 2 1 2 3 3 2
425 3 43 F N
426 3 50 M Y 27 27 2 1 2 3 3 2
427 3 44 M Y 1 19 3 1 2 2 3 3
428 3 51 M N
429 3 52 M N
430 3 36 M N
431 3 51 M N
432 3 33 F N
433 3 64 F Y 28 2 2 1 2 3 4 2
434 3 61 F N
435 3 46 F Y 7 16 8 2 1 2 3 3 1
436 3 56 M N
437 3 49 M N
438 3 51 F N
439 3 49 M N
440 3 20 M N
441 3 60 M N
442 3 63 M N
443 3 33 M N
444 3 34 M N
445 3 31 F N
446 3 35 F Y 23 8 2 1 3 3 4 1
447 3 46 F Y 23 3 2 1 3 3 4 1
448 3 51 F N
449 3 52 F Y 27 3 2 1 2 3 3 2
450 3 47 M N
451 3 46 M N
452 3 46 M N
453 3 32 F N
454 3 31 F N
455 3 52 F N
456 3 57 M N
457 3 59 F N
458 3 61 M Y 25 3 3 2 2 2 3 2
459 3 64 M Y 27 3 2 1 2 3 3 3
460 3 63 F N
461 3 15 M N
462 3 14 F N
463 3 16 F Y 10 27 1 1 2 3 3 2
464 3 25 M N
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465 3 16 M N
466 3 35 M N
467 3 34 M N
468 3 62 F N
469 3 64 F Y 1 20 2 1 2 3 2 2
470 3 34 F N
471 3 34 F N
472 3 67 F N
473 3 69 F Y 24 20 3 2 2 2 2 3
474 3 54 F N
475 3 53 F N
476 3 36 F N
477 3 33 F N
478 3 26 F N
479 3 31 F N
480 3 48 F N
481 3 54 M Y 22 8 1 1 2 3 4 1
482 3 46 M N
483 3 47 M N
484 3 42 F N
485 3 43 F Y 21 8 2 1 2 3 3 2
486 3 41 F Y 22 8 3 1 2 3 4 2
487 3 45 F N
488 3 56 M N
489 3 55 F Y 21 8 3 1 2 3 3 2
490 3 52 F N
491 3 51 F Y 16 3 1 1 2 3 4 2
492 3 48 M N
493 3 47 M N
494 3 49 M Y 4 7 3 1 1 2 3 3 2
495 3 42 M N
496 3 45 M Y 23 3 1 1 2 3 4 1
497 3 62 F N
498 3 63 F Y 1 3 2 1 2 3 3 2
499 3 51 F Y 1 3 3 1 2 3 3 2
500 3 41 F N
501 3 57 F N
502 3 28 F Y 28 3 1 1 2 3 3 2
503 3 62 M N
504 3 27 F N
505 3 32 M N
506 3 25 M N
507 3 34 F N
508 3 30 F N
509 3 24 M N
510 3 51 F Y 1 21 27 2 2 2 3 3 2
511 3 18 M N
512 3 33 F Y 5 3 1 1 2 3 3 1
513 3 25 M N
514 3 18 F N
515 3 18 F Y 4 8 1 1 2 3 3 1
516 3 38 F N
517 3 18 F N
518 3 50 F N
519 3 27 F N
520 3 24 M N
521 3 35 F N
522 3 47 M N
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523 3 40 F Y 1 3 2 1 2 3 3 2
524 3 45 F N
525 3 40 F N
526 3 26 F N
527 3 50 F Y 28 19 1 1 2 2 3 2
528 3 32 M N
529 3 38 M N
530 3 18 M N
531 3 32 M N
532 3 36 F Y 17 27 1 1 2 3 3 2
533 3 30 F Y 4 3 1 1 2 3 3 2
534 3 42 F N
535 3 18 F Y 4 8 1 1 2 2 3 2
536 3 34 M N
537 3 40 M N
538 3 20 M N
539 3 44 F Y 7 27 1 1 2 2 3 2
540 3 38 F N
541 3 42 M N
542 3 22 F Y 17 27 1 1 2 3 4 2
543 3 35 F N
544 3 30 F N
545 3 23 F N
546 3 47 F Y 27 27 2 1 2 3 3 2
547 3 40 M Y 21 3 1 1 2 3 3 2
548 3 18 F N
549 3 20 F N
550 3 20 F N
551 3 46 M Y 4 8 1 1 2 3 3 2
552 3 55 M N
553 3 70 F N
554 3 48 M Y 1 21 3 3 1 2 3 3 2
555 3 38 F N
556 3 44 M N
557 3 59 F Y 1 27 20 2 1 2 4 3 2
558 3 61 M N
559 3 64 M N
560 3 63 F N
561 3 15 M N
562 3 22 F N
563 3 16 F N
564 3 25 M N
565 3 26 M N
566 3 35 M N
567 3 34 M N
568 3 62 F Y 1 3 20 2 1 2 4 3 2
569 3 64 F Y 24 20 3 2 2 4 3 1
570 3 34 F N
571 3 35 M N
572 3 67 F Y 4 20 1 1 1 3 3 1
573 3 65 F Y 27 20 2 1 2 4 3 2
574 3 54 F N
575 3 53 F N
576 3 36 F N
577 3 33 F N
578 3 26 F N
579 3 31 F N
580 3 48 F N
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581 3 54 M N
582 3 46 M Y 4 10 8 1 1 2 3 3 1
583 3 47 M N
584 3 42 F Y 10 3 2 1 2 3 3 3
585 3 43 F N
586 3 41 F Y 5 4 3 1 1 2 3 3 1
587 3 45 F N
588 3 56 M N
589 3 55 F N
590 3 52 F Y 3 27 20 1 1 2 4 4 2
591 3 51 F N
592 3 48 M N
593 3 47 M Y 4 25 8 2 1 2 2 4 2
594 3 49 M N
595 3 42 M Y 1 20 1 1 2 3 3 2
596 3 25 M N
597 3 62 F N
598 3 63 F Y 1 20 1 1 2 3 3 2
599 3 51 F N
600 3 41 F Y 27 27 2 1 2 4 4 2
601 4 45 M N
602 4 43 F N
603 4 58 F N
604 4 60 F N
605 4 37 F Y 15 23 10 1 1 2 2 3 1
606 4 30 F N
607 4 70 M N
608 4 27 M N
609 4 45 F N
610 4 60 M N
611 4 40 F N
612 4 63 F Y 25 26 8 1 2 2 2 3 2
613 4 20 F N
614 4 65 M N
615 4 32 F N
616 4 68 F N
617 4 47 F Y 17 3 3 1 1 2 3 3 2
618 4 62 F N
619 4 37 F N
620 4 24 M N
621 4 19 F N
622 4 18 M N
623 4 65 F N
624 4 21 M N
625 4 30 M N
626 4 65 M N
627 4 19 F N
628 4 65 F N
629 4 40 M N
630 4 26 M N
631 4 50 M N
632 4 33 F N
633 4 26 F N
634 4 69 F Y 27 20 1 1 2 4 4 2
635 4 46 F N
636 4 28 M N
637 4 49 M N
638 4 51 F Y 1 27 20 1 1 2 3 3 2
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639 4 49 M N
640 4 20 M N
641 4 60 M N
642 4 63 M Y 24 20 2 2 2 2 2 1
643 4 33 M N
644 4 34 M N
645 4 31 F N
646 4 35 F N
647 4 46 F N
648 4 51 F Y 1 22 3 1 1 2 3 3 2
649 4 52 F N
650 4 47 M N
651 4 46 M N
652 4 60 M Y 10 20 1 1 2 3 3 1
653 4 32 F N
654 4 31 F N
655 4 52 F N
656 4 57 M N
657 4 59 F N
658 4 61 M N
659 4 64 M N
660 4 63 F N
661 4 17 M N
662 4 18 F N
663 4 16 F N
664 4 25 M N
665 4 16 M N
666 4 35 M N
667 4 34 M N
668 4 62 F N
669 4 64 F N
670 4 34 F N
671 4 39 M N
672 4 67 M Y 19 3 20 1 1 2 3 3 2
673 4 69 F N
674 4 54 F N
675 4 53 F N
676 4 36 F Y 15 8 2 1 2 2 3 2
677 4 33 F N
678 4 26 M N
679 4 31 M N
680 4 48 F Y 15 10 1 1 2 2 3 2
681 4 54 M N
682 4 46 M N
683 4 47 M N
684 4 42 F Y 23 8 1 1 2 3 3 1
685 4 43 F N
686 4 41 F N
687 4 45 F N
688 4 56 M N
689 4 55 F N
690 4 52 F N
691 4 51 F N
692 4 48 M N
693 4 47 M N
694 4 49 M N
695 4 42 M N
696 4 45 M N
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697 4 62 F Y 1 27 20 1 2 1 3 2 3
698 4 63 M N
699 4 51 F N
700 4 41 F N
701 4 40 F N
702 4 58 M Y 7 3 1 1 2 3 3 1
703 4 52 M N
704 4 60 M N
705 4 24 M N
706 4 52 F N
707 4 42 F Y 4 9 3 1 1 2 3 3 1
708 4 25 F N
709 4 17 M N
710 4 65 F Y 5 3 1 1 2 3 3 1
711 4 35 M N
712 4 43 F N
713 4 52 M N
714 4 38 F N
715 4 38 F N
716 4 45 M N
717 4 20 M N
718 4 15 M N
719 4 21 M N
720 4 50 F N
721 4 50 M Y 9 10,24 8 1 1 2 3 3 1
722 4 18 M N
723 4 23 F N
724 4 50 F N
725 4 43 F N
726 4 50 M N
727 4 24 M N
728 4 51 M N
729 4 52 M N
730 4 36 M N
731 4 51 M N
732 4 33 F N
733 4 64 F N
734 4 61 F N
735 4 46 F N
736 4 56 M N
737 4 49 M N
738 4 51 F N
739 4 49 M N
740 4 20 M N
741 4 60 M N
742 4 63 M Y 1 27 3 1 1 2 3 3 1
743 4 33 M N
744 4 34 M N
745 4 31 F N
746 4 35 F N
747 4 46 F N
748 4 51 F N
749 4 52 F N
750 4 47 M N
751 4 46 M N
752 4 46 M N
753 4 32 F N
754 4 31 F N
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755 4 52 F N
756 4 57 M N
757 4 59 F N
758 4 61 M N
759 4 64 M Y 1 25 8 1 1 2 3 3 1
760 4 63 F N
761 4 15 M N
762 4 14 F N
763 4 16 F N
764 4 25 M N
765 4 16 M N
766 4 35 M Y 17 25 1 1 2 4 4 2
767 4 34 M N
768 4 62 F N
769 4 64 F N
770 4 34 F N
771 4 34 F N
772 4 67 F N
773 4 69 F N
774 4 54 F N
775 4 53 F N
776 4 36 F N
777 4 33 F N
778 4 26 F N
779 4 31 F N
780 4 48 F N
781 4 54 M Y 17 20 1 1 2 3 3 1
782 4 46 M N
783 4 47 M N
784 4 42 F N
785 4 43 F N
786 4 41 F Y 1 27 20 1 1 2 3 3 2
787 4 45 F N
788 4 56 M N
789 4 55 F N
790 4 52 F N
791 4 51 F Y 3 27,21 19 1 1 2 3 3 2
792 4 48 M N
793 4 47 M Y 19 3 1 1 2 4 3 1
794 4 49 M N
795 4 42 M N
796 4 45 M Y 24 27 2 2 2 3 2 2
797 4 62 F N
798 4 63 F N
799 4 51 F N
800 4 41 F N
801 5 4 F N
802 5 8 M N
803 5 2 M N
804 5 6 M N
805 5 4 M N
806 5 2 F N
807 5 4 F N
808 5 2 F N
809 5 7 M N
810 5 6 F Y 7 20 1 1 2 3 3 2
811 5 3 M N
812 5 3 F N
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813 5 5 M N
814 5 8 F N
815 5 8 F N
816 5 5 M N
817 5 2 M N
818 5 5 M N
819 5 2 M N
820 5 5 F N
821 5 5 M N
822 5 8 M N
823 5 3 F N
824 5 5 F N
825 5 4 F N
826 5 5 M N
827 5 2 M N
828 5 9 M N
829 5 5 M N
830 5 6 M N
831 5 5 M N
832 5 3 F N
833 5 6 F N
834 5 9 F N
835 5 6 F N
836 5 6 M N
837 5 9 M Y 15 8 2 1 2 3 3 2
838 5 5 F N
839 5 9 M N
840 5 2 M N
841 5 6 M N
842 5 3 M N
843 5 3 M N
844 5 4 M N
845 5 3 F N
846 5 5 F N
847 5 6 F N
848 5 5 F N
849 5 2 F N
850 5 7 M Y 4 8 1 1 2 3 3 3
851 5 6 M N
852 5 4 M N
853 5 2 F N
854 5 3 F N
855 5 2 F N
856 5 7 M N
857 5 9 F Y 10 20 1 1 2 4 3 3
858 5 6 M Y 9 8 1 1 2 3 3 2
859 5 6 M N
860 5 3 F N
861 5 5 M N
862 5 4 F N
863 5 6 F N
864 5 5 M N
865 5 6 M N
866 5 3 M N
867 5 4 M N
868 5 2 F N
869 5 6 F N
870 5 3 F N
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871 5 4 F N
872 5 7 F N
873 5 6 F N
874 5 4 F N
875 5 3 F N
876 5 6 F N
877 5 3 F N
878 5 6 F N
879 5 1 F N
880 5 8 F N
881 5 4 M N
882 5 6 M N
883 5 7 M N
884 5 2 F N
885 5 3 F N
886 5 1 F N
887 5 5 F N
888 5 6 M N
889 5 5 F N
890 5 2 F N
891 5 1 F N
892 5 8 M Y 15 8 1 1 2 4 3 2
893 5 7 M N
894 5 9 M N
895 5 4 M N
896 5 5 M N
897 5 2 F N
898 5 3 F N
899 5 1 F N
900 5 4 F N
901 6 4 F N
902 6 5 M N
903 6 2 M N
904 6 6 M N
905 6 4 M N
906 6 5 F Y 7 3 1 1 2 3 3 1
907 6 4 F N
908 6 5 F N
909 6 1 M N
910 6 5 F N
911 6 3 M N
912 6 3 F N
913 6 5 M N
914 6 3 F N
915 6 8 F N
916 6 5 M N
917 6 2 M N
918 6 1 M N
919 6 1 M N
920 6 5 F N
921 6 5 M N
922 6 8 M N
923 6 3 F N
924 6 5 F N
925 6 4 F N
926 6 5 M N
927 6 4 M N
928 6 5 M N
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929 6 5 M N
930 6 6 M N
931 6 5 M N
932 6 3 F N
933 6 4 F N
934 6 6 F N
935 6 6 F N
936 6 5 M N
937 6 9 M N
938 6 5 F N
939 6 9 M N
940 6 2 M N
941 6 6 M N
942 6 6 M N
943 6 3 M N
944 6 4 M N
945 6 1 F N
946 6 5 F N
947 6 4 F N
948 6 5 F N
949 6 5 F N
950 6 4 M N
951 6 6 M N
952 6 4 M N
953 6 3 F N
954 6 3 F N
955 6 5 F N
956 6 5 M N
957 6 9 F N
958 6 1 M N
959 6 6 M N
960 6 3 F N
961 6 5 M N
962 6 4 F N
963 6 6 F N
964 6 5 M N
965 6 6 M N
966 6 5 M N
967 6 10 M N
968 6 12 F N
969 6 6 F N
970 6 4 F N
971 6 3 F N
972 6 7 F N
973 6 6 F N
974 6 5 F N
975 6 3 F N
976 6 6 F N
977 6 3 F N
978 6 6 F N
979 6 3 F N
980 6 8 F N
981 6 5 M N
982 6 4 M N
983 6 7 M N
984 6 2 F N
985 6 4 F N
986 6 11 F N
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987 6 5 F N
988 6 6 M N
989 6 5 F N
990 6 5 F N
991 6 1 F N
992 6 10 M N
993 6 7 M N
994 6 9 M N
995 6 4 M N
996 6 5 M N
997 6 6 F N
998 6 3 F N
999 6 1 F N
1000 6 1 F N
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Code  of  Variables 
 
* Code of Departments  
 
1. Orthopedics OPD Patients  
2. Orthopedics IPD Patients 
3. Medicine OPD Patients 
4. Medicine IPD Patients 
5. Pediatrics OPD Patients 
6. Pediatrics IPD Patients 
 
* Code of NSAIDs  
  
 Cox -1  inhibitors                     Cox – 2   inhibitors 
 
1. Aspirin 24.  Celecoxib  
2. Aceclofenac 25.  Etoricoxib 
3. Diaclofenac 26.  Meloxicam 
4. Diflunisal 27.  Nimesulide 
5. Flurbiprofen 28.  Nabumetone 
6. Etodolac 29.  Parecoxib 
7. Fenaprofen 30.  Valdecoxib 
8. Ibuprofen 31.  Lumaricoxib 
9. Flufenamic acid 
10. Indomethacin  
11. Ketoprofen  
12. Ketorolac 
13. Mephenamic acid 
14. Naproxen                                                         
15. Oxyphenbutazone 
16. Meclofenamate 
17. Phenylbutazone 
18. Oxaprozin  
19. Piroxicam 
20. Paracetamol 
21. Tenoxicam  
22. Sulindac 
23. Tolmetin  
 
* Code of Diagnosis                                           *  Code of Gastroprotective agents 
 
1. Cardiovascular                                              1   Yes 
2. Respiratory                                                    0   No 
3. Endocrine 
4. Infections                                                 *  Code of OTC use of NSAIDs 
5. Musculoskeletal                                           1   Yes 
                                                                                 0    No         
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* Code of Symptoms of ADR according to the system: (check list) 
       
     CVS     CNS 
1. Increase blood pressure 15.  Headache 
2. Increase mean blood pressure 16.  Confusion 
3. Palpitation 17.  Giddiness 
  18.  Paresthesia 
 GIT Eye Disorder   
4. Gastritis / pain in abdomen  19.  Blurred vision 
5. Diarrohoea 20.  Ocular discomfort 
6. GI bleed Electrolyte imbalance 
7. Vomiting  21.  Edema / Puffiness of face 
8. Constipation  Heamatological  
9. Nausea 22.  Anemia 
10. Decreased Appetite 23.  Abnormal TC / RBC 
11. Hematemasis Liver 
12. Blood in Stool 24.  Derranged LFT 
  Kidney 
 Respiratory System 25.  Increase Creatinine 
 13. Breathlessness 26.  Decrease creatinine clearance  
 14. Cough  27.  Oliguria 
  Skin  
  28.  Urticaria  
  29.  Maculopapular rash 
  30.  Vesicular / Exfoliative lesion  
 
* Code of Causality assessments of ADRs 
WHO – UMC Scale Naranjo's  Scale 
1. Certain / Definite 1.   Definite 
2. Probable 2.   Probable  
3. Possible 3.   Possible 
4. Unlikely / Doubtful 4.   Doubtful  
5. Conditional / unclassifiable  
 
* Code of Preventability of ADRs * Code of outcome  of ADRs 
1. definitely preventable 1.   Cured 
2. Probably preventable 2.   Relieved 
3. Not preventable 3.   Same  
           4.   Worsened 
  5.   Death  
 
* Onset of day of development of ADRs              *  Code of Severity of ADRs  
1. 3rd day ( 1-3 days)                                        1.   Mild 
2. 7th day ( 3 - 7th days)                                    2.   Moderate 
3. 1 mt. Day (7th – 1 mth)                                3.    Severe 
  
 
